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Abstract 
 
Background: Home-based HIV counselling and testing (HBHCT) is highly acceptable 
and may be an effective strategy for HIV prevention and population-based test-and-treat 
programmes in sub-Saharan Africa (SSA). However, few data are available on linkage 
to care or on the effectiveness of strategies to increase linkage to care among HIV-
positive persons identified through HBHCT in SSA. The aims of this PhD were to (i) 
systematically review the literature on linkage to care among HIV-positive adults 
diagnosed through HBHCT in SSA; and (ii) to conduct a cluster-randomised controlled 
trial to measure the effectiveness of a counselling intervention after HIV diagnosis 
through HBHCT in increasing linkage to care in rural Masaka district, Uganda. 
 
Methods: (i) Five databases (Medline, Embase, Global Health, Web of Science, and 
Africa-Wide information) were systematically searched for studies published between 
1st January 2000 and 19th August 2016. Authors of studies for which some required 
information was missing were requested to provide additional data. (ii) For the trial, 28 
rural communities were randomly allocated (1:1) to the intervention (HBHCT, referral, 
and brief home-based counselling sessions one and two months after HBHCT) or 
control group (HBHCT and referral only). HIV-positive adults (≥18 years) not yet in 
care were enrolled. Primary outcomes were linkage (registration with an HIV clinic) at 
6 months after HBHCT, and time to linkage. Analyses were by intention-to-treat using 
random effects logistic regression and Cox regression with shared frailty.  
 
Results: (i) 19 eligible studies were identified; one had all the required data. Additional 
data were obtained for 13 studies; thus, 14 studies were included in the review. Linkage 
to care was generally lower (<33%) if HBHCT was followed by referral only, and 
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higher (>80%) if some strategy was used to facilitate uptake of referral. Only one study 
was a randomised trial and most were susceptible to outcome ascertainment bias. (ii) In 
the trial, 551 individuals tested HIV-positive; 205 (37.2%) were already in care and thus 
ineligible. 302 (87.3% of those eligible) were enrolled (intervention, n=149). Retention 
was similar across trial arms (92% overall). Overall linkage to care was 42.1%. 
Counselling was associated with a 2.18-fold [95% confidence interval (CI)=1.26-3.78] 
increase in the odds of linkage. There was no evidence of a difference between arms in 
the rate of linkage in the first two months, but subsequently the rate of linkage was 
higher in the intervention arm (hazard ratio=4.87, 95% CI=1.79-13.27).   
 
Conclusion: Counselling substantially increases linkage to care among HIV-positive 
adults identified through HBHCT and can increase antiretroviral therapy coverage in 
SSA.   
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Chapter 1: Background to the study 
 
1.1 Introduction 
Access to anti-retroviral therapy (ART) in sub-Saharan Africa (SSA) has expanded 
considerably but AIDS-related mortality remains high [1]. This is mostly due to the late 
presentation of patients for treatment. Most HIV-positive persons in the region initiate 
ART at CD4 counts <200 cells/mm [2], the ART eligibility threshold in earlier treatment 
guidelines [3]. The World Health Organisation (WHO) currently recommends ART 
initiation for all adults living with HIV at any CD4 count [4]. This recommendation is 
based on evidence showing that earlier initiation of ART reduces HIV-related mortality 
and morbidity [5-9] and sexual transmission of HIV [10]. Also, a growing body of 
evidence suggests that earlier initiation of ART may reduce the development of non-
AIDS defining conditions such as cardiovascular disease, kidney disease, liver disease, 
and cancer [11, 12].  
 
Early ART initiation is dependent on early HIV diagnosis through HIV counselling and 
testing (HCT) and prompt linkage to care [13]. HCT is essential in expanding HIV 
prevention and treatment services [14] but its uptake in SSA remains low [15]. For 
instance, the proportion of HIV-positive adults who are aware of their HIV status is 
estimated to be only 60% [16]. In order to expand access to HIV testing in generalised 
epidemic settings, WHO recommends community-based HCT with linkage to prevention, 
care and treatment services, in addition to facility-based HCT [4]. 
 
1.2 HCT models  
HCT approaches may be categorised as facility- and community-based strategies [17, 18]. 
The former can be client- or provider-initiated [14, 17]. The client-initiated approach was 
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the primary HCT model in SSA before ART became widely available [14, 15]. This 
model requires availability of facilities, public awareness of that availability, and an 
individual’s decision to actively seek HCT [14]. Its uptake depends on an individual’s 
perception of his/her risk of HIV infection, availability of transport, service quality [14], 
and level of stigma [14, 19-22]. Increased ART availability led to the adoption of 
provider-initiated HCT in many SSA countries [23-25], in which HCT is routinely 
recommended by health workers to anybody attending health facilities [14, 23, 26, 27]. 
Provider-initiated HCT can identify many new HIV-positive individuals [26-29]. 
However, it is limited to people attending health facilities [26], may be associated with 
coercion [23, 24], and may not be a priority to health-care staff in busy clinics [26].  
 
In the community-based approach, services are delivered through mobile, workplace-, 
school-, and home-based models [14]. Community-based HCT may also be delivered as 
part of multi-disease campaigns (campaign HCT) [30]. Mobile HCT achieves higher 
testing uptake compared to facility-based HCT [31], reaches many individuals who are 
unaware of their HIV status [32], facilitates access for remote populations [31, 33], and 
is cost-effective for expanding HCT coverage and identifying previously undiagnosed 
HIV-positive persons compared to facility-based HCT [34]. The disadvantages of mobile 
HCT include high workload [14], high cost [14], and insufficient linkage to care [30, 35]. 
Workplace-based HCT provides employees with confidential voluntary HCT at work [17, 
36]. It can increase HIV testing [37], especially among men [18], and those who are 
young, single, and do manual work [37]. School-based testing targets sexually active 
youth and initiates access to care for HIV-positive adolescents and prevention services 
for HIV-negatives [38, 39]. Concerns with workplace- and school-based HCT relate to 
lack of confidentiality [18, 38, 40, 41], potential coercion [38, 42], and weaknesses in 
linking persons who test HIV-positive to HIV care services [38, 39, 42].  
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Home-based HCT (HBHCT) is provided to everyone in a community through a door-to-
door approach or may be targeted at the household members of known tuberculosis or 
HIV-positive persons. HBHCT is highly acceptable [43, 44] and increases testing uptake 
[45, 46], is cost-effective at reaching previously untested persons compared with other 
HCT models [47], promotes equitable access of services [48] and may help to promote 
HCT for couples [49, 50] and prevention of mother-to-child HIV transmission [50]. 
HBHCT facilitates early HIV diagnosis and may promote early linkage to care [50]. Its 
disadvantages include concerns about confidentiality, privacy, potential coercion, 
domestic conflicts and fear of stigma [49]. Campaign HCT involves intensive community 
mobilization lasting 1-2 weeks followed by mobile HIV testing, often coupled with other 
preventive medical services [44] such as childhood immunisations, antenatal 
consultations, and screening for communicable and non-communicable diseases [51, 52]. 
A major advantage of this HCT delivery model is the normalisation of HIV testing as a 
part of a broader healthcare package, thus reducing stigma [51, 52].  
 
1.3 HCT in Uganda 
In Uganda HCT began in 1990 with the client-initiated HCT model. Following increased 
access to ART, provider-initiated HCT and HBHCT models were introduced in 2005 to 
identify individuals that need care [53]. Nevertheless, HCT uptake is still low. A national 
AIDS indicator survey conducted in 2011 found that only 57% of adults (15-49 years) 
had undergone HCT and received the results [54]. Also, about 60% of HIV-positive adults 
were unaware of their HIV status [54]. In order to increase access to HCT, the Uganda 
Ministry of Health (MoH) recommends the use of a mix of facility- and community-based 
HCT models [55, 56].  
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1.4 Linkage to HIV care in SSA 
Since 2011, four systematic reviews [44, 57-59] have investigated linkage to care after 
HIV testing in SSA. The first review found eight studies [facility-based HCT (5), HBHCT 
(1), mobile HCT (1), and mobile- and facility-based HCT (1)] that reported the proportion 
of patients who enrolled in care after HIV diagnosis [57]. The median proportion of 
patients who enrolled in care after testing HIV-positive was 44% (range: 31%–68%). The 
review also found ten studies [facility-based HCT (9) and mobile HCT (1)] that reported 
the proportion of patients who were assessed for ART eligibility i.e. patients who 
provided samples for CD4 count testing and/or returned for the results following HIV 
diagnosis. The median proportion of patients that completed one or both of these steps 
was 59% (range: 35%-88%). The second review found 19 studies [facility-based HCT 
(16), HBHCT (2), mobile- and facility-based HCT (1)] that had data on the period 
between HIV diagnosis and ART eligibility assessment (WHO clinical staging or CD4 
count testing) [58]. The pooled proportion of patients who completed ART eligibility 
assessment was 57% [95% Confidence Interval (CI), 48%-66%]. The third review found 
six studies (all used facility HCT) that covered the period between HIV diagnosis and 
initiation of ART [59]. The pooled proportion of patients who had a CD4 count measured 
was 72% (95% CI, 60%-84%).  
 
In the fourth review, linkage to care was reported separately for each HCT strategy [44]. 
Facility HCT was divided into: patient-initiated testing i.e. voluntary counselling and 
testing (VCT) and routine HCT that is initiated by a provider i.e. provider-initiated HCT. 
Linkage to care was defined as visiting a clinic for community-based HCT, and returning 
to the clinic to obtain CD4 count results (or enrolling in pre-ART care) for facility HCT. 
Linkage was reported for 31 studies [HBHCT (10), mobile HCT (6), campaign HCT (2), 
facility VCT (8), and facility provider-initiated HCT (5)]: 4 of these studies had been 
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included in the previous reviews. Linkage to care was reported separately for home and 
campaign HCT interventions with facilitated linkage (e.g. follow-up counselling to 
encourage referral uptake) and those where no such strategies were used. Linkage to care 
was highest for home and campaign HCT with facilitated linkage [95%, 95% CI (87–
98%)] and lowest for home and campaign HCT without facilitated linkage [26%, 95% CI 
(18%–36%)]. Linkage to care was low for mobile HCT [37%, 95% CI (24%–51%)] but 
fairly high for facility VCT [61%, 95% CI (48%–72%)] and facility provider-initiated 
HCT [55%, 95% CI (39%–71%)].  
 
In summary, these reviews show that linkage to HIV care in SSA is generally low, that 
facility-based HCT achieves higher linkage to HIV care than community-based HCT, and 
that interventions to facilitate referral uptake could increase linkage to HIV care for HIV-
positive persons identified through community-based HCT.  
 
1.5 Barriers for linkage to HIV care 
Barriers for linkage to care may be at the individual, socio-cultural, programme/health-
facility, and structural levels [60]. Individual-level barriers include fear of stigma [61-
65], non-disclosure of HIV-positive status [35, 61, 65-67], denial of HIV diagnosis [62, 
64, 65, 67], absence of physical symptoms [65, 68], misconceptions about ARVs [64, 65, 
69], and fear of their side effects [65, 69], lack of partner [64, 65, 68] and other social 
support [61, 66, 67, 70], perceived disrespect for patients by HIV care staff [65] and fear 
of possible breach of patient confidentiality [64, 70]. Socio-cultural barriers include 
poverty [60, 64], lack of formal community support networks [60, 64], presence and use 
of alternative medicines [61, 62, 64, 68, 70] and traditional/spiritual healers [64, 71].  
Program/health facility-level barriers include: high transport costs [57, 61, 65, 68], long 
distance [61, 65, 68, 72] to and waiting times at [65, 68] the HIV clinics, inappropriate 
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ART eligibility screening tests [60], and inadequate  supply of ARVs [64, 70]. Structural 
barriers include unintegrated HCT and ART services, absence of robust referral tracking 
mechanisms, and human resource limitations such as shortage of staff, lack of incentives, 
inadequate training, and supervision [60].  
 
1.6 Interventions to improve linkage to HIV care 
A few, mostly observational studies, have evaluated interventions aimed at improving 
linkage to HIV care in SSA [73]. These interventions include: provision of immediate or 
point-of-care (POC) CD4 count testing to decrease time to ART eligibility assessment 
[51, 52, 66, 74-77], home-based ART initiation [78], integration of ART care into 
antenatal services [79], assisted partner notification for index patients with HIV infection 
(this involves elicitation of information about sex partners and contacting them to ensure 
that they test for HIV and link to care) [80], use of peer navigators [66], community 
escorts [62], or lay counsellors [77] to help with the linkage process, provision of funds 
for transportation to the HIV clinic [52, 62, 81], and follow-up counselling to encourage 
referral uptake [74, 75, 77, 82, 83]. 
 
1.7 Rationale for the research 
HBHCT has the potential to increase HIV testing uptake in SSA [18] and may be an 
effective platform for HIV prevention and population-based test-and-treat strategies [84]. 
However, few data are available on linkage to HIV care after HBHCT or on the 
effectiveness of strategies to increase linkage to HIV care for HIV-positive persons 
identified through HBHCT in SSA [73]. Overall, the available evidence shows that 
HBHCT without additional strategies to facilitate referral achieves inadequate linkage to 
HIV care [44, 85-89]; and that such strategies could substantially increase linkage [44, 
74, 75, 77, 90]. However, most of this evidence comes from uncontrolled observational 
studies, not trials. Hence, it is difficult to exclude the possibility of confounding due to 
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differences in levels of stigma, healthcare seeking behaviour, familiarity with the health 
care services, and other factors. Moreover, linkage to care in most of these studies was 
not separately estimated for newly and previously diagnosed HIV-positive individuals, or 
children/adolescents and adults. Linkage outcomes for individuals who have previously 
tested HIV-positive and those that are newly identified through HBHCT have been shown 
to vary substantially [84, 85]. Similarly, linkage to HIV care among children/adolescents 
may be influenced by factors that are unique to this population [91, 92] and has been 
shown to differ from that in adult patients [88]. A further issue is that in some of the 
studies [74, 75, 90], two or more linkage interventions were used concurrently, making it 
difficult to estimate the individual effects of each intervention on linkage to care.  
 
The aim of my PhD was to summarise available data on linkage to HIV care among adults 
(≥18 years) newly identified with HIV through HBHCT in SSA, and to evaluate the 
impact of home-based follow-up counselling on linkage to HIV care among HIV-positive 
adults identified through HBHCT in Uganda. Counselling is an essential component of 
HIV prevention and treatment and may reduce psychosocial barriers of linkage to care 
[65]. For instance, counselling facilitates disclosure of HIV positive status to sexual 
partners [93, 94], friends [94] and family members [73]. In turn, disclosure makes it 
possible for the HIV-positive individual to receive psychosocial support, a key facilitator 
of linkage to HIV care [60]. Follow-up counselling may also be used to provide 
information about ART, locally available HIV care services and encourage linkage to 
care [82]. Moreover, it is a relatively simple strategy that may be delivered through non-
medical personnel [69, 95], an attribute that makes its adoption in low resource settings 
feasible. 
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1.8 Research questions 
 What is the rate of linkage to HIV care achieved by HBHCT in SSA?  
 Does home-based follow-up counselling after HIV diagnosis through HBHCT 
increase linkage to HIV care in Uganda?  
 Does home-based follow-up counselling after HIV diagnosis through HBHCT 
reduce time between HIV diagnosis and linkage to HIV care in Uganda?  
 Does home-based follow-up counselling after HIV diagnosis through HBHCT 
reduce time between HIV diagnosis and receipt of CD4 count results in Uganda?  
 Does home-based follow-up counselling after HIV diagnosis through HBHCT 
reduce time between HIV diagnosis and ART initiation in Uganda?  
 Does home-based follow-up counselling after HIV diagnosis through HBHCT 
increase adherence to cotrimoxazole prophylaxis (CTXp) in Uganda?  
 What are the facilitating factors for and barriers to linkage to HIV care after 
HBHCT in Uganda?  
 Does home-based follow-up counselling increase uptake of repeat HIV testing 
among individuals who test HIV negative through HBHCT?  
 
1.9 Overall aims 
 To document the currently available information on linkage to HIV care in SSA 
among individuals diagnosed as HIV positive through HBHCT. 
 To evaluate the impact of home-based follow-up counselling after HIV diagnosis 
through HBHCT on linkage to HIV care in Uganda. 
 
1.10 Overall objectives 
(i) Using a systematic review;  
 To review the literature on linkage to HIV care after HBHCT in SSA.  
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 (ii) Using an open-label cluster-randomised trial in Masaka, south-western 
Uganda; 
 To determine the effect of follow-up counselling on the proportion of individuals 
linking to HIV care within 6 months of HIV diagnosis through HBHCT.  
 To determine the effect of follow-up counselling on the time to linkage to HIV 
care after HIV diagnosis through HBHCT.  
 To investigate the effect of follow-up counselling on time to obtaining CD4 counts 
after HIV diagnosis through HBHTC.  
 To investigate the effect of follow-up counselling on time to ART initiation after 
HIV diagnosis through HBHTC.  
 To determine the effect of follow-up counselling on adherence to CTXp six 
months after HIV diagnosis through HBHTC. 
 To determine the facilitating factors and barriers associated with linkage to HIV 
care.  
 To determine the effect of follow-up counselling on the uptake of repeat HIV 
testing among HIV negative individuals six months after HBHTC.  
 
1.11 Thesis structure 
This thesis follows the ‘research paper’ style format. Chapter 1 provides background 
information, chapter 2 describes the general methods, and chapters 3-6 comprise 
manuscripts that have been published in or submitted to peer-reviewed journals. The 
manuscripts are:  
 Linkage to HIV care after home-based HIV counselling and testing in SSA: A 
systematic review (submitted; received reviewers’ comments and preparing a 
response)  
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 An open-label cluster randomised trial to evaluate the effectiveness of a 
counselling intervention on linkage to care among HIV-infected patients in 
Uganda: Study design (published) 
 Brief counselling after home-based HIV counselling and testing strongly 
increases linkage to care: a cluster-randomised trial in Uganda (submitted) 
 Factors associated with uptake of home-based HIV counselling and testing and 
access to HIV care services among identified HIV-positive persons in Masaka, 
Uganda (submitted) 
 
Chapter 7 gives a summary of the main findings, methodological strengths and challenges 
of this research, other ongoing and planned studies that are related to this work, and 
concluding remarks. The analysis plan, data collection tools, study monitor’s report, and 
ethics approvals are provided in the appendices.  
 
1.12 Role of the candidate 
I developed the systematic review protocol under the guidance of Ms Kathy Baisley (KB) 
and Professor Heiner Grosskurth (HG). I performed the database search, screened the 
abstracts, and extracted data from the eligible studies. Dr. Samuel Biraro, a clinical 
epidemiologist and staff member of the Medical Research Council/Uganda Virus 
Research Institute (MRC/UVRI) Uganda research Unit on AIDS with experience in HIV 
epidemiology and HIV intervention research; and experience with systematic reviews, 
was the second independent reviewer. For papers that suggested that unpublished data 
relevant to the review may be available, I corresponded with the authors of the original 
papers, incorporated additional data in the review and obtained final approval from 
authors (who all agreed to become part of a ‘working group’ that I coordinated). 
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I developed the research concept for the trial. I wrote the study protocol and revised it 
after receiving input from KB, HG, and Dr. Anatoli Kamali (AK). I obtained the 
necessary ethical approvals, recruited and trained study staff, secured the collaboration of 
HIV care providers and community leaders, supervised mapping of the study area and 
defined the study clusters, and organised and supervised randomisation of the clusters. I 
developed the study tools, supervised data collection and entry, and was responsible for 
data management. I requested and obtained co-funding from the international AIDS 
Vaccine Initiative (IAVI) and the London School of Hygiene & Tropical Medicine 
(LSHTM) for HIV and CD4 count test expenditures. 
 
I developed the data analysis plan (Appendix 1) with input from KB, HG, and Professor 
Richard Hayes. I performed the analyses under KB’s and HG’s supervision. I wrote the 
manuscripts arising from the above work, incorporated feedback from my supervisors 
and other co-authors, and submitted the final drafts for publication as corresponding 
author. For the papers that have already been published or reviewed at the time of thesis 
submission, I revised the manuscripts and responded to reviewers’ comments.  
 
1.13 Funding 
This PhD research was jointly funded by the UK Medical Research Council (MRC) and 
the UK Department for International Development (DFID) under the MRC/DFID 
Concordat agreement and is also part of the Second European & Developing Countries 
Clinical Trials Partnership (EDCTP2) programme supported by the European Union. The 
field work was co-funded by IAVI and LSHTM. The funds were provided through the 
training budget of the MRC/UVRI Uganda Research Unit on AIDS. 
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Chapter 2: General methods  
 
2.1 Introduction  
Two studies were conducted in order to achieve the objectives of this PhD:  
1) A systematic review  
 To document the currently available information on linkage to HIV care in SSA 
among adult (≥18 years) individuals newly diagnosed with HIV infection 
through HBHCT 
 
2) An open-label cluster randomised controlled trial  
 To evaluate the impact of home-based follow-up counselling after HIV diagnosis 
through HBHCT on linkage to HIV care in Masaka south-western Uganda 
 
The studies are described briefly in this chapter, and in detail in subsequent chapters.  
 
2.2 Systematic review  
Five databases (Medline, Embase, Global Health, Web of Science, and Africa-Wide 
information) were searched for studies published between 1st January 2000 and 19th 
August 2016 using combined terms for “HIV”, “voluntary counselling and testing”, 
“home-based”, “mobile”, “community”, “door-to-door”, “survey”, “linkage”, “pre-
ART” and “Africa or individual names of countries in SSA”. Abstracts were screened 
and all potentially eligible papers subjected to full text screening. Studies were included 
if they were conducted in SSA and had original data on linkage to care among adults 
(≥18 years) newly identified with HIV infection through HBHCT. Data from eligible 
papers were extracted using a data extraction form. Studies for which the required 
information was not published but might have been collected were identified and 
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corresponding authors asked to share these data, if available. Risk of bias in the 
included studies was assessed on three items i.e. selection bias, outcome ascertainment, 
and attrition, based on the recommendations of the Cochrane Collaboration [1]. The 
results were summarised using the PRISMA guidelines [2]. A meta-analysis was not 
performed because the studies identified varied widely with regard to design, setting, 
and definitions of, time points for assessing, method used to ascertain, and strategies to 
facilitate linkage to care. 
 
2.3 Open-label cluster randomised controlled trial  
The primary objectives of the trial were:  
1) To determine the effect of home-based follow-up counselling on the proportion 
of individuals linking to HIV care within 6 months of HIV diagnosis through 
HBHCT.  
2) To determine the effect of home-based follow-up counselling on the time to 
linkage to HIV care after HIV diagnosis through HBHCT.  
 
2.3.1 Study design 
The study was a cluster randomised controlled trial of referral to HIV care and follow-
up counselling (14 clusters) compared to referral to HIV care only (14 clusters), for 
participants diagnosed as HIV-positive through HBHCT (Table 1) .  
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Table 1: Study design 
 Enrolment Month 1 Month 2 Month 6 
Intervention 
(14 clusters)  
HBHCT + 
referral for 
care  
Home-based  
follow-up  
counselling 
Home-based 
follow-up  
counselling 
Outcome assessments:  
 Linkage to HIV care  
 Adherence to CTXp  
 Receipt of CD4 count results 
 ART initiation 
 Uptake of repeat HCT 
Control  
(14 clusters) 
HBHCT + 
referral for 
care   
Outcome assessments:  
 Linkage to HIV care  
 Adherence to CTXp  
 Receipt of CD4 count results 
 ART initiation 
 Uptake of repeat HCT 
 
At enrolment, participants in the control arm received HBHCT (pre-test counseling, 
rapid HIV testing, post-test counselling and HIV test results) and a written referral for 
HIV care. Participants in the intervention arm received home-based follow-up 
counselling at 1 and 2 months after enrolment in addition to HBHCT and written 
referral. Study outcomes were assessed 6 months after enrolment in both study arms.  
 
2.3.2 Study setting 
The study was conducted in 3 rural subcounties of Masaka, a district in south-western 
Uganda (Figure 1). The district has 6 rural (Mukungwe, Bukakata, Buwunga, 
Kyanamukaaka, Kabonera, Kyesiiga) and 3 urban (Nyendo-Ssenyange, Katwe-Butego, 
Kimanya-Kyabakuza) sub-counties (Figure 2). The sub-counties are further divided into 
39 parishes and 352 villages [3]. The urban sub-counties together constitute the 
municipaility of Masaka, a town located approximately 140 kilometres to the southwest 
of Kampala, Uganda’s capital. The district has a total population of 297,004 [4].  
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HIV prevalence  
Surveys in Masaka district have consistently reported a high adult HIV prevalence. 
General population surveys conducted in 1994 [5] and 2004 [6] found a HIV prevalence 
of 10% and 11% respectively. In a 2011 national AIDS indicator survey, the district was 
surveyed jointly with 10 other districts that have similar language and cultural 
characteristics; this regional group had the highest HIV prevalence in the country at 
11% [7]. HIV prevalence is higher in some sub-populations. For instance, a 2009 survey 
among persons aged ≥13 years in fishing communities found an HIV prevalence of 24% 
[8]. 
 
HIV care services  
The major ART care providers in the district are Uganda Cares, a partnership between 
the AIDS Healthcare Foundation (USA) and the Uganda MoH; and The AIDS Support 
organisation (TASO), a private not-for-profit (PNFP) organisation; both are located 
within Masaka Regional Referral Hospital in Masaka municipality. Other providers 
include Kitovu hospital, a PNFP facility also located in the municipality and eight lower 
level government (6) and PNFP (2) health centres located in four of the six rural sub-
counties.  
 
The minimum care package for HIV-positive persons in Uganda includes: clinical 
evaluation and monitoring of HIV disease; ART; daily CTXp for life; screening, 
prevention, and management of HIV-related co-infections and comorbidities; sexual and 
reproductive health services; nutritional services; and psychosocial support and 
palliative care [9, 10]. At the time of the study, ART was recommended for all HIV-
positive individuals with CD4 <500 cells/mm3; and those who were co-infected with 
tuberculosis or hepatitis B, pregnant, breastfeeding, categorised as most-at-risk persons, 
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and partners in sero-discordant couples irrespective of WHO clinical stage or CD4 
count [11].  
 
 
 
 
Figure 1: Map of Uganda showing location of Masaka district1 
                                                 
1 Source: MRC/UVRI Uganda Research Unit on AIDS 
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Figure 2: Masaka district map showing the subcounties and parishes2 
                                                 
2Source: Uganda Bureau of Statistics 
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Research facilities and staff 
The study was based at the MRC/UVRI Unit’s clinical research site in Masaka 
municipality (Figure 3). The site has administrative, clinical, counselling, community 
liaison, laboratory, and data management staff and facilities. The study team comprised 
13 counsellors, 3 community mobilisers, 1 driver, 3 data entry staff, 1 community 
liaisons officer, and myself. I coordinated all the study activities.  
 
 
Figure 3: A clinic facility at MRC/UVRI Masaka 
 
2.3.3 Study population 
The study population comprised HIV-positive adults identified through HBHCT in 
Mukungwe, Buwunga, and Kyanamukaka, 3 of the 6 rural sub-counties in the district. 
These sub-counties were selected because of their proximity to the MRC/UVRI research 
facility.  
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HIV-negative individuals were also recruited from each randomised community 
primarily to reduce the possibility of revealing the sero-status of HIV-positive (main 
study) participants. However, this opportunity was used to investigate whether follow-
up counselling increases the uptake of repeat testing among HIV-negative individuals.  
 
Participant eligibility criteria 
 
HIV-positive participants  
 
Inclusion criteria 
1. HIV-positive adult (≥18 years)  
2. Willing to provide informed consent 
3. Willing to receive follow-up counselling at home 
 
Exclusion criteria 
1. Previous or current receipt of HIV care  
2. On-going participation in other health-related research  
3. Planning to change residence within the next 6 months  
4. Inability to give informed consent e.g. due to an on-going psychiatric illness 
 
HIV-negative participants 
 
Inclusion criteria 
1. HIV negative adult (≥18 years) 
2. Willing to provide informed consent 
3. Willing to receive follow-up counselling at home 
42
 
 
Exclusion criteria 
1. Planning to change residence in the next 6 months  
2. Inability to give informed consent e.g. due to on-going psychiatric illness 
 
2.3.4 Identification of clusters 
All villages (n=158) in the study area were mapped (Figure 2) and all resident adults 
(≥18 years) in each village enumerated. To ensure a reasonable number of eligible 
participants in each cluster, I combined small (<400 adults) villages with adjacent 
villages into larger clusters of at least 400 adults. The number of villages combined to 
form larger clusters ranged from 2 to 4. Therefore, a cluster was defined as a village or a 
set of villages with at least 400 adults. Clusters were separated by a buffer zone of at 
least one non-participating village to minimise the risk of contamination.  
 
2.3.5 Sample size assumptions  
The sample size was calculated to ensure adequate power to address the hypothesis that 
follow-up counselling would increase the proportion of individuals that link to care. 
Based on previous studies in the area [6, 7], I assumed an adult HIV prevalence of 10%. 
The 2011 Uganda national HIV sero-prevalence survey (in which Masaka district 
participated) found that 60% of HIV-positive adults were unaware of their HIV status 
and therefore not in care [7]. However, anticipating an increase in HCT coverage since 
the survey, I adjusted this figure to 40%. Based on these figures and the population 
estimates from the mapping data, the estimated harmonic mean number of available 
study participants in a cluster was 21. Assuming that 10% of the potential participants 
would be ineligible or refuse to participate, and that a further 10% would be lost to 
follow-up, the harmonic mean number of individuals that was expected to be available 
for enrolment and completion of the study in each cluster was 17.  
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Across clusters, I assumed a coefficient of variation, k, of 0.25. This was based on past 
studies of linkage to HIV care [12-14] that were conducted in settings similar to Masaka 
in which k ranged from 0.12 to 0.33 (Table 2).  
 
Table 2: Coefficient of variation values for settings similar to Masaka3 
Study Country, setting Type of study Outcome 
Time of 
evaluation 
(months) k 
Study 1 [12] 
 
Kenya, 6 rural 
communities 
 
Community-
based HCT Clinic attendance 
3 0.33 
10  0.18 
Study 2 [13] 
Uganda, 15 peri-
urban villages  HBHCT Clinic attendance  3  0.13 
Study 3 [14] 
Uganda, 25 rural 
villages HIV sero-survey 
Screening for 
ART  24 0.12 
 
Table 3 shows estimates for the power of the study at the 5% significance level for 
different sample sizes, k values, and levels of linkage. From the different possible 
scenarios in Table 3, I chose the scenario with a linkage of 35% in the control arm based 
on findings from studies in which no additional strategies had been used to facilitate 
linkage to care after HBHCT [15-18]. The estimated intervention effect was based on 
findings from observational studies that had used follow-up counselling to facilitate 
linkage to care after HBHCT [13, 19-21]. With a sample of 22 clusters (11 per arm) and 
a harmonic mean of 17 participants expected to complete the study in each cluster, the 
study was assumed to have 90% power to detect an increase in linkage to care from 
35% in the control arm to 60% in the intervention arm at a significance level of 0.05. 
This sample size would also give 95% power to detect a hazard ratio of 1.7 for the effect 
of the intervention on time to linkage, or 80% power to detect a hazard ratio of 1.5. 
                                                 
3
Data for estimation of k was kindly provided by Abigail M. Hatcher (study 1), Connie Celum (study 2), 
and Kathy Baisley (study 3).  
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After completing enrolment in the first seven clusters, I observed that 12% (419/3546) 
of registered resident adults from the mapping exercise were not found at home and 
could not be contacted in spite of repeated attempts. Of those found at home, 11% 
(358/3127) declined to have HBHCT. Furthermore, among HIV positive persons, there 
was a higher than expected level of engagement in HIV care: only 26% (75/294) of 
those who tested positive in HBHCT were not in care. As a result, the number of 
participants enrolled per cluster was much lower (harmonic mean <10) than anticipated. 
Based on these preliminary findings, the number of clusters was increased to 28 (14 per 
arm) with an expected harmonic mean of 7 participants completing the study in each 
cluster; this would allow for detection of the same difference in proportions with a 
power of 83%, or a hazard ratio of 1.7 with a power of 85%. 
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 2.3.6 Preparatory activities  
Preparatory activities included mapping of the study area, community mobilisation, 
discussion of the study with the MRC/UVRI Masaka site community advisory board 
(CAB) (Figure 4), staff recruitment and training, and meetings with HIV care providers 
to establish procedures for tracking of study participants and verification of reported 
linkage.  
 
Figure 4: Discussing the study with the MRC/UVRI Masaka CAB members 
 
2.3.7 Randomisation  
Randomisation was stratified on distance (≤10 km or >10 km) and on cluster make-up, 
i.e. whether the cluster was composed of a single large village or several small villages. 
Restricted randomisation was then used to achieve balance on the following cluster-
level characteristics: cluster size; presence of a trading centre; location along a major 
road; lakeshore location; and presence of an HIV clinic within 5 km. The tolerance 
thresholds for balance were defined through an iterative process in which different 
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 thresholds were tried and the number and the validity of all acceptable allocations 
examined. Of the 70,560 possible allocations under the stratified design, 28,932 (41%) 
were found to satisfy the additional balance criteria. Of these, a list of 1000 allocations 
was randomly generated from which one allocation was selected at a public 
randomisation ceremony. Each allocation had a unique running number. 
 
Public randomisation ceremony  
  
The randomisation ceremony was held on 13th March 2015 and attended by 1-2 leaders 
from each of the villages. Three sacks each containing 10 balls labelled 0 to 9 were 
prepared, representing allocations 001 to 999, and 000 representing 1000. The 
principles underlying the random selection procedure were carefully explained in simple 
words (Figure 5). Three community leaders, selected by their peers, were then invited 
and one after the other asked to draw one ball from one sack (3 balls total) thus 
generating a 3-digit number (Figure 6). This number corresponded to a running number 
on the list and thus indicated the selected allocation.  
 
The six clusters added later were treated as a separate stratum. Possible allocations for 
these clusters were generated using the same procedure described above and one 
allocation selected at a second public randomization ceremony on 30th June 2015.  
49
  
Figure 5: Explaining the randomisation procedure to community leaders 
 
Figure 6: Three community leaders display the selected allocation at a randomisation ceremony 
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 2.3.8 Follow-up counselling intervention  
 
Development of the intervention 
Development of the intervention was based on: i) published evidence indicating that 
psychosocial factors are common barriers of linkage to HIV care in SSA [12, 18, 22-
30], that counselling can reduce the effects of these barriers [26, 31-35] and may 
increase linkage to care [13, 20, 21]; ii) anecdotal evidence from the same population – 
obtained through discussions with counsellors at the MRC/UVRI-Masaka research site 
– suggesting that psychosocial factors such as fear of stigma, denial of HIV-positive 
status, and lack of information about HIV and HIV care services were common reasons 
for not linking to care among HIV-positive persons identified through previous HCT 
programmes in Masaka.   
 
In keeping with previous studies that have used counselling to promote linkage to care 
[13, 20, 21, 36], intervention counselling sessions in this study were conducted at one 
and two months after HBHCT and referral for care. The sessions were conducted at 
participants’ homes; each lasted approximately 45 minutes.   
 
Barriers targeted by the intervention 
The intervention targeted previously identified individual psychosocial barriers of 
linkage to care such as fear of stigma [22-26], non-disclosure of HIV-positive status 
[12, 18, 22, 26, 27], denial of HIV diagnosis [18, 23, 25, 26], absence of physical 
symptoms [26, 28], misconceptions about ARVs [25, 26, 29] and fear of their side 
effects [26, 29], belief in spiritual healing [26] and/or use of alternative medicines [22, 
23, 25, 28, 30], lack of partner [25, 26, 28] and other social support [12, 18, 22, 30], 
perceived disrespect for patients by HIV care staff [26] and fear of possible breach of 
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 patient confidentiality [25, 30]. The intervention did not target barriers related to 
program-level factors such as access to care [22, 26, 28, 37], availability of care 
services, and quality of care [26, 28]; socio-cultural factors such as social norms, 
poverty, and lack of formal community support networks [25, 31]; or structural factors 
such as HIV care policies [31], health systems [31], and socio-economic environment 
[31].  
 
Content of the intervention 
The counselling sessions covered the following general issues: acceptance of HIV 
diagnosis, fear of or experience of stigma, plans to seek HIV care and support services, 
importance of HIV status disclosure and availability of psychosocial support for linkage 
to and retention in care; and information about decentralised locally available HIV care 
services, ARV medication, and the rationale for early linkage to and retention in care. 
The sessions were also used to address specific issues e.g. family or marital discord 
arising after disclosure of HIV status, occurrence of adverse effects following initiation 
of CTXp and/or ART etc. Any issues identified in the first session were followed up in 
the second session.  
 
Staff training 
The intervention was delivered by counsellors who did not have medical training but 
were trained in HCT. The counsellors comprised existing MRC/UVRI staff with 
experience working in Masaka district as well as new staff that were specifically 
recruited to work on the study; all had at least one year’s experience in conducting 
community-based HCT including HBHCT. Specific training on the intervention was 
conducted in the 4 weeks prior to study initiation. Prior to the training, study 
counsellors were asked to read the study protocol in order to get a basic understanding 
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 of the study background, rationale, and objectives. The training was conducted using 
two approaches: i) one group seminar attended by all counsellors that comprised a 
didactic 30-minute presentation and 60-minute session to discuss any issues that weren’t 
clear in the protocol or the presentation; ii) a single 30-minute one-on-one session with 
each of the counsellors. The one-on-one sessions were conducted within 1-2 weeks of 
the group seminar. These sessions were used to go over the main points in the group 
presentation and discuss any remaining concerns that the individual counsellors may 
have had.   
 
Maintaining fidelity of the intervention  
To ensure that the intervention was delivered as intended and as consistently as 
possible, counsellors were provided with a list of the counselling content that they could 
refer to during the counselling sessions. In addition, counsellors made written notes 
summarising the issues discussed in each counselling session. I reviewed the 
counselling notes at least twice every week during the trial and followed up any 
omissions or deviations with the individual counsellors.  
 
Choice of time point for assessing intervention effect 
The effect of the intervention on linkage to care was assessed 4 months after the second 
counselling visit (6 months after HBHCT and referral). This time point was chosen 
because: i) funding was limited and could not allow for a longer period of follow-up; ii) 
it would allow for the assessment of the intervention effect on post-linkage outcomes 
i.e. ART initiation and adherence to CTXp; and iii) it would enable comparisons with 
other studies that used the 6 month time point to assess linkage.  
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 2.3.9 Study procedures 
 
Screening and enrolment procedures 
 
HCT 
HCT was the first step in the screening process. Counsellors visited households in the 
randomised villages, enumerated all residents aged ≥18 years using a household data 
collection form (Appendix 2), and offered HBHCT to those present. Households where 
some or all adults were not at home at the initial counsellor visit were revisited two 
more times. HCT was conducted in accordance with the national guidelines [38]. Pre-
test counselling covered the following: benefits of HCT, the testing process, possible 
results, HIV risk assessment, HIV prevention, importance of disclosure, referral, and 
linkage to care. Participants were given an opportunity to ask questions and discuss any 
issues of concern before testing. Finger-prick blood specimens were obtained and 
screened using the Alere Determine HIV-1/HIV-2 rapid test kit (Alere Medical, Japan). 
Individuals whose samples tested negative on the screening test were given HIV 
negative results. Samples that tested positive were subjected to confirmatory testing 
using Stat-Pak HIV 1/2 (Chembio Diagnostic systems, USA). Individuals whose 
samples tested positive on the confirmatory test were given HIV positive results. 
Samples with discordant screening and confirmatory test results were further tested with 
Uni-Gold HIV 1/2 (Trinity Biotech, Ireland) as tie-breaker. The Uni-Gold HIV 1/2 test 
result was issued as the final result. Post-test counselling included assessment of 
readiness to receive test result, communication of result, assessment of the individual’s 
understanding of the result, a discussion on risk reduction strategies, partner notification 
and testing, disclosure plans, available HIV care services, and referral plans. HCT was 
conducted separately for each individual. However, married/cohabiting individuals had 
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 the option of receiving HCT as a couple. On average, 30 minutes were required for each 
HCT session and an extra 15 minutes for completion of study procedures. Details of 
persons accepting HCT including the results were recorded on a HCT worksheet 
(Appendix 3). 
 
Informed consent and participant recruitment  
Individuals who tested HIV-positive were provided detailed information about the study 
using an informed consent document (see Appendices 4-7 for English and Luganda 
versions of the informed documents used in the study). If an individual was illiterate, 
the counsellor read the document to them in the presence of a literate impartial witness. 
An opportunity was given for the individual to consider the information, ask questions, 
and discuss any issues before consenting to participate. Individuals indicated their 
consent to participate by signing/marking the consent form. Consenting individuals 
were assessed for eligibility using the eligibility assessment form (Appendix 8) and 
those meeting the eligibility criteria assigned a study number and enrolled. HIV-positive 
persons who were excluded from the study for any reason were documented and 
referred for care as necessary.  
 
Recruitment of HIV-negative participants 
Once 3 HIV-positive participants were enrolled, the next person that tested HIV 
negative was also invited to join the study after consenting and satisfying the study 
eligibility criteria. This procedure was repeated until all households in the randomised 
villages were visited.  
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 Collection of sociodemographic data 
A counsellor-administered questionnaire (Appendix 9) was used to collect data on sex, 
age, marital status, occupation, education, religion, house-hold characteristics including 
ownership of specified items by household members, travel time to the nearest HIV 
clinic, HCT history, knowledge of own, and partner’s HIV status. A locator form 
(Appendix 10) was used to collect detailed locator information from each enrolled 
participant.  
 
Referral for HIV care  
All individuals identified as HIV-positive and not in care were referred to their 
preferred HIV clinic for care. Two referral forms (Appendix 11) were completed for 
each referral; one was provided to the participant to take to the HIV clinic and the other 
kept in a central file at the MRC/UVRI Masaka site.  
 
Follow-up procedures 
 
Home-based follow-up counselling (intervention)  
At 1 and 2 months after HIV diagnosis, counsellors visited all participants in the 
intervention arm to conduct follow-up counselling. Participants not found at home were 
revisited at least two more times.  
 
Content of counselling (HIV-positive participants)  
 Developments since HIV diagnosis including the individual’s acceptance of HIV-
positive status, experience of stigmatisation, plans to seek HIV care and support 
services.  
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  The significance of disclosing ones HIV status to friends and/or family and the 
importance of obtaining psychosocial support for linkage to and retention in HIV 
care.  
 Information about local HIV care services, ARVs, pre-ART and ART care  
 The importance of regular HIV clinic attendance following linkage to HIV care 
 
Content of counselling (HIV-negative participants)  
 Information on HIV risk reduction strategies 
 The importance of regular HIV HCT  
 
Each follow-up counselling session lasted approximately 45 minutes. 
 
Collection of linkage to HIV care data  
The linkage status questionnaire (Appendix 12) was administered at the month-6 visit. 
Data was collected on whether or not the participant had linked to care, HIV clinic name 
and address, participant’s clinic registration number, and dates of linkage, obtaining 
CD4 counts and ART initiation. Data was also collected on participants’ knowledge of: 
HIV-positive status prior to enrolment to confirm responses obtained at the enrolment 
visit; any fellow participants in neighboring villages they may have heard of, and if they 
had discussed the study with these individuals. This information was used to assess the 
possibility and extent of contamination between trial arms. Approximately 30 minutes 
was required to administer the questionnaire.  
 
Measurement of adherence to CTXp 
At month 6, participants were also asked if they had initiated CTXp and if so, if they 
had missed any doses, reasons for missed doses, and number of doses missed in the past 
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 month. Participants were categorised as ‘adherers’ and ‘non-adherers’, using an intake 
of >80% of prescribed pills as threshold.  
 
CD4 count testing 
CD4 count test results for participants that linked to care were obtained from the HIV 
clinics. Participants who had not undergone a CD4 count test despite linking to care as 
well as those that had not linked to care were offered CD4 count testing by study staff at 
the month 6 visit. In this case, about 5ml of venous blood was collected at participants’ 
homes and transported to the MRC/UVRI-Masaka laboratory for testing. Results were 
recorded on the CD4 count & repeat HIV test form (Appendix 13) and delivered to 
participants’ homes within one week.  
 
Repeat HIV testing 
Repeat HIV testing was offered to HIV-negative participants in both trial arms at the 
month-6 visit. Venous samples were obtained and transported to the MRC/UVRI-
Masaka laboratory where repeat HIV testing was conducted. The results were recorded 
on the CD4 count & repeat HIV test form (Appendix 13) and the results delivered to 
participants’ homes within one week. At this occasion, laboratory HIV testing was 
preferred over rapid testing in participants’ homes in order to avoid unmasking the HIV-
positive status of participants who provided venous samples for CD4 count testing at 
this visit. 
 
Status of participants during follow-up 
At each visit following enrolment, a follow-up visit form (Appendix 14) was completed 
to document if the participant had completed the visit and if not, whether they had 
refused follow-up, were not contacted, or had died.  
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Referral tracking and confirmation of linkage to care 
Referrals were tracked for all participants who self-reported linking to care. A 
counsellor visited the HIV clinic that the participant had reported attending at the month 
6 visit, and with the help of the staff at the HIV clinic used information provided by the 
participant (e.g. names, unique clinic-assigned registration numbers) and referral forms 
to identify participant’s clinic records. Once the participant’s clinic records were 
positively identified, clinic documents e.g. pre-ART, ART registers, and individual files 
were examined and the following data recorded on a medical records questionnaire 
(Appendix 15): details (including dates) of initial registration with and subsequent visits 
to the provider, clinical staging, CD4 count testing history and results, CTXp and ART 
initiation.  
 
Figures 7-12 depict a follow-up meeting between a participant and the counselor to 
establish whether the participant linked to care and the documentation examined by the 
counselor at the participant’s home, and at the HIV clinic to confirm linkage. 
Participants for whom linkage was not confirmed were revisited and interviewed about 
any discrepancies.  
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Figure 7: A notebook retrieved from a participant at a follow-up visit with documentation of the 
care that he is receiving from an HIV clinic (note the unique patient registration number) 
 
 
Figure 8: A study counsellor examines a participant’s HIV care documentation during a home 
follow-up visit 
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Figure 9: Prescription for ARVs, cotrimoxazole (CTX) and other drugs as recorded in the 
participant’s notebook 
 
 
Figure 10: Baseline CD4 count and other clinical observations as recorded in the participant’s 
notebook. 
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Figure 11: Participant’s HIV clinic file (note the unique patient registration number) 
 
 
Figure 12: A study referral form retrieved from a participant’s file at one of the HIV clinics 
 
2.3.10 Data management and analysis 
Data were collected using paper-based questionnaires. Before data entry, questionnaires 
were checked for completeness, logical consistency, and entry. Data were double-
entered and validated in Microsoft Access. Checks were run on the entered data every 
fortnight and queries sent to the study field team for resolution. Data corrections arising 
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 from these queries were submitted for entry and the process repeated until no more 
queries were generated. A detailed description of the methods used for analysis is 
provided in the analysis plan (Appendix 1) and the manuscript addressing the main trial 
objectives (chapter 5).  
 
2.3.11 Study management  
I was responsible for the overall conduct of the trial. A study working group comprising 
of the lead counsellor, community liaisons officer, and myself met weekly to review the 
progress of the trial, plan community mobilisation activities, and address study related 
issues. The trial was monitored by an internal MRC/UVRI study monitor. The 
monitor’s report is included in appendix 16. Dr. Anatoli Kamali, the MRC/UVRI based 
associate supervisor provided additional oversight for the trial. 
 
2.3.12 Ethical considerations  
The trial was approved by the Ethics Committee of UVRI (reference number 
GC/127/14/12/491) (Appendix 17), the Ethics Committee of LSHTM (reference 
number 8833) (Appendices 18 & 19), and the Uganda National Council for Science and 
Technology (reference number HS 1732) (Appendix 20). Written informed consent 
(including consent to track referrals and review medical records for persons who link to 
care) was obtained from each participant prior to conduct of study procedures. The trial 
was registered at ClinicalTrials.gov (NCT02497456).  
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Abstract 
 
Objective: To systematically review the literature on linkage to care among adults newly 
identified with HIV infection through home-based HIV counselling and testing (HBHCT) 
in sub-Saharan Africa (SSA).  
 
Methods: Five databases were searched for studies published between 1st January 2000 
and 19th August 2016. Eligible studies were reviewed, assessed for risk of bias and 
findings summarised using the PRISMA guidelines.  
 
Results: Fourteen studies from six countries met the eligibility criteria. Nine studies used 
specific strategies (point-of-care CD4 count testing, follow-up counselling, provision of 
transport funds to clinic, and counsellor-facilitated clinic linkage) in addition to routine 
referral to facilitate linkage to care. Time intervals for ascertaining linkage ranged from 
one week to twelve months post-HBHCT. Linkage to care ranged from 8.2% (95% CI, 
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6.8%-8.8%) to 99.1% (95% CI, 96.9%-99.9%). Linkage to care was generally lower 
(<33%) if HBHCT was followed by referral only, and higher (>80%) if additional 
strategies were used. Only one study assessed linkage to care by means of a randomised 
trial. Five studies had data on cotrimoxazole (CTX) prophylaxis and twelve on ART 
eligibility and initiation. CTX uptake among those eligible ranged from 0% to 100%. The 
proportion of persons eligible for ART ranged from 16.5% (95% CI, 12.1-21.8) to 77.8% 
(95% CI, 40.0-97.2). ART initiation among those eligible ranged from 14.3% (95% CI, 
0.36%-57.9%) to 94.9% (95% CI, 91.3%-97.4%). Additional linkage strategies, whilst 
seeming to increase linkage to care, were not associated with higher uptake of CTX and/or 
ART. Most of the studies were susceptible to risk of outcome ascertainment bias. A 
pooled analysis was not performed because of heterogeneity across studies with regard to 
design, setting, and the key variable definitions.  
 
Conclusion: Only few studies from SSA investigated the proportion of patients linking 
to HIV care among adults newly diagnosed with HIV through HBHCT. Linkage to care 
was often low after routine referral but higher if additional interventions were used to 
facilitate it. The effectiveness of promising linkage strategies should be confirmed 
through randomised controlled trials.  
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Introduction 
Access to antiretroviral therapy (ART) in sub-Saharan Africa (SSA) has expanded 
considerably but AIDS-related mortality remains high1. A major cause of this mortality 
is the late presentation of patients for treatment2. Early ART initiation is dependent on 
early HIV diagnosis, and prompt linkage to and retention in care3. HIV counselling and 
testing (HCT) is essential in expanding HIV prevention and treatment services4. 
However, HCT uptake in SSA remains low5. For instance, the proportion of HIV-positive 
adults in SSA who are aware of their HIV status has been estimated to be only 60%6. In 
order to expand access to HIV testing in settings with generalised HIV epidemics, WHO 
recommends community-based HCT with linkage to prevention, care and treatment 
services, in addition to facility-initiated HCT7. 
 
Home-based HIV counselling and testing (HBHCT) is highly acceptable and has the 
potential to substantially increase HIV testing uptake in SSA8. It is cost-effective at 
reaching previously untested persons compared with other HCT models9, promotes 
equitable access of services10 and may help to promote HCT among couples11 and 
prevention of mother-to-child HIV transmission12. Importantly, HBHCT facilitates early 
HIV diagnosis and therefore provides an opportunity for early linkage to care12. These 
attributes highlight the potential of HBHCT as an effective platform for HIV prevention 
and population-based test-and-treat strategies. Despite these advantages, few data are 
available on linkage to care after HBHCT particularly among newly identified HIV-
positive persons or on the effectiveness of strategies to increase linkage after HCT13. In 
order to identify effective linkage strategies, data are specifically required on linkage to 
care soon (e.g. within a year) after HBHCT. The reasons for this include the current WHO 
recommendation to initiate ART among all HIV-positive adults regardless of WHO 
clinical stage and at any CD4 count; increasing use of HBHCT in Africa; and growing 
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importance of early treatment for improved clinical outcomes and HIV prevention. A 
recent systematic review on linkage to care following community- and facility-based 
HCT14 included ten HBHCT studies, but did not distinguish linkage outcomes between 
newly and previously diagnosed HIV-positive individuals, or between 
children/adolescents and adults. Individuals who previously tested HIV-positive and have 
not yet linked to care are likely to differ from newly identified patients with regard to 
barriers that may prevent service uptake15. Similarly linkage to care among 
children/adolescents may be influenced by factors that are unique to this population16,17.  
 
The specific objectives of our review were to: estimate the proportion of individuals in 
SSA linking to care [i.e. the people who registered (reported or confirmed) with an HIV 
care provider] within 12 months among those who were newly diagnosed with HIV; the 
proportion initiating daily cotrimoxazole (CTX) prophylaxis (i.e. the people who initiated 
daily CTX prophylaxis among those who linked to care and were eligible for CTX); and 
the proportion initiating ART (i.e. the people who initiated ART among those who linked 
to care and were eligible for ART); and to summarise data on the strategies that have been 
used to increase linkage to care after HBHCT.  
 
Methods 
Search strategy 
We searched five databases (Medline, Embase, Global Health, Web of Science, and 
Africa-Wide information) for studies published between 1st January 2000 (time at which 
roll-out of ART programmes began in SSA8) and 19th August 2016. The following key 
terms were used: (HIV diagnosis OR HIV voluntary counselling and testing OR HIV 
testing and counselling OR HIV counselling and testing) AND (home based OR mobile 
OR community OR household OR door-to-door OR survey) AND (linkage OR access 
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OR uptake OR enrolment OR non-enrolment OR retention OR loss to follow-up OR loss 
to care OR care OR treatment OR pre- antiretroviral therapy) AND (Africa OR individual 
names of countries in SSA). No language restriction was applied to the literature search. 
Identified articles were exported using Endnote reference management software and 
duplicates removed. Two authors (ER and SB) independently screened titles and abstracts 
of articles to identify eligible publications, discussed inconsistencies, and reached a 
consensus on their eligibility. Studies were eligible if they were conducted in SSA, and 
had original data on linkage to care among adults (≥18 years) newly identified with HIV 
infection through HBHCT. Studies whose study populations included persons <18 years 
were eligible but only data for participants aged ≥18 years were utilised for this review. 
Studies for which the required information was not published but might have been 
collected were identified and the corresponding authors approached with requests for 
additional data. Where two or more eligible articles reported on similar or overlapping 
populations, the article with the most complete data was included. Review articles were 
excluded but their bibliographies as well as those of the identified articles were manually 
checked to identify any additional studies. Conference abstracts were excluded. All 
potentially eligible papers were then subjected to full text screening.  
 
Data extraction and synthesis 
A data extraction form was used to collect the following information from each eligible 
article: first author’s name, publication year, country and setting where study was 
conducted, study population, sample size, study design, definition of linkage to care, 
strategies used to promote and time for evaluation of linkage to care. We also obtained 
the number of HIV-positive adults who were newly diagnosed, and, among those, the 
numbers who linked to care, were eligible for, and initiated CTX prophylaxis and ART. 
Risk of bias in the included studies was assessed using a component approach, similar to 
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the Cochrane Collaboration’s18, and based on three items: selection bias, outcome 
ascertainment, and attrition. The results were summarised using the PRISMA 
guidelines19. 
 
We used the reported data to calculate the proportions (and their 95% confidence 
intervals, using the Clopper–Pearson method) who linked to care, initiated CTX 
prophylaxis, were eligible for and initiated ART. The denominator for linkage was all 
newly diagnosed HIV-positive adults (≥18 years) who had a potential minimum follow-
up period corresponding to the time point when linkage was assessed (i.e. including those 
who out-migrated, died, or were lost to follow-up, but excluding those who entered the 
study at a later date so had a shorter potential follow-up period). The denominator for 
ART eligibility was all individuals who linked within the specified time period and those 
for initiation of CTX prophylaxis and ART were all individuals who linked and were 
eligible for CTX and ART respectively. We did not perform a meta-analysis because the 
identified studies varied widely with regard to design, setting, definition of linkage to 
care, the time points of and method for ascertaining linkage, and with regard to the 
strategies used to facilitate linkage.  
 
Results 
Summary of search results 
The search identified 5,905 articles of which 61 were subjected to full text screening. Of 
those screened, 21 were eligible for detailed review; two were excluded on the basis of 
reporting on overlapping study populations20,21. Of the remaining 19 articles, one22 had 
all the required data. Additional data were obtained for 1315,23-34 of the remaining 18 
articles after contacting the respective corresponding authors. Thus, 14 studies were 
included in the review (Figure 1). A summary description of the included studies is 
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presented in Table 1. The studies were conducted in six countries i.e. Uganda23,24,28,29, 
South Africa26,28-30,33,34, Kenya15,22, Malawi27,31, Lesotho32, and Swaziland25 between 
2005 and 2015. Most (92%) studies were based in rural15,23,25,26,28-32,34 or semirural 
settings24,27; two were conducted in both rural and urban22,33 populations. The number of 
newly identified HIV-positive adults varied widely across studies (range: 15–1637). 
 
Risk of bias 
Only two28,30 studies had a low risk of bias for all assessed items (Table 2). Risk of 
selection bias was low (≥80% HBHCT coverage) in four22,24,28,30 studies. Risk of attrition 
bias was low (≥80% participant retention) in eight24,26-30,33,34 of ten studies in which 
participants were followed. Self-reported linkage to care was confirmed by tracking 
referrals and review of records at the referral clinic in only two studies23,26. In the first 
study23, no information was reported on the proportion of participants for whom clinic 
records were not found. In the second study26, clinic records were found for only 71% of 
the tracked referrals and self-reported data was used to ascertain linkage for the rest of 
the participants. Self-reported linkage to care was confirmed by review of documentation 
issued to patients by HIV clinics (e.g. clinic cards) in three studies28-30; linkage was not 
verified with the HIV clinics. In five studies15,25,31,32,34, ascertainment of linkage to care 
was based on data from HIV clinics in the areas where the studies were conducted; 
participants who may have linked to HIV clinics outside of the study areas were not 
tracked. Self-reported data was used to ascertain linkage to care in the rest of the 
studies22,24,27,33. 
 
Summary of study objectives and populations 
Genberg et al.15 conducted a retrospective analysis using HBHCT data from Bunyala, a 
rural sub-county in western Kenya and HIV care provider clinical data to assess linkage 
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to and engagement in care in previously and newly diagnosed individuals. HBHCT was 
offered to all resident persons aged ≥13 years as part of a standard HIV care service in 
the area. 3,482 persons tested HIV-positive; 1329 (38%) were newly identified HIV-
positive adults (≥18 years) and hence eligible for the review.  
 
Dalal et al.22 conducted an HBHCT study among participants in a population-based 
disease surveillance program in two areas in Kenya: Lwak, a rural area in the west of the 
country and Kibera, an informal urban settlement in Nairobi. The aim of the study was to 
assess HBHCT acceptance, HIV prevalence, and linkage to care. HBHCT was offered to 
persons aged ≥13 years and children (≤12 years) whose biologic mother was HIV-positive 
or deceased. 2759 persons tested HIV-positive; 1637 (59%) were eligible for the review.  
 
Nakigozi et al.23 conducted a retrospective study to assess the frequency and determinants 
of non-enrolment into HIV care services among all 15-49 year old persons testing HIV-
positive through HBHCT in a rural population-based survey in Rakai, Uganda. 1451 
persons tested HIV-positive; 1137 (78.4%) were eligible for the review.  
 
Tumwebaze et al.24 conducted an uncontrolled prospective intervention study of HBHCT 
with CD4 count laboratory testing (results were returned to participants a week later), 
referral for care, and follow-up counselling in Kabwohe, a mixed rural and peri-urban 
area in southwest Uganda to evaluate this strategy as a platform for delivery of 
combination HIV prevention services. All residents aged ≥18 years were eligible to 
participate. 152 persons tested HIV-positive; 77 (51%) were eligible for the review. 
 
Parker et al.25 evaluated HBHCT and mobile HCT programmes with regard to uptake, 
costs, HIV positivity rates and linkage to care in Shiselweni, Swaziland. HBHCT was 
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offered as part of routine HIV care services to persons aged ≥18 months in three rural 
communities in the region. 170 persons tested HIV-positive through HBHCT; 142 (84%) 
were eligible for the review. 
 
Naik et al.26 conducted a prospective cohort analysis to determine linkage to care and 
factors that influence the rate of linkage to care among clients who tested HIV-positive 
through HBHCT in Umzimkhulu, a rural area in Kwazulu-Natal, South Africa. HBHCT 
was offered to individuals aged ≥14 years in 19 communities as a standard HIV care 
service (11 communities) and in the context of a cluster randomised trial comparing 
HBHCT to standard-of-care (mainly facility-based) HCT with regard to HIV testing rates 
(eight communities) 21. 492 persons tested HIV-positive; 410 (83%) were eligible for the 
review. 
 
Becker et al.27 conducted a prospective study to estimate the uptake of HBHCT and 
testing and family planning services among couples in three villages in Mpemba, a peri-
urban area of Blantyre, Malawi. HBHCT was offered as part of a research study. Couples 
were eligible if the woman was aged 15-49 years and the man aged ≥15 years. 46 
individuals tested HIV-positive of whom 15 (33%) were eligible for the review.  
 
Barnabas et al.28 conducted an uncontrolled prospective intervention study of HBHCT 
with point-of-care (POC) CD4 count testing, referral for care, and follow-up counselling 
in two rural communities in KwaZulu-Natal, South Africa, and in Mbarara, southwest 
Uganda to assess the effects of this strategy on linkage to care, ART initiation, and viral 
suppression at 12 months. Eligible participants were HIV-positive adults aged ≥18 years. 
635 persons tested HIV-positive; 229 (36%) were eligible for the review. 
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Barnabas et al.29 conducted a multisite, open-label, household randomised controlled trial 
to assess the effectiveness of community-based HCT and linkage strategies compared 
with standard referral for linking HIV-positive persons to ART and HIV-negative 
uncircumcised men to voluntary medical male circumcision (VMMC) in two rural 
settings in uMgungundlovu District, KwaZulu-Natal, South Africa, and Sheema District, 
southwest Uganda. HIV-positive ART naïve individuals aged ≥16 years identified 
through home-based or mobile HCT were randomly assigned in a factorial design to 
receive lay counsellor clinic linkage facilitation, lay counsellor follow-up home visits, or 
standard-of-care referral, and then either to POC CD4 count testing or referral for clinic 
CD4 count testing. 1325 HIV positive individuals were randomised; 511 (39%) were 
eligible for the review.  
 
van Rooyen et al.30 conducted an uncontrolled pilot study of a HBHCT intervention 
combined with POC CD4 count testing, referral for care, and follow-up visits in the rural 
Vulindlela sub district of KwaZulu-Natal, South Africa among persons aged ≥18 years to 
assess the effect of this strategy on HIV testing coverage, identification of HIV infected 
persons who are unaware of their HIV serostatus, linkage to care, and reduced HIV 
infectiousness through high uptake of and adherence to ART. 201 persons tested HIV-
positive; 73 (36%) were eligible for the review. 
 
Wringe et al.31 conducted a retrospective analysis to examine HIV testing and ART 
uptake in four community based HIV cohort studies in Africa. HBHCT was offered as 
part of a research study in one of the cohorts located in Karonga, a rural district in 
Northern Malawi. The cohort comprised all residents aged ≥15 years. 473 HIV-positive, 
ART naïve persons were included in the analysis; 431 (91%) were eligible for the review.  
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Labhardt et al.32 conducted a cluster randomized trial to compare HBHCT and mobile 
HCT with regard to HCT uptake in Butha-Buthe and Thaba-Tseka, two rural districts 
with high HIV prevalence in Lesotho. HCT was provided in the context of a multi-disease 
campaign that included provision of other health care services. The target population 
included persons of all ages who were not known to be HIV-positive. 39 individuals were 
newly diagnosed with HIV in the HBHCT clusters; 37 (95%) were eligible for the review. 
 
Velen et al.33 evaluated the uptake of HCT among household contacts (≥14 years) of 
index TB patients and linkage to care among those newly diagnosed with HIV. The study 
was part a cluster randomized trial designed to determine the effectiveness of adding 
isoniazid preventative therapy and point-of-care CD4 count testing in a TB contact tracing 
program based in rural and urban regions of South Africa. The study was limited to trial 
participants in the standard of care arm (TB contact tracing only). 26 persons were newly 
identified with HIV; 25 (96%) were eligible for the review.  
 
Iwuji et al.34 reported the uptake of home-based HIV testing, linkage to care, uptake of 
ART, and community attitudes about ART from the first phase of the ANRS 12249 TasP 
cluster-randomised trial conducted in rural KwaZulu-Natal, South Africa. The trial 
compared the effect of early ART, initiated irrespective of CD4 count, to that of ART 
initiated according to national guidelines (CD4 count ≤350 cells/μL, WHO stage 3 or 4 
until December 2014, ≤500 cells/μL from January 2015) on HIV incidence in the general 
population. HBHCT was provided to all persons aged ≥16 years who were resident in 
participating communities. A total of 2,569 persons were ascertained as HIV-positive in 
the first phase of the trial [942 tested HIV-positive (including 539 previously undiagnosed 
individuals aged ≥18 years) and 1,627 reported a known HIV-positive status]; 358 (14%) 
were eligible for the review.  
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Linkage to HIV care 
In all studies, persons who tested HIV positive were referred for care. Additional 
strategies to facilitate linkage to care were used in nine (64%)23,24,26-30,32,34 of the studies. 
These strategies included: provision of funds for transport to the HIV clinic27; follow-up 
counselling23,24,26,28-30,34; lay counsellor facilitation of the initial HIV clinic visits (the 
counsellor met the HIV-positive participant at the clinic and explained the clinic 
processes and the benefits of ART)29; POC CD4 count28-30,32 and home-based collection 
of samples for viral load28 testing and provision of results. Linkage to care was ascertained 
within 3 months of HBHCT in 50% of studies15,22,24,26,27,32,33. Ascertainment of linkage in 
the remaining studies was done >3 to 623,25,30 and >6 to 1228,29,31,34 months after HBHCT.  
 
Linkage to care ranged from 8.2% (95% CI, 6.8%-8.8%)15 to 85.4% (95% CI, 75.8%-
92.2%)29 when only referral was offered, and 24.3% (95% CI, 11.8%-41.2%)32 to 99.1% 
(95% CI, 96.9%-99.9%)28 when referral plus additional interventions to facilitate linkage 
were offered. In general, linkage to care was lower (<33%) in the studies that offered 
referral only15,22,25,31,33 and higher (>80%) in those that used a combination of additional 
linkage strategies24,28-30.  
 
Uptake of CTX prophylaxis and ART 
Five studies conducted in Kenya22, Uganda23,24, and Uganda and South Africa28,29 had 
data on initiation of CTX prophylaxis among eligible individuals who linked to care. CTX 
prophylaxis is only recommended for patients with CD4 count ≤200 cells/μL, WHO stage 
3 or 4 or HIV/TB co-infection in South Africa35 but is routinely provided to all HIV-
positive persons irrespective of CD4 count or WHO disease stage in Uganda36 and 
Kenya37. Of the studies conducted in Uganda and Kenya, additional interventions to 
facilitate referral uptake were offered in all except one. CTX uptake in these studies 
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ranged from 78.2% (95% CI, 69.3-85.5%)28 to 100%23,24,29. CTX uptake was also high 
[90.6% (95% CI, 87.3%-93.2%)] in the study that offered referral only22. Interventions to 
facilitate linkage were offered in the two studies that were conducted in South Africa. 
Uptake of CTX among patients with CD4 count ≤200 cells/μL in these studies ranged 
from 0%29 to 33.3% (95% CI, 4.3-77.7)29.  
 
Twelve studies15,22-26,28-32,34 had data on ART eligibility and ART initiation among 
patients who linked to care. The proportion of individuals eligible for ART initiation 
ranged from 16.5% (95% CI, 12.1-21.8)26 to 77.8% (95% CI, 40.0-97.2)32. ART uptake 
among those who linked to care ranged from 33% (95% CI, 24.2%-41.7%)22 to 94.0% 
(95% CI, 85.4%-98.3%)31 in the studies that provided referral only. A similar range i.e. 
14.3% (95% CI, 0.36%-57.9%)32 to 94.9% (95% CI, 91.3%-97.4%)23 was observed in the 
studies that provided referral plus additional linkage interventions. ART initiation rates 
were highest (≥90%) in the two studies in which HIV care services were provided through 
community-based research clinics23,31.  
 
Discussion 
Home based HIV counselling and testing is increasingly being used in SSA, and an 
effectively conducted HBHCT strategy would be a key precondition for HIV control 
programmes that propagate a test-and-treat approach for HIV prevention26. The success 
of such programmes will partly depend on their capacity to achieve high levels of linkage 
to care following HIV diagnosis38. Hence, it is necessary to identify and set up strategies 
that will effectively link persons identified with HIV through HBHCT to care and 
treatment. As observed in this review however, only a few studies have investigated 
linkage to care among adults newly identified with HIV through HBHCT in SSA. Linkage 
to care was below 33% in five of six studies where participants were only referred for 
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care with no further interventions to facilitate referral15,22,25,31,33. With the exception of 
two studies32,34, studies that used additional linkage strategies recorded moderate (>50% 
to <80%)23,27 to high (>80%)24,28-30 levels of linkage. In general, linkage to care was 
highest when participants were offered POC CD4 count testing and follow-up 
counselling24,28-30. These findings suggest that interventions that facilitate referral uptake 
could enhance linkage to care among adults newly identified with HIV through HBHCT.  
 
Only a small number of studies included in this review investigated the uptake of CTX. 
In Kenya and Uganda where routine CTX prophylaxis is recommended irrespective of 
CD4 count or clinical stage36,37, uptake was high (>70%) irrespective of whether or not 
additional interventions were applied. This may be because CTX is widely available, 
inexpensive, and simple to use39. In contrast and in spite of facilitated linkage, uptake of 
CTX prophylaxis among those eligible (CD4 count ≤200 cells/μL35) in South Africa was 
low (≤33%). The reasons for this are not clear. However previous studies have found 
irregular supply and lack of stocks of CTX, lack of awareness among health care workers, 
and perceived low priority of CTX prophylaxis due to the absence of a reporting 
requirement, to be some of the barriers to implementation of CTX prophylaxis policies40.  
 
Consistent with previous findings8, significant proportions of HIV-positive persons 
identified through HBHCT were still ineligible for ART (based on national guidelines 
that were in use at the time of the respective studies). The finding that ART uptake was 
highest in the studies where services were provided through community-based research 
clinics may be attributed to such clinics being more accessible and less prone to 
limitations that characterise many public sector ART care programmes in SSA, including 
the requirement for several visits to prepare patients for ART29, crowded, busy and 
unwelcoming clinics41, non-functioning laboratories41, and inadequate supply or lack of 
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antiretroviral drugs42. Additionally, some research clinics are likely to have close and 
long standing relationships with communities in which they are located.  
 
HBHCT studies with facilitated linkage have been shown to achieve higher ART 
initiation rates among participants who link to care compared to those without facilitated 
linkage14. However, ART initiation rates were high in some but not all studies with 
facilitated linkage described in this review. Additionally, some studies without facilitated 
linkage achieved higher ART initiation rates than some of those with facilitated linkage. 
For instance although participants in the study by van Rooyen et al.30 received POC CD4 
count testing and follow-up counselling following HBHCT and referral, only 54% of 
eligible linkers initiated ART compared to 94% in the Wringe et al.31 study where 
participants were only given referrals for HIV care. It is likely that clinic level factors 
such as those mentioned above may be more important in influencing events after linkage 
to care. Also, people who link to care in the absence of facilitated linkage may be more 
motivated to receive care.  
 
This review has some limitations. First, the number of relevant studies found is small and 
represents only six countries in particular areas. This may limit the generalizability of the 
findings. Second, the methodologies used in these studies varied widely, making it 
impractical to combine findings from individual studies into a pooled analysis. Third, 
outcome assessments in most of the included studies were based solely on self-reports or 
records in HIV clinics within the respective study areas; hence linkage to care may have 
been overestimated in the case of self-reports or underestimated if some individuals 
linked to clinics outside of their communities. Findings from our own trial43 show that 
about 5% of patients reporting that they have linked to care after HBHCT, have actually 
not done so, probably due to social desirability bias. Because participants in our trial are 
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informed early on that self-reported linkage will be verified, we believe that this figure 
may be substantially higher in other studies. Also, 6% of linkers in our trial have been 
confirmed to have reported to HIV clinics outside of the study area.  
 
Importantly, most of the linkage intervention studies reported were observational, 
determining intervention effects without control groups. Randomised trials represent the 
gold-standard methodology in the evaluation of an intervention including its likely effect 
size44. It is therefore desirable to confirm the impact and establish the cost effectiveness 
of these strategies in randomised controlled trials. Apart from the trial included in this 
review29, we are aware of five other trials to investigate the effectiveness of a variety of 
strategies on linkage to care following HIV diagnosis through HBHCT. None of these 
other trials have been reported yet. They include: i) a recently completed individually 
randomised trial aiming to assess the accuracy, feasibility and acceptability of POC CD4 
testing for persons found HIV positive through HBHCT, and to determine the (cost-) 
effectiveness of this intervention in improving linkage to care and time to ART initiation 
in rural Western Kenya45; ii) our own soon to be completed cluster randomised trial to 
evaluate the impact of follow-up counselling after HIV diagnosis through home-based 
HIV counselling and testing (HBHCT), on linkage to care in Uganda43; iii) an ongoing 
cluster randomised trial that will evaluate the effectiveness of a linkage to care 
counselling intervention at achieving HIV viral suppression and intermediate outcomes 
of linkage/time to care, time to/receipt of opportunistic infection prophylaxis, and 
antiretroviral therapy (ART) among people testing HIV positive during (HBHCT) in rural 
Uganda46; iv) an ongoing household randomised trial in rural Lesotho to evaluate the 
effectiveness of same day home-based ART initiation after HIV diagnosis coupled with 
a reduced frequency of clinic follow-up visits in improving linkage to care, retention in 
care, and viral suppression47; and v) a planned individually randomised trial that will 
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compare home and other community recruitment strategies, HIV testing strategies (self-
testing, HCT in a home/mobile setting, and facility-based HCT), and different linkage 
strategies (referral only, text message reminder, and financial incentive) among young at-
risk women, 15-24 years old, in Homa Bay County, western Kenya48.  
 
In conclusion, we found that only few published studies investigated linkage to HIV care 
among adults newly diagnosed with HIV through HBHCT in SSA. In general, HBHCT 
without additional intervention strategies to increase service uptake achieved inadequate 
linkage while HBHCT combined with some kind of additional strategy seemed to achieve 
higher linkage. There is a need to confirm the impact of the most promising linkage 
strategies through randomised controlled trials before they can be recommended for large 
scale adoption.  
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Figure 1: Systematic search flow diagram 
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(9
7
.4
, 
8
6
.2
-
9
9
.9
) 
U
G
 
4
3
 (
5
8
.9
, 
4
6
.8
-7
0
.3
) 
2
5
 (
5
8
.1
, 
4
2
.1
-7
3
.0
) 
R
ef
er
ra
l 
&
 
co
u
n
se
ll
o
r 
cl
in
ic
 
li
n
k
ag
e 
fa
ci
li
ta
ti
o
n
 
≤
3
5
0
  
9
 
1
0
4
 (
2
3
1
) 
1
0
2
 (
9
8
.1
, 
9
3
.2
-9
9
.8
) 
1
/3
 (
3
3
.3
, 
0
.8
4
-9
0
.6
) 
S
A
; 
1
8
/2
1
 
(8
5
.7
, 
6
3
.7
-
9
7
.0
) 
U
G
 
5
1
 (
5
0
.0
, 
3
9
.9
-6
0
.1
) 
3
9
 (
7
6
.5
, 
6
2
.5
-8
7
.2
) 
R
ef
er
ra
l,
 
P
O
C
 C
D
4
 
co
u
n
t 
te
st
in
g
, 
&
 
co
u
n
se
ll
o
r 
cl
in
ic
 
li
n
k
ag
e 
fa
ci
li
ta
ti
o
n
 
≤
3
5
0
 
9
 
7
2
 (
2
0
6
) 
6
9
 (
9
5
.8
, 
8
8
.3
-9
9
.1
) 
0
/3
 (
0
.0
) 
S
A
; 
2
3
/2
7
 
(8
5
.2
, 
6
6
.3
-
9
5
.8
) 
U
G
 
4
3
 (
6
2
.3
, 
4
9
.8
-7
3
.7
) 
2
3
 (
5
3
.5
, 
3
7
.7
-6
8
.8
) 
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A
u
th
o
r
, 
y
ea
r
  
C
o
u
n
tr
y
, 
se
tt
in
g
 
S
tu
d
y
 
p
e
r
io
d
 
S
tu
d
y
 d
e
si
g
n
 
H
IV
 c
a
r
e 
p
r
o
v
id
er
 
L
in
k
a
g
e
 t
o
 
c
a
re
 
d
e
fi
n
it
io
n
 
L
in
k
a
g
e
 
st
r
a
te
g
ie
s 
C
D
4
 A
R
T
 
e
li
g
ib
il
it
y
 
th
r
e
sh
o
ld
 
(c
e
ll
s/
μ
L
) 
L
in
k
a
g
e
 
a
ss
es
sm
e
n
t 
ti
m
e
 
(m
o
n
th
s)
 
N
u
m
b
e
r
 
in
 
a
n
a
ly
si
s 
(N
u
m
b
e
r
 
o
f 
H
IV
-
p
o
si
ti
v
e 
p
e
r
so
n
s 
in
 s
tu
d
y
) 
L
in
k
e
d
  
In
it
ia
te
d
 
C
T
X
a
  
E
li
g
ib
le
 
fo
r
 A
R
T
b
  
In
it
ia
te
d
 
A
R
T
  
n
 (
%
, 
9
5
%
 C
I)
 
n
/N
 (
%
, 
9
5
%
 C
I)
 
n
 (
%
, 
9
5
%
 C
I)
 
n
 (
%
, 
9
5
%
 C
I)
 
R
ef
er
ra
l 
&
 
fo
ll
o
w
-u
p
 
co
u
n
se
ll
in
g
 
(1
, 
3
, 
&
 6
 
m
o
n
th
s)
  
≤
3
5
0
  
9
 
8
7
 (
2
2
9
) 
8
0
 (
9
2
.0
, 
8
4
.1
-9
6
.7
) 
0
/1
2
 (
0
.0
) 
S
A
; 
3
0
/3
0
 
(1
0
0
.0
) 
U
G
 
4
1
 (
5
1
.3
, 
3
9
.8
-6
2
.6
) 
3
1
 (
7
5
.6
, 
5
9
.7
-8
7
.6
) 
R
ef
er
ra
l,
 
P
O
C
 C
D
4
 
co
u
n
t 
te
st
in
g
 &
 
fo
ll
o
w
-u
p
 
co
u
n
se
ll
in
g
 
(1
, 
3
, 
&
 6
 
m
o
n
th
s)
 
≤
3
5
0
  
9
 
8
5
 (
2
2
0
) 
8
1
 (
9
5
.3
, 
8
8
.4
-9
8
.7
) 
1
/5
 (
2
0
.0
, 
0
.5
1
-7
1
.6
) 
S
A
; 
2
8
/2
8
 
(1
0
0
.0
) 
U
G
 
4
6
 (
5
6
.8
, 
4
5
.3
-6
7
.8
) 
3
6
 (
7
8
.3
, 
6
3
.6
-8
9
.1
) 
a U
p
ta
k
e 
o
f 
C
T
X
 p
ro
p
h
y
la
x
is
 i
s 
sh
o
w
n
 s
ep
ar
at
el
y
 f
o
r 
S
o
u
th
 A
fr
ic
a 
(S
A
) 
an
d
 U
g
an
d
a 
(U
G
) 
b
ec
au
se
 e
li
g
ib
il
it
y
 c
ri
te
ri
a 
ar
e 
d
if
fe
re
n
t 
in
 e
ac
h
 c
o
u
n
tr
y
. 
 
b
B
as
ed
 o
n
 l
o
ca
ll
y
 r
ec
o
m
m
en
d
ed
 C
D
4
 c
o
u
n
t 
el
ig
ib
il
it
y
 t
h
re
sh
o
ld
 d
u
ri
n
g
 t
h
e 
st
u
d
y
 p
er
io
d
. 
c F
o
ll
o
w
-u
p
 c
o
u
n
se
ll
in
g
 w
as
 o
ff
er
ed
 t
o
 i
n
d
iv
id
u
al
s 
w
h
o
 d
id
 n
o
t 
li
n
k
 t
o
 c
ar
e 
w
it
h
in
 3
 m
o
n
th
s 
o
f 
re
fe
rr
al
; 
n
u
m
b
er
 a
n
d
 t
im
in
g
 o
f 
fo
ll
o
w
-u
p
 v
is
it
s 
w
er
e 
n
o
t 
sp
ec
if
ie
d
. 
d
In
fo
rm
at
io
n
 o
n
 A
R
T
 e
li
g
ib
il
it
y
 a
n
d
 i
n
it
ia
ti
o
n
 w
as
 n
o
t 
av
ai
la
b
le
 f
o
r 
p
er
so
n
s 
w
h
o
 l
in
k
ed
 t
o
 t
h
e 
p
u
b
li
c 
h
ea
lt
h
 f
ac
il
it
ie
s.
 H
en
ce
, 
th
e 
d
en
o
m
in
at
o
r 
u
se
d
 f
o
r 
A
R
T
 e
li
g
ib
il
it
y
 (
n
=
1
4
1
) 
is
 t
h
e 
n
u
m
b
er
 o
f 
p
er
so
n
s 
w
h
o
 l
in
k
ed
 
to
 t
h
e 
T
as
P
 t
ri
al
 r
es
ea
rc
h
 c
li
n
ic
s.
  
e T
im
in
g
 o
f 
fo
ll
o
w
-u
p
 v
is
it
s 
w
as
 n
o
t 
sp
ec
if
ie
d
. 
f T
h
e 
n
u
m
b
er
 o
f 
p
ar
ti
ci
p
an
ts
 w
h
o
 d
is
cl
o
se
d
 t
h
ei
r 
H
IV
 s
ta
tu
s 
to
 t
h
ei
r 
p
ar
tn
er
s 
w
as
 n
o
t 
re
p
o
rt
ed
. 
g
N
u
m
b
er
 a
n
d
 t
im
in
g
 o
f 
fo
ll
o
w
-u
p
 v
is
it
s 
w
er
e 
n
o
t 
sp
ec
if
ie
d
. 
h
R
es
u
lt
s 
fo
r 
li
n
k
ag
e 
to
 c
ar
e 
an
d
 o
th
er
 o
u
tc
o
m
es
 a
re
 p
re
se
n
te
d
 s
ep
ar
at
el
y
 f
o
r 
ea
ch
 o
f 
th
e 
si
x
 g
ro
u
p
s 
in
 t
h
e 
tr
ia
l.
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a
b
le
 2
: 
R
is
k
 o
f 
b
ia
s 
w
it
h
in
 s
tu
d
ie
s 
 
A
u
th
o
r,
 y
ea
r
 
S
el
ec
ti
o
n
 o
f 
p
a
rt
ic
ip
a
n
ts
a  
 
O
u
tc
o
m
e 
a
sc
er
ta
in
m
e
n
tb
  
L
o
ss
 t
o
 f
o
ll
o
w
-
u
p
c
 
G
en
b
er
g
, 
2
0
1
5
1
5
 
P
ar
ti
ci
p
an
ts
 c
o
m
p
ri
se
d
 p
er
so
n
s 
ag
ed
 ≥
1
3
 y
ea
rs
 w
h
o
 t
es
te
d
 H
IV
-p
o
si
ti
v
e 
in
 a
 p
o
p
u
la
ti
o
n
-b
as
ed
 
st
u
d
y
. 
H
B
H
C
T
 c
o
v
er
ag
e 
co
u
ld
 n
o
t 
b
e 
es
ti
m
at
ed
 b
ec
au
se
 t
h
e 
si
ze
 o
f 
th
e 
ta
rg
et
 p
o
p
u
la
ti
o
n
 w
as
 
n
o
t 
re
p
o
rt
ed
. 
U
n
cl
ea
r 
ri
sk
 
C
li
n
ic
-v
er
if
ie
d
 d
at
a.
 N
o
 i
n
fo
rm
at
io
n
 o
n
 
p
er
so
n
s 
w
h
o
 m
ay
 h
av
e 
li
n
k
ed
 t
o
 c
li
n
ic
s 
o
u
ts
id
e 
th
e 
st
u
d
y
 a
re
a.
 U
n
cl
ea
r 
ri
sk
 
 N
o
 p
ar
ti
ci
p
an
t 
fo
ll
o
w
-u
p
 
D
al
al
, 
2
0
1
3
2
2
 
P
ar
ti
ci
p
an
ts
 c
o
m
p
ri
se
d
 H
IV
-p
o
si
ti
v
e 
p
er
so
n
s 
ag
ed
 ≥
1
3
 y
ea
rs
 a
n
d
 c
h
il
d
re
n
 a
g
ed
 ≤
1
2
 y
ea
rs
 w
h
o
se
 
b
io
lo
g
ic
 m
o
th
er
 w
as
 H
IV
-p
o
si
ti
v
e 
o
r 
d
ec
ea
se
d
 w
h
o
 w
er
e 
en
ro
ll
ed
 i
n
 a
 p
o
p
u
la
ti
o
n
-b
as
ed
 d
is
ea
se
 
su
rv
ei
ll
an
ce
 p
ro
g
ra
m
. 
H
B
H
C
T
 c
o
v
er
ag
e 
w
as
 8
2
%
. 
L
o
w
 r
is
k 
 
S
el
f-
re
p
o
rt
 f
o
r 
al
l 
p
ar
ti
ci
p
an
ts
. 
H
ig
h
 r
is
k 
4
8
%
 (
8
8
1
/1
8
3
9
) 
lo
ss
 t
o
 f
o
ll
o
w
-u
p
. 
H
ig
h
 r
is
kd
 
W
ri
n
g
e,
 
2
0
1
2
3
1
 
P
ar
ti
ci
p
an
ts
 c
o
m
p
ri
se
d
 p
er
so
n
s 
ag
ed
 ≥
1
5
 y
ea
rs
 w
h
o
 t
es
te
d
 H
IV
-p
o
si
ti
v
e 
in
 a
 p
o
p
u
la
ti
o
n
-b
as
ed
 
co
h
o
rt
. 
H
B
H
C
T
 c
o
v
er
ag
e 
co
u
ld
 n
o
t 
b
e 
es
ti
m
at
ed
 b
ec
au
se
 t
h
e 
to
ta
l 
n
u
m
b
er
 o
f 
p
er
so
n
s 
in
 t
h
e 
ta
rg
et
 p
o
p
u
la
ti
o
n
 w
as
 n
o
t 
re
p
o
rt
ed
. 
U
n
cl
ea
r 
ri
sk
 
C
li
n
ic
-v
er
if
ie
d
 d
at
a.
 N
o
 i
n
fo
rm
at
io
n
 o
n
 
p
er
so
n
s 
w
h
o
 m
ay
 h
av
e 
li
n
k
ed
 t
o
 c
li
n
ic
s 
o
u
ts
id
e 
th
e 
st
u
d
y
 a
re
a.
 U
n
cl
ea
r 
ri
sk
 
N
o
 p
ar
ti
ci
p
an
t 
fo
ll
o
w
-u
p
 
P
ar
k
er
, 
2
0
1
5
2
5
 
P
ar
ti
ci
p
an
ts
 c
o
m
p
ri
se
d
 p
er
so
n
s 
w
h
o
 t
es
te
d
 H
IV
-p
o
si
ti
v
e 
in
 a
 h
o
u
se
-t
o
-h
o
u
se
 H
B
H
C
T
 p
ro
g
ra
m
. 
H
B
H
C
T
 w
as
 c
o
n
d
u
ct
ed
 i
n
 o
n
ly
 2
6
%
 o
f 
h
o
u
se
h
o
ld
s 
in
 t
h
e 
ta
rg
et
 a
re
a 
d
u
e 
to
 t
im
e 
co
n
st
ra
in
ts
. 
It
 
is
 n
o
t 
cl
ea
r 
h
o
w
 t
h
es
e 
h
o
u
se
h
o
ld
s 
w
er
e 
se
le
ct
ed
. 
H
ig
h
 r
is
k 
 
C
li
n
ic
-v
er
if
ie
d
 d
at
a.
 P
ar
ti
ci
p
an
ts
 w
h
o
 w
er
e 
re
fe
rr
ed
 h
ea
lt
h
 f
ac
il
it
ie
s 
o
u
ts
id
e 
th
e 
st
u
d
y
 
ar
ea
 w
er
e 
ex
cl
u
d
ed
 f
ro
m
 a
n
al
y
si
s.
 U
n
cl
ea
r 
ri
sk
 
N
o
 p
ar
ti
ci
p
an
t 
fo
ll
o
w
-u
p
 
V
el
en
, 
2
0
1
6
3
3
 
P
ar
ti
ci
p
an
ts
 c
o
m
p
ri
se
d
 h
o
u
se
h
o
ld
 c
o
n
ta
ct
s 
o
f 
T
B
 p
at
ie
n
ts
 i
n
 a
 T
B
 c
o
n
ta
ct
 t
ra
ci
n
g
 t
ri
al
. 
H
B
H
C
T
 
w
as
 o
ff
er
ed
 t
o
 h
o
u
se
h
o
ld
 c
o
n
ta
ct
s 
o
f 
T
B
 p
at
ie
n
ts
 s
el
ec
te
d
 t
h
ro
u
g
h
 c
o
n
v
en
ie
n
ce
 s
am
p
li
n
g
. 
H
ig
h
 
ri
sk
 
S
el
f-
re
p
o
rt
 f
o
r 
al
l 
p
ar
ti
ci
p
an
ts
. 
H
ig
h
 r
is
k 
1
2
%
 (
3
/2
6
) 
lo
ss
 t
o
 
fo
ll
o
w
-u
p
. 
L
o
w
 
ri
sk
 
Iw
u
ji
, 
2
0
1
6
3
4
 
P
ar
ti
ci
p
an
ts
 c
o
m
p
ri
se
d
 p
er
so
n
s 
ag
ed
 ≥
1
6
 y
ea
rs
 w
h
o
 t
es
te
d
 H
IV
-p
o
si
ti
v
e 
o
r 
se
lf
-r
ep
o
rt
ed
 b
ei
n
g
 
H
IV
-p
o
si
ti
v
e 
in
 a
 c
o
m
m
u
n
it
y
-r
an
d
o
m
is
ed
 t
ri
al
. 
H
B
H
C
T
 c
o
v
er
ag
e 
w
as
 6
4
%
. 
H
ig
h
 r
is
k 
C
li
n
ic
 v
er
if
ie
d
 d
at
a.
 N
o
 i
n
fo
rm
at
io
n
 o
n
 
p
er
so
n
s 
w
h
o
 m
ay
 h
av
e 
li
n
k
ed
 t
o
 c
li
n
ic
s 
o
u
ts
id
e 
th
e 
st
u
d
y
 a
re
a.
 U
n
cl
ea
r 
ri
sk
 
1
6
%
 (
5
8
/3
5
8
) 
lo
ss
 
to
 f
o
ll
o
w
-u
p
. 
L
o
w
 
ri
sk
e
 
N
ai
k
,2
0
1
5
2
6
 
P
ar
ti
ci
p
an
ts
 c
o
m
p
ri
se
d
 a
ll
 p
er
so
n
s 
ag
ed
 ≥
1
4
 y
ea
rs
 w
h
o
 t
es
te
d
 H
IV
-p
o
si
ti
v
e 
in
 1
9
 c
o
m
m
u
n
it
ie
s.
 
H
B
H
C
T
 c
o
v
er
ag
e 
co
u
ld
 n
o
t 
b
e 
es
ti
m
at
ed
 b
ec
au
se
 t
h
e 
si
ze
 o
f 
th
e 
p
o
p
u
la
ti
o
n
 t
ar
g
et
ed
 f
o
r 
te
st
in
g
 
in
 t
h
e 
p
ar
ti
ci
p
at
in
g
 c
o
m
m
u
n
it
ie
s 
w
as
 n
o
t 
re
p
o
rt
ed
. 
U
n
cl
ea
r 
ri
sk
  
S
el
f-
re
p
o
rt
 &
 c
li
n
ic
-v
er
if
ie
d
 d
at
a 
o
r 
se
lf
-
re
p
o
rt
 o
n
ly
 (
2
9
%
 o
f 
p
ar
ti
ci
p
an
ts
).
 H
ig
h
 r
is
k 
1
8
%
 (
7
9
/4
3
8
) 
lo
ss
 
to
 f
o
ll
o
w
-u
p
. 
L
o
w
 
ri
sk
f  
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A
u
th
o
r,
 y
ea
r
 
S
el
ec
ti
o
n
 o
f 
p
a
rt
ic
ip
a
n
ts
a  
 
O
u
tc
o
m
e 
a
sc
er
ta
in
m
e
n
tb
  
L
o
ss
 t
o
 f
o
ll
o
w
-
u
p
c
 
L
ab
h
ar
d
t,
 
2
0
1
4
3
2
 
P
ar
ti
ci
p
an
ts
 c
o
m
p
ri
se
d
 n
ew
ly
 i
d
en
ti
fi
ed
 H
IV
-p
o
si
ti
v
e 
p
er
so
n
s 
al
l 
o
f 
ag
es
 f
ro
m
 c
o
m
m
u
n
it
ie
s 
ra
n
d
o
m
is
ed
 t
o
 r
ec
ei
v
e 
H
B
H
C
T
 i
n
 a
 c
lu
st
er
-r
an
d
o
m
is
ed
 t
ri
al
. 
H
B
H
C
T
 c
o
v
er
ag
e 
co
u
ld
 n
o
t 
b
e 
es
ti
m
at
ed
 b
ec
au
se
 t
h
e 
to
ta
l 
n
u
m
b
er
 o
f 
p
er
so
n
s 
in
 t
h
e 
ta
rg
et
 p
o
p
u
la
ti
o
n
 w
as
 n
o
t 
re
p
o
rt
ed
. 
U
n
cl
ea
r 
ri
sk
 
C
li
n
ic
-v
er
if
ie
d
 d
at
a.
 N
o
 i
n
fo
rm
at
io
n
 o
n
 
p
er
so
n
s 
w
h
o
 m
ay
 h
av
e 
li
n
k
ed
 t
o
 c
li
n
ic
s 
o
u
ts
id
e 
th
e 
st
u
d
y
 a
re
a.
 U
n
cl
ea
r 
ri
sk
 
N
o
 p
ar
ti
ci
p
an
t 
fo
ll
o
w
-u
p
 
B
ec
k
er
, 
2
0
1
4
2
7
 
P
ar
ti
ci
p
an
ts
 w
er
e 
m
ar
ri
ed
 i
n
d
iv
id
u
al
s 
(F
em
al
e,
 1
5
-4
9
 y
ea
rs
; 
M
al
e,
 ≥
1
5
 y
ea
rs
) 
w
h
o
 t
es
te
d
 H
IV
-
p
o
si
ti
v
e 
th
ro
u
g
h
 h
o
u
se
-t
o
-h
o
u
se
 c
o
u
p
le
 H
B
H
C
T
 i
n
 t
h
re
e 
v
il
la
g
es
. 
H
B
H
C
T
 w
as
 o
ff
er
ed
 t
o
 a
ll
 
el
ig
ib
le
 p
ar
ti
ci
p
an
ts
 i
n
 o
n
e 
v
il
la
g
e 
an
d
 a
p
p
ro
x
im
at
el
y
 o
n
e
-t
h
ir
d
 i
n
 t
h
e 
o
th
er
 t
w
o
 v
il
la
g
es
 (
n
o
 
in
fo
rm
at
io
n
 o
n
 h
o
w
 p
ar
ti
ci
p
an
ts
 i
n
 t
h
es
e 
tw
o
 v
il
la
g
es
 w
er
e 
se
le
ct
ed
).
 H
ig
h
 r
is
k 
 
S
el
f-
re
p
o
rt
 f
o
r 
al
l 
p
ar
ti
ci
p
an
ts
. 
H
ig
h
 r
is
k 
2
%
 (
1
/4
6
) 
lo
ss
 t
o
 
fo
ll
o
w
-u
p
. 
L
o
w
 
ri
sk
 
N
ak
ig
o
zi
, 
2
0
1
1
2
3
 
P
ar
ti
ci
p
an
ts
 c
o
m
p
ri
se
d
 1
5
-4
9
 y
ea
r 
o
ld
 p
er
so
n
s 
w
h
o
 t
es
te
d
 H
IV
-p
o
si
ti
v
e 
in
 a
 p
o
p
u
la
ti
o
n
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Introduction: Home-based HIV counselling & testing (HBHCT) is highly acceptable and has the potential
to increase HIV testing uptake in sub-Saharan Africa. However, data are lacking on strategies that can
effectively link HIV-positive individuals identiﬁed through HBHCT to care. This trial was designed to
assess the effectiveness of two brief home-based counselling sessions on linkage to care, provided
subsequent to referral for care among HIV-positive patients identiﬁed through HBHCT in a rural com-
munity in Masaka district, Uganda.
Methods: 28 communities (clusters) were randomly allocated to control (referral only) and intervention
(referral and follow-up counselling) arms (n ¼ 14 clusters/arm). Randomisation was stratiﬁed on distance
from the district capital (10 km vs > 10 km) and cluster size (larger single village vs combined small
villages), and restricted to ensure balance on selected cluster characteristics. A list of possible allocations
was generated and one randomly selected at a public ceremony. HBHCT is being offered to all adults (18
years), and HIV-positive individuals not yet in care are eligible for enrolment. The intervention is pro-
vided at one and two months post-enrolment. Primary outcomes, assessed 6 months after enrolment,
are: the proportion of individuals linking to HIV care within 6 months of HIV diagnosis and time to
linkage. The primary analysis will be based on individual-level data.
Discussion: This study will provide evidence on the impact of a counselling intervention on linkage to
care among adults identiﬁed with HIV infection through HBHCT. Interpretation of the trial outcomes will
be aided by results from an on-going qualitative sub-study.
© 2016 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved. This is
an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Access to anti-retroviral therapy (ART) in sub-Saharan Africa has
expanded considerably but AIDS-related mortality remains high
[1]. A major cause of mortality is the late presentation of patients
for care [2,3]. Early ART initiation depends on early HIV diagnosis
through HIV counselling and testing (HCT) and prompt linkage to
care [4]. HCT is essential in expanding HIV prevention and treat-
ment services [5,6], but its uptake in sub-Saharan Africa remains
low [7]. For instance, up to 74% of men and 58% of women in the
region have never been tested for HIV [8].
In sub-Saharan Africa, home-based HIV testing and counselling
(HBHCT) has the potential to substantially increase people's
awareness of their HIV status [9]. HBHCT is highly acceptable
[10e12], cost-effective at reaching previously untested persons
compared with other HCT models [13], promotes equitable access
of services [14] and may promote couples HCT [15,16] and pre-
vention of mother-to-child HIV transmission [16]. Additionally,
HBHCT facilitates early HIV diagnosis and may promote early
linkage to care [16]. However few studies have reported data on
linkage to HIV care after HBHCT [17,18]. Unfortunately, these studies
suggest that without additional strategies to facilitate linkage, less
than half of HIV-positive persons identiﬁed through HBHCT link to
care [18,19]. In contrast, HBHCT studies in which such linkage
strategies were used showed an increase of linkage of up to 90%
[20e25]. However, most of these were uncontrolled observational
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studies. There is a need for rigorous evaluation of promising linkage
strategies, using randomised controlled trials in order to identify
the most effective approach.
Follow-up counselling after HIV diagnosis and referral is one of
the strategies that has been utilised to facilitate linkage to care
[21,24,25]. Counselling may mitigate psychosocial barriers of link-
age to care [26]. For instance, counselling facilitates disclosure of
HIV positive status [27]. In turn, disclosure makes it possible for the
patient to receive psychosocial support, a key facilitator of linkage
to care [28]. Follow-up counselling may also be used to provide
information about ART, other care services and encourage linkage
to care [29]. It is also a relatively simple strategy that may be
delivered through non-medical personnel [30,31], which makes it
feasible also in low resource settings. We describe an ongoing
cluster randomised controlled trial of follow-up counselling after
referral to HIV care, compared to referral only, among individuals
diagnosed with HIV infection through HBHCT in Masaka district,
Uganda.
1.1. Study objectives and outcomes
The objective of the study is to determine the effectiveness of
follow-up counselling on linkage to HIV care, deﬁned as active
registration with an HIV clinic. Primary outcomes are: the propor-
tion of individuals linking to care within 6 months of HIV diagnosis
through HBHCT, and time between HIV diagnosis and linkage to
care. Secondary outcomes include time between HIV diagnosis and
receipt of CD4 cell count test results, time between HIV diagnosis
and ART initiation, and the proportion of participants who report
adherence to daily cotrimoxazole prophylaxis 6 months after HIV
diagnosis. A further secondary outcome is the proportion of HIV-
negative participants who agree to repeat HIV testing 6 months
after HBHCT.
2. Methods
2.1. Study design and population
2.1.1. HIV-positive participants
The study is an open-label cluster randomised controlled trial
being conducted in three rural sub-counties in Masaka district,
Uganda. It is based at the MRC/UVRI Unit station in Masaka. The
study population consists of newly and previously diagnosed HIV-
positive adults (18 years) identiﬁed through HBHCT who are not
in care and are willing to provide informed consent and receive
follow-up counselling at home. Exclusion criteria include: previ-
ous/current receipt of HIV care, on-going participation in other
health-related research, planned change of residence in the next 6
months, and inability to provide informed consent.
2.1.2. HIV-negative participants
HIV-negative adults (18 years) who are willing to provide
informed consent, receive follow-up counselling at home, and have
no intention of changing residence in the next 6 months are
recruited from each randomised community primarily to reduce
the possibility of revealing the HIV positive status of the main trial
participants. Data from these participants will also be used to
investigate whether follow-up counselling increases the uptake of
repeat HIV testing.
2.2. Identiﬁcation and selection of clusters
Clusters comprised one or more villages i.e. the smallest
administrative areas. All villages (n ¼ 158) in the study area were
mapped (Fig. 1) and the number of adults in each village obtained
(range: 50e1500). To ensure a reasonable number of eligible par-
ticipants in each cluster, we combined small (<400 adults) villages
with adjacent villages into larger clusters of at least 400 adults.
Therefore, a cluster was deﬁned as a village or a set of villages with
at least 400 adults. Clusters were separated by a buffer zone of at
least one non-participating village to minimise the risk of
contamination.
2.3. Sample size estimates
Sample size was calculated to ensure adequate power to address
the hypothesis that follow-up counselling would increase the
proportion of individuals that link to care. Based on previous
studies in the area [32,33], we assumed an adult HIV prevalence of
10%. The 2011 Uganda national HIV sero-prevalence survey
(Masaka district was included in the survey) found that 60% of HIV-
positive adults are unaware of their HIV status and are therefore not
in care [33]. However, anticipating increased HCT coverage since
the survey, we adjusted this ﬁgure to 40%. Based on these ﬁgures
and the population estimates from the mapping data (harmonic
mean of 525 adults in each cluster), we estimated that the har-
monic mean number of HIV-positive persons who would not be in
care in a cluster was 21 (i.e. 525  0.10  0.40). After further
adjusting for persons who would be excluded due to ineligibility or
refusal to participate (10%) as well as loss to follow-up (10%) after
enrolment, we estimated that the harmonic mean number of in-
dividuals completing the study in each cluster would be 17.
We assumed a between cluster coefﬁcient of variation, k, of 0.25.
This was based on past studies of linkage to HIV care [22,34,35] that
were conducted in settings similar to Masaka in which k ranged
from 0.12 to 0.33. We assumed linkage of 35% in the control arm
based on ﬁndings from earlier HBHCT studies [36e39]. The esti-
mated intervention effect was based on ﬁndings from HBHCT
studies that have used follow-up counselling to facilitate linkage to
care in Uganda [21,22]. Using methods for stratiﬁed cluster rand-
omised trials [40], and assuming a k of 0.25 and a harmonic mean of
17 participants completing the study in each cluster, we estimated
that 11 clusters per arm would be required to have 90% power to
detect an increase in linkage to care from 35% in the control arm to
60% in the intervention arm as statistically signiﬁcant (p < 0.05).
This sample size would also give us 95% power to detect a hazard
ratio of 1.7 for the effect of the intervention on time to linkage, or
80% power to detect a hazard ratio of 1.5 [41].
After completing enrolment in the ﬁrst seven clusters, we
observed that 12% (419/3546) of registered resident adults from the
mapping exercise were not found at home and could not be con-
tacted in spite of repeated attempts. Of those found at home, 11%
(358/3127) declined to have HBHCT. Furthermore, among HIV pos-
itive persons, therewas a higher than expected level of engagement
in HIV care: only 26% (75/294) of those who tested positive in
HBHCT were not in care. As a result, the number of participants
enrolled per cluster was much lower (harmonic mean < 10) than
anticipated. Based on these preliminary ﬁndings, the number of
clusters was increased to 28 (14 per arm) with an expected har-
monic mean of 7 participants completing the study in each cluster;
this would allow for detection of the same difference in proportions
with a power of 83%, or a hazard ratio of 1.7 with a power of 85%.
2.4. Randomisation of clusters
We used a combination of stratiﬁcation and restriction in order
to minimise between-cluster variation and achieve overall balance
between study arms with regard to key variables. First, random-
isation was stratiﬁed on distance (10 km or >10 km) from the
Masaka district capital, as this may inﬂuence accessibility to HIV
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Fig. 1. Study clusters.
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care, and on cluster make-up, i.e. whether the cluster was
composed of a single large village or several small villages: 70,560
possible allocations (possible ways in which clusters could be
randomised to intervention or control arms) were generated under
the stratiﬁed design. Restricted randomisation was then applied to
achieve balance on the following covariates: cluster size; presence
of a trading centre; location along a major road; lakeshore location;
and presence of an HIV clinic within 5 km. The tolerance thresholds
for balance were deﬁned through an iterative process in which
different thresholds were tried and the number and the validity of
the acceptable allocations examined. Of the possible allocations
under the stratiﬁed design, 28,932 (41%) were found to satisfy the
additional balance criteria after restriction. Of these, a list of 1000
acceptable allocations was randomly generated from which one
was selected at public randomisation ceremony. Each allocation
had a unique running number.
2.4.1. Public randomisation ceremony
The ceremony was held on 13th March 2015 and attended by
1e2 leaders from each of the villages. Three sacks each containing
10 balls labelled 0 to 9 were prepared, representing allocations 001
to 999, and 000 representing 1000. The principle underlying the
random selection procedure was carefully explained in simple
words. Three community leaders, selected by their peers, were then
invited and one after the other each asked to draw one ball from
one sack (3 balls total) thus generating a 3-digit number, corre-
sponding to the allocation running number on the list. The six
clusters added later were treated as a separate stratum. Possible
allocations for these clusters were generated using the same pro-
cedure described above and one allocation selected at a second
public randomisation ceremony on 30th June 2015.
2.5. Study interventions
Participants in the control and intervention clusters receive
HBHCT and a written referral to an HIV care clinic of their choice if
found to be HIV-positive. In addition, participants in the interven-
tion clusters receive two follow-up counselling sessions at their
home, delivered within 2 months after testing. Each session lasts
about 45 min. The counselling intervention is designed to address
common previously described psychosocial barriers of linkage to
HIV care such as stigma [42e45], non-disclosure of HIV status
[34,46,47], denial of HIV diagnosis [43,45,47], misconceptions
about antiretroviral drugs (ARV) [26,30,45], and fear of their side
effects [26,30], lack of partner [45,48] and other social support
[34,47,49], and misconceptions about ART provider practices
[45,49]. The content of the counselling intervention includes: a
discussion of the individual's acceptance of HIV diagnosis, experi-
ence of stigma, plans to seek care and support services, importance
of HIV status disclosure and psychosocial support for linkage to and
retention in care; and provision of information about local HIV care
services, ARVs, and rationale for early linkage to care. In keeping
with previous observational studies of linkage to care interventions
[21,22,25,29], follow-up counselling in our study is conducted at
one and two months after HBHCT. HIV-negative participants in the
intervention arm are offered home-based risk reduction counsel-
ling and encouraged to seek regular HIV testing.
2.6. Study procedures
A summary of the study procedures is provided in Table 1.
2.6.1. Preparatory phase
Mapping of the study area, community mobilisation meetings,
staff recruitment and training, setting up of referral tracking and
linkage veriﬁcation procedures with HIV care providers were con-
ducted in the three months prior to study initiation. In each cluster,
additional community mobilisation is conducted one week prior to
HBHCT.
2.6.2. Screening and enrolment
Accompanied by a community guide, study counsellors visit all
the households in the randomised clusters, enumerate all resident
adults aged 18 years and offer them HBHCT. HCT is conducted in
accordance with national guidelines [50]. Married/cohabiting in-
dividuals are given the option of couple or individualised HCT.
Identiﬁed HIV-positive individuals who are not yet in care are given
a written referral letter (a copy is retained for the study ﬁle) to take
to their preferred HIV care provider for initiation of cotrimoxazole
prophylaxis, CD4 count testing (results available within 4 weeks),
and ART initiation if eligible under national guidelines (CD4
<500 cells/mL). Additionally, they are given detailed information
about the study and invited to consent and participate. After
obtaining consent, the individual's eligibility for the study is
assessed, he/she is enrolled if eligible, and informed of his/her
cluster allocation. A questionnaire is then administered to collect
data on socio-demographic characteristics and history of previous
HIV testing history. Households in which some or all adults are not
at home are revisited at least two more times.
Once 3e4 HIV-positive participants are enrolled, enrolment is
also offered to the ﬁrst consenting person that tests HIV negative in
the next household. We expect to recruit at least 84 HIV-negative
participants.
2.6.3. Participant follow-up
There are four post-enrolment home-based follow-up visits.
 Months 1 and 2 (intervention arm only): to provide follow-up
counselling.
 Month 6: to collect data on linkage to care and other outcomes,
perform CD4 cell count testing for participants who have not
had a CD4 count test at an HIV clinic or are not aware of the
result, and repeat HCT for HIV-negative participants. CD4 cell
count and repeat rapid HIV tests are conducted at theMRC/UVRI
laboratory in Masaka town. Repeat rapid HIV tests are con-
ducted at the laboratory instead of participants' homes in order
to make the procedures for HIV-positive and HIV-negative
participants as similar as possible and thus minimise the risk
of revealing participants' HIV status.
 Month 6 þ 1 week: to provide CD4 cell count or repeat HIV test
results.
Participants not found at home at any of the post-enrolment
visits are revisited at least two more times.
2.6.4. Collection of outcome data
Outcome data are collected using two methods: Firstly, a
questionnaire is administered by the counsellor to collect infor-
mation on whether and when the participant linked to care, pro-
vided a blood sample for CD4 cell count testing and received the
results, was informed of his/her ART eligibility and initiated ART,
initiated cotrimoxazole prophylaxis andwhether he/she adhered to
cotrimoxazole prophylaxis. Good adherence to cotrimoxazole
prophylaxis is deﬁned as self-report of having taken >80% (25) of
30 doses in the past month. Secondly, clinic records are reviewed,
looking for a participant's referral letter and medical forms, and
pre-ART and/or ART register books to verify self-reported linkage
and other outcomes. Participants whose records are not found at
the HIV clinic are re-contacted, informed of the veriﬁcation
outcome, and asked to clarify if they actually registered for care or
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not. Except for adherence to cotrimoxazole, which is not recorded
in the clinic records, only veriﬁed data will be used for the analysis
of primary and secondary outcomes.
2.6.5. Data management
Data are collected using paper-based questionnaires. Before
data entry, questionnaires are checked for completeness and logical
consistency. Data are double-entered and validated in Microsoft
Access. Queries are run on the entered data every fortnight and
reports sent to the study team for resolution. Data arising from the
resolved queries are resubmitted for entry and the process is
repeated until no more queries are generated.
2.7. Analysis plan
Analyses will be by intention to treat and based on individual-
level data, since there is a reasonable number of clusters per arm
and the cluster size varies considerably [51]. Random effects logistic
regression and Cox regression with shared frailty will be used to
estimate the effect of the intervention on the proportion of par-
ticipants linking to care and time to linkage, respectively. Likeli-
hood ratio tests will be performed for hypothesis testing. Similar
methods will be used to estimate the effect of the intervention on
the proportions of participants that adhere to cotrimoxazole pro-
phylaxis and undergo repeat HIV testing, and on the time to receipt
of CD4 count results, and ART initiation. The primary analysis of the
intervention effect for all outcomes will be adjusted for random-
isation stratum as a ﬁxed effect. Exploratory analyses adjusting for
age and sex a priori, and other characteristics that show substantial
baseline imbalance, will also be carried out. Although the primary
analyses will be based on individual-level approaches, analyses
based on cluster-level approaches will also be performed to check
the robustness of the results. Kaplan-Meier methods will be used to
calculate time to linkage, receipt of CD4 count results, and ART
initiation in each arm. Median and interquartile ranges for time to
these outcomes will be estimated. A detailed statistical analysis
plan will be prepared prior to data analysis.
Ethical approval
The initial study protocol and subsequent amendments were
approved by Uganda Virus Research Institute Research Ethics
Committee (GC/127/14/12/491), the Uganda National Council for
Science and Technology (HS 1732), and The London School of Hy-
giene and Tropical Medicine Ethics Committee (8833). Written
informed consent (including consent to track referrals and review
medical records for persons who link to care) is obtained from each
participant before study procedures are conducted. The trial is
registered at ClinicalTrials.gov (NCT02497456).
3. Discussion
This study is one of the few randomised trials from sub-Saharan
Africa designed to evaluate the effect of an intervention to increase
linkage to HIV care following HIV diagnosis through HBHCT. We are
aware of ﬁve other such trials. The ﬁrst is a recently completed
individually randomised controlled trial from South Africa and
Uganda that assessed whether community-based HIV testing
(including HBHCT) with counsellor support (home-based follow-up
counselling and accompanied referral) and POC CD4 cell count
testing increases uptake of ART. In this trial, linkage to care was
high (89%) across all linkage strategies used [20]. The second is a
completed but not yet reported individually randomised trial from
rural western Kenya aiming to assess the accuracy, feasibility and
acceptability of point-of-care (POC) CD4 testing for persons found
HIV positive through HBHCT, and to determine the (cost-) effec-
tiveness of this intervention in improving linkage to care and time
to ART initiation [52]. The third is an ongoing cluster randomised
trial in rural Uganda to evaluate the effectiveness of linkage to care
counselling in achieving HIV viral suppression and to determine
intermediate outcomes (linkage, time to initiation of opportunistic
infection prophylaxis, and time to initiation of ART among people
testing HIV positive during HBHCT) [53]. The fourth is an ongoing
household randomised trial in rural Lesotho to evaluate the effec-
tiveness of same day home-based ART initiation after HIV diagnosis
coupled with a reduced frequency of clinic follow-up visits in
improving linkage to care, retention in care, and viral suppression
[54]. The ﬁfth is a planned individually randomised trial in western
Kenya that will compare home and other community recruitment
strategies, HIV testing strategies (self-testing, HCT in a home/mo-
bile setting, and facility-based HCT), and different linkage strategies
(referral only, text message reminder, and ﬁnancial incentive) to an
adaptive (SMART trial design) linkage to care intervention, among
young at-risk women [55]. Primary outcomes for this trial include
uptake of recruitment strategies, uptake of testing modalities,
linkage to and retention in care.
A major strength of our trial is that referrals for care are tracked
and medical records examined to verify self-reported linkage.
Hence it is unlikely that the proportion of persons linking to care
will be overestimated. Despite concerns about inadequate routine
Table 1
Study procedures.
Procedure 3 months 1 week Month 0 Month 1 Month 2 Month 6 Month 6 þ 1 week
Mapping & identiﬁcation of clusters X
Community mobilisationa X X
Recruitment and training of staff X
Set up of referral tracking and linkage veriﬁcation procedures X
Census & HBHCT X
Study information & informed consent X
Eligibility screening & enrolment X
Collection of socio-demographic data X
Referral for care X
Follow-up counselling (Intervention arm) X X
Collection of outcome data (participant interview) X
Collection of outcome data (review of HIV clinic records) X
Sample collection for CD4 cell count testingb X
Sample collection for repeat HIV testing X
Delivery of CD4 cell count and repeat HIV test resultsc X
a Community mobilisation activities are conducted up to one week before onset of HBHCT in each cluster.
b CD4 count testing is done for participants who have not had a CD4 count test or are not aware of the result.
c Testing is conducted at the MRC/UVRI in Masaka town.
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record keeping at health care facilities in Uganda [56], we have so
far not encountered such a problem at HIV care clinics. All infor-
mation on reported linkage collected and analysed to date have
either been veriﬁed by clinical records, or have been withdrawn as
false when individual patients were re-interviewed in case of dis-
crepancies. Participants who self-report not linking to care are not
tracked further, as it is unlikely that individuals would link to care
but choose to report otherwise.
We randomised communities instead of individuals in order to
minimise the risk of contamination between trial arms e.g. through
sharing of follow-up counselling information, which would result
in a dilution of intervention effects. Also, individual randomisation
may not have been acceptable to participants especially if they
perceive one of the interventions to be inferior to the other.
The study has some limitations. First, some individuals in the
study communities may have knowledge of their cluster allocation
which may inﬂuence their decision to enrol in the study. In-
dividuals may obtain prior knowledge of cluster allocation through
community leaders who attended the pre-enrolment public ran-
domisation ceremony or from those in the same community who
have enrolled before them. Tominimise the effect of this potentially
differential enrolment, individuals are only informed of their
cluster allocation after they have consented and enrolled in the
study. Additionally, within each village, participants are enrolled
over 2e4 days, tominimise the time available for individuals to ﬁnd
out their allocation from fellow village residents. Related to this is
the risk of differential loss to follow-up after enrolment e.g. because
different proportions of participants may withdraw from the trial
after becoming aware of their allocation. To mitigate against this,
part of the eligibility criteria is “availability for the entire duration
of the study and willingness to be followed up at home”. Partici-
pants who indicate that they will not be available for follow-up are
excluded from the study. Second, despite the creation of buffer
zones between clusters, there might still be a risk of contamination
resulting from possible interaction between study participants
from different trial arms. Data on the occurrence of such interaction
is collected at the month-6 visit; the results will be reported along
with the main trial ﬁndings.
We did not include a component to evaluate cost-effectiveness
of the home-based follow-up intervention. Such evaluation may
be necessary to inform policy if the intervention is found to be
effective. However, given the fact that it is a relatively simple
intervention, the costs of incorporating it into the routine HBHCT
work are likely to be minimal.
Whereas quantitative methods such as those used in our trial
are appropriate for investigating the effect of a health care inter-
vention, a qualitative exploration of experiences, attitudes, beliefs
and understandings is needed to ﬁnd out why the intervention
works or does not work [57,58]. For this reason, a qualitative sub-
study is being conducted in both trial arms in a sub-set of partici-
pants who linked successfully to care and others who did not in
order to better understand the reasons for linkage or lack of linkage
to HIV care.
This study will contribute evidence on the impact of referral
plus home-based follow-up counselling on linkage to care, as
compared to only referral among adults identiﬁed with HIV infec-
tion through HBHCT in Uganda. Interpretation of trial outcomes
will be aided by ﬁndings from the qualitative sub-study.
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Abstract 
Introduction: The aim of this study was to determine whether counselling provided 
subsequent to HIV testing and referral for care increases linkage to care among HIV-
positive persons identified through home-based HIV counselling and testing (HBHCT) 
in Masaka, Uganda. 
 
Methods: The study was an open-label cluster randomised trial. 28 rural communities 
were randomly allocated (1:1) to intervention (HBHCT, referral, and counselling at one 
and two months) or control (HBHCT and referral only). HIV-positive care-naïve adults 
(≥18 years) were enrolled. To conceal participants’ HIV status, one HIV-negative person 
was recruited for every 3 HIV-positive participants. Primary outcomes were linkage 
(registration with an HIV clinic) status at 6 months, and time to linkage. Primary analyses 
were intention-to-treat using random effects logistic regression or Cox regression with 
shared frailty, as appropriate.  
 
Results: 302 (intervention, n=149; control, n=153) HIV-positive participants were 
enrolled. Except for travel time to the nearest HIV clinic, baseline participant 
characteristics were generally balanced between trial arms. Retention was similar across 
trial arms (92% overall). 127 (42.1%) participants linked to care: 76 (51.0%) in the 
intervention arm versus 51 (33.3%) in the control arm [odds ratio=2.18, 95% confidence 
interval (CI)=1.26-3.78; p=0.008)]. There was evidence of interaction between trial arm 
and follow-up time (p=0.009). The probability of linkage, did not differ between arms in 
the first two months of follow-up but was subsequently higher in the intervention arm 
versus the control arm [hazard ratio=4.87, 95% CI=1.79-13.27, p=0.002].  
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Conclusion: Follow-up counselling substantially increases linkage to care among HIV-
positive adults identified through HBHCT and may enhance efforts to increase 
antiretroviral therapy coverage in sub-Saharan Africa.  
 
Clinical Trial Number: NCT02497456 
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Introduction 
Home-based HIV counselling and testing (HBHCT) is highly acceptable [1-3], cost-
effective at reaching previously untested persons compared with other HIV counselling 
and testing (HCT) models [4], and has the potential to substantially increase knowledge 
of HIV status in Sub-Saharan Africa (SSA) [5]. However, linkage to care following 
HBHCT is often inadequate. A recent review found that in the absence of interventions 
to facilitate linkage, less than one-third of HIV-positive persons identified through 
HBHCT in SSA link to care [6].  
 
In order for the populations targeted by HBHCT to fully benefit from HIV prevention and 
care services, interventions that can link them to these services need to be identified and 
utilised. Results from observational studies suggest that counselling provided after 
referral could increase linkage to care among HIV-positive persons identified through 
HBHCT in SSA [7-11]. A major limitation of observational studies however is that it is 
difficult to account for the effects of confounding factors such as stigma, healthcare 
seeking behaviour, and familiarity with the health care services. Moreover, counselling 
in some of these studies [7, 8, 10] was delivered alongside other interventions to increase 
linkage, making it difficult to distinguish the effects of each. Therefore, randomised trials 
are required to determine the potential effects of counselling and other interventions on 
linkage. One randomised trial conducted in South Africa and Uganda evaluated the effect 
of follow-up counselling after community-based HCT on linkage. In this trial, follow-up 
counselling had modest effects on linkage [12].  
 
In the current study, we evaluated the effectiveness of counselling after HIV diagnosis 
and referral to care, compared to referral to care only, on linkage to care among HIV-
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positive individuals identified through HBHCT in Masaka district, Uganda. We used a 
cluster randomised design in order to reduce the risk of contamination between trial arms 
and increase acceptability of the interventions.  
 
Methods  
Study design and participants 
The study was an open-label cluster randomised controlled trial. A description of the 
methods has been previously reported [13]. Briefly, 28 rural communities (clusters) were 
randomly allocated (1:1) to intervention (HBHCT, referral and counselling at one and 
two months) or control (HBHCT and referral only). HBHCT was offered to all adults 
(≥18 years). HIV-positive persons were eligible to participate if they were able to consent, 
not previously or currently in care, available for follow-up, and not participating in other 
health-related research. To reduce the possibility of revealing participants’ HIV-positive 
status to other community members, one HIV-negative adult (≥18 years) who was willing 
to be followed-up was recruited for every 3 HIV-positive participants. Participants were 
recruited between March and September 2015. 
 
Intervention 
The intervention comprised two 45-minute counselling sessions delivered at participants’ 
homes one and two months after HBHCT. The content of the counselling included: a 
discussion of the individual’s acceptance of HIV diagnosis, fear of or experience of 
stigma, plans to seek care, importance of HIV status disclosure and availability of 
psychosocial support for linkage to and retention in care; and information about local HIV 
care services, antiretroviral drugs, and rationale for early linkage to HIV care. HIV-
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negative participants in the intervention arm received HIV risk reduction counselling and 
information on the importance of regular HCT.  
 
Outcomes 
Primary outcomes were linkage to care (registration with an HIV clinic), determined 
6 months after HIV diagnosis, and time to linkage. Secondary outcomes were time to 
obtaining a CD4 count, time to antiretroviral therapy (ART) initiation, and adherence 
(≥80% intake) to daily cotrimoxazole prophylaxis (CTXp) at 6 months. Uptake of repeat 
HCT at the 6 month visit by HIV-negative participants was also defined as a secondary 
study outcome.  
 
Randomisation 
To ensure a reasonable number of participants in each cluster, small villages were 
combined with adjacent villages into larger clusters of ≥400 adults. Clusters were 
separated by a buffer zone of ≥1 non-participating villages to minimise the risk of 
contamination between trial arms. Clusters were randomly allocated to intervention and 
control arms. Stratification and restricted randomisation were used to minimise between-
cluster variation and achieve overall balance between trial arms with regard to key 
variables [13]. Stratification was defined by distance (≤10 km or >10 km) from the district 
capital, and by cluster make-up, i.e. whether the cluster was composed of a single large 
village or several small villages. Restricted randomisation was then applied to achieve 
balance on the following cluster-level variables: size (number of adults in a cluster); 
presence of a trading centre; location along a major road; lakeshore location; and presence 
of an HIV clinic within 5 km.  
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Procedures  
Preparatory activities: these included mapping of the study area, enumeration of all 
adults, community mobilisation, and setting of up referral tracking and outcome 
verification procedures.  
 
HCT: HIV testing was conducted in accordance with national guidelines [14] by 
experienced counsellors. Married/cohabiting individuals had the option of receiving HCT 
as a couple. Blood obtained by finger-prick was tested using HIV rapid test kits: Alere 
Determine HIV-1/HIV-2 (Alere Medical, Japan) for screening, Stat-Pak HIV 1/2 
(Chembio Diagnostic systems, USA) for confirmation of positive results, and Uni-Gold 
HIV 1/2 (Trinity Biotech, Ireland) as tie-breaker.  
 
Enrolment: Eligible individuals were given study information, informed that their 
community could either be in either of the study arms, and invited to consent. Individuals 
were informed about which trial arm their community was allocated to after enrolment. 
Participants completed a counsellor-administered questionnaire on socio-demographic 
characteristics and HCT history.  
 
Collection of outcome data: 6 months after HBHCT, participants were visited by a 
counsellor to collect information on study outcomes. To assess the potential of 
contamination between trial arms, participants were asked if they knew of persons from 
other villages who were participating in the study and if they had discussed the study with 
them. Self-reported linkage and other outcomes were confirmed by tracking referrals and 
reviewing clinic records. Participants whose records could not be found at the clinics were 
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informed of the verification outcome and asked to clarify if they had actually linked or 
not.  
 
HIV-negative study component: similar enrolment procedures were applied to the HIV-
negative participants. Study counsellors visited participants in the intervention arm at one 
and two months to conduct counselling, and in both arms at 6 months, to offer repeat 
HCT.  
 
Ethical considerations 
The trial was approved by Uganda Virus Research Institute Research Ethics Committee, 
the Uganda National Council for Science and Technology, and the Ethics Committee of 
the London School of Hygiene and Tropical Medicine. Written informed consent was 
obtained from each participant before study procedures were conducted. The trial is 
registered at ClinicalTrials.gov (NCT02497456). 
 
Sample size 
Based on findings from HBHCT studies in which only referral was provided following 
HIV diagnosis [15-18] and those in which counselling was provided after referral [7, 8], 
we assumed linkage of 35% in the control arm and that this would increase to 60% in the 
intervention arm. We aimed to have 80% power to detect this increase in linkage at a 
significance level of 5%. Based on data from settings similar to Masaka [13], we assumed 
that the between-cluster coefficient of variation (k) for linkage in the absence of 
intervention was 0.25. Based on these assumptions and an estimated harmonic mean of 7 
participants per cluster, 28 clusters would be needed. This sample size would also provide 
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>80% power to detect a hazard ratio of 1.7 for the effect of the intervention on time to 
linkage [19].  
 
Analysis 
All analyses were pre-specified in an analysis plan. The primary analyses were intention-
to-treat and based on individual-level data, since there was a sufficient number of clusters 
per arm and the cluster size varied considerably [20]. Random effects logistic regression 
and Cox regression with shared frailty were used to estimate the effect of the intervention 
on the linkage and time to linkage, respectively. Participants who were lost to follow-up 
were assumed not to have linked to care. Those who were reported at the 6 month follow-
up visit to have permanently left the study area were censored midway between enrolment 
and that visit. Those who were still in the study area but did not attend the 6 month visit 
were censored at that visit. The primary analyses of the intervention effect were adjusted 
for randomisation stratum as a fixed effect. Secondary analyses were adjusted for age and 
sex a priori, and other characteristics that showed substantial baseline imbalance. Due to 
the nature of the intervention i.e. repeated counselling sessions, it was expected that the 
effect of the intervention might change over time. Therefore, the proportional hazards 
assumption was examined by splitting follow-up time into two intervals (0-2 months and 
>2 months) at a point corresponding with the time of the second counselling session, and 
testing for an interaction between trial arm and time. Similar methods were used to 
estimate the effect of the intervention on the proportions that adhered to CTXp, and on 
the time to obtaining CD4 counts, and ART initiation among HIV-positive participants, 
and on the proportion that accepted repeat HCT among HIV-negative participants.  
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Analyses based on cluster-level summaries (Additional file 1) were also performed to 
check the robustness of the individual-level analysis, using methods for stratified cluster 
randomised trials [21]. Intervention effects on binary outcomes were measured using 
prevalence ratios (PR), calculated as the ratio of the arithmetic mean of the cluster-
specific prevalence of the outcome in each arm. The 95% confidence interval (CI) was 
calculated with variance estimated from the residual mean square from a two-way 
analysis of variance (ANOVA) of cluster-specific prevalence on stratum and trial arm. 
Adjusted PR were calculated as the arithmetic mean ratio of observed to expected 
prevalences in each cluster, with logistic regression used to estimate the expected 
prevalence, adjusted for age, sex, stratum, and other variables that showed baseline 
imbalance. CIs were obtained from an ANOVA of the observed/expected prevalences on 
stratum and trial arm, as described above. Intervention effects on time-to-event outcomes 
were measured using rate ratios (RR) by similar methods; Poisson regression was used to 
estimate expected number of events for the adjusted analyses.  
 
Data from the control arm was used to estimate k for linkage to care. STATA version 12.0 
(StataCorp, College Station, Texas) was used for all analyses. 
 
Results 
The trial profile is shown in Figure 1.  
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Figure 1: Flow of clusters and participants through the trial  
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13,455 people (89.1% of those enumerated) were contacted of which 12,100 (89.9%) 
accepted HBHCT. Common reasons for declining HBHCT were being HIV-positive and 
already engaged in care (437, 32.3%), not wanting to know one’s HIV status (397, 
29.3%), and having recently undergone HCT (214, 15.8%). Of those who accepted 
HBHCT, 551 (4.6%) tested HIV-positive, and of these 205 (37.2%) were already in care 
and thus ineligible. Of those eligible, 302 (87.3%) were enrolled. Baseline participant 
characteristics are summarized in Table 1.  
 
Table 1: Baseline characteristics of participants 
 HIV-positive participants  HIV-negative participants 
 Intervention  Control  Intervention  Control  
 N (%) N (%) N (%) N (%) 
Total enrolled  149  153 52  58  
Sex      
Female  76 (51.0) 89 (58.2) 26 (50.0) 37 (63.8) 
Male  73 (49.0) 64 (41.8) 26 (50.0) 21 (36.2) 
Mean age in years (SD)  32.6 (11.3)  33.7 (12.0)  36.1 (11.9) 33.6 (12.5) 
Age group      
18-24 years 34 (22.8) 37 (24.2) 10 (19.2) 16 (27.6) 
25-34 years  63 (42.3) 58 (37.9) 15 (28.9) 18 (31.0) 
35-44 years 29 (19.5) 30 (19.6) 14 (26.9) 13 (22.4) 
45+ years 23 (15.4) 28 (18.3)  13 (25.0) 11 (19.0) 
Marital status      
Married/cohabiting 85 (57.1) 97 (63.4) 38 (73.1) 43 (74.1) 
Single  22 (14.8) 26 (17.0)  6 (11.5) 10 (17.2)  
Divorced/separated/widowed 42 (28.2) 30 (19.6) 8 (15.4) 5 (8.6) 
Education      
None/incomplete primary 86 (57.7) 96 (62.8) 22 (42.3)  25 (43.1) 
Primary 34 (22.8) 32 (20.9) 9 (17.3) 14 (24.1) 
Above primary 29 (19.5) 25 (16.3) 21 (40.4) 19 (32.8) 
Occupation     
Subsistence farmer  84 (56.4) 80 (52.3) 16 (30.8) 25 (43.1) 
Other  65 (43.6) 73 (47.7) 36 (69.2) 33 (56.9) 
Socio-economic status*     
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 HIV-positive participants  HIV-negative participants 
 Intervention  Control  Intervention  Control  
 N (%) N (%) N (%) N (%) 
Low  56 (37.6)  61 (39.9) 10 (19.2) 19 (32.8) 
Middle  52 (34.9) 56 (36.6) 18 (34.6) 14 (24.1) 
High  41 (27.5) 36 (23.5)  24 (46.2) 25 (43.1) 
Travel time to nearest HIV clinic     
<30 minutes  52 (34.9)  34 (22.2) 21 (40.4) 12 (20.7) 
30 minutes or more  97 (65.1) 119 (77.8) 31 (59.6) 46 (79.3) 
Ever tested for HIV      
No  30 (20.1) 29 (19.0) 1 (1.9) 1 (1.7)  
Yes  119 (79.9) 124 (81.0) 51 (98.1) 57 (98.3)  
Tested for HIV in the last 12 months     
No  71 (47.7) 81 (52.9) 6 (11.5) 5 (8.6) 
Yes  78 (52.4) 72 (47.1) 46 (88.5) 53 (91.4) 
Previously aware of HIV-positive 
status      
No  131 (87.9)  134 (87.6)  - - 
Yes   18 (12.1)  19 (12.4) - - 
SD = standard deviation; *Socio-economic status categories were obtained from a wealth index scale based 
on ownership of household and other properties using principal component analysis.  
 
The mean age of HIV-positive participants was 33.2 years (standard deviation, 11.7); the 
majority were female (54.6%), married/cohabiting (60.3%), had incomplete primary 
school/no formal education (60.3%), and had previously undergone HCT (80.5%). 265 
(87.8%) were newly diagnosed. Baseline variables were generally balanced between trial 
arms; however, participants in the intervention arm were more likely to report <30 
minutes travel time to the nearest HIV clinic than those in the control arm (34.9% vs. 
22.2%). 25 (8.3%) HIV-positive participants were lost to follow-up (12 in the intervention 
arm): 13 (4.3%) permanently left the study area; 8 (2.6) for unknown reasons; 2 (<1%) 
died; and 2 (<1%) were unwilling to continue follow-up. 
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110 HIV-negative individuals were enrolled (Table 1). The distribution of baseline 
characteristics among HIV-negative participants was similar to that of HIV-positive 
participants. 8 (7.3%) were lost to follow-up.  
 
Linkage to care: 127 (42.1%) of the 302 HIV-positive participants linked to care: 76 
(51.0%) in the intervention arm versus 51 (33.3%) in the control arm [odds ratio 
(OR)=2.18, 95% CI=1.26-3.78; Table 2].  
128
  
 
 T
a
b
le
 2
: 
E
ff
ec
t 
o
f 
fo
ll
o
w
-u
p
 c
o
u
n
se
ll
in
g
 o
n
 l
in
k
a
g
e,
 a
d
h
er
en
ce
 t
o
 C
T
X
p
 a
n
d
 u
p
ta
k
e 
o
f 
re
p
ea
t 
H
C
T
 
 
In
te
rv
en
ti
o
n
 a
r
m
 
C
o
n
tr
o
l 
a
r
m
 
O
R
 (
9
5
%
 C
I)
 
p
-v
a
lu
e 
a
O
R
 (
9
5
%
 C
I)
¶ 
p
-v
a
lu
e 
A
m
o
n
g
 H
IV
-p
o
si
ti
v
e 
p
a
rt
ic
ip
a
n
ts
 
 
 
 
 
 
 
L
in
k
a
g
e 
to
 c
ar
e 
7
6
/1
4
9
 (
5
1
.0
) 
5
1
/1
5
3
 (
3
3
.3
) 
2
.1
8
 (
1
.2
6
-3
.7
8
) 
0
.0
0
8
 
2
.1
4
 (
1
.2
4
-3
.7
0
) 
0
.0
0
9
 
A
d
h
er
en
ce
 t
o
 C
T
X
p
 
6
6
/1
4
9
 (
4
4
.3
) 
4
3
/1
5
3
 (
2
8
.1
) 
2
.1
5
 (
1
.1
6
-3
.9
8
) 
0
.0
2
 
2
.1
7
 (
1
.2
0
-3
.9
3
) 
0
.0
1
 
A
m
o
n
g
 H
IV
-n
eg
a
ti
v
e 
p
a
rt
ic
ip
a
n
ts
 
 
 
 
 
 
 
U
p
ta
k
e 
o
f 
re
p
ea
t 
H
IV
 t
es
t 
4
2
/5
2
 (
8
0
.8
) 
4
6
/5
8
 (
7
9
.3
) 
1
.0
8
 (
0
.4
2
-2
.7
8
) 
0
.8
7
 
0
.7
0
 (
0
.2
4
-2
.0
3
) 
0
.5
2
 
O
R
 =
 O
d
d
s 
ra
ti
o
; 
aO
R
 =
 a
d
ju
st
ed
 o
d
d
s 
ra
ti
o
; 
C
I 
=
 C
o
n
fi
d
en
c
e 
in
te
rv
al
; 
¶
A
d
ju
st
ed
 f
o
r 
ag
e,
 s
ex
, 
st
ra
ta
 &
 t
ra
v
el
 t
im
e 
to
 t
h
e
 n
ea
re
st
 H
IV
 c
li
n
ic
 
129
  
 
 
The effect of the intervention was similar after adjusting for age, sex, and travel time to 
the HIV clinic [adjusted (a)OR=2.14, 95% CI=1.24-3.7)]. The crude and adjusted effect 
estimates from the cluster-level analysis were attenuated but consistent with a higher 
linkage in the intervention versus the control arm [prevalence ratio (PR)=1.59, 95% 
C=1.09-2.33; aPR=1.58, 95% CI=1.07-2.34].  
 
The probability of linkage was similar in both trial arms up to the first month of follow-
up. Subsequently, more participants linked in the intervention arm than in the control arm 
with the difference becoming more marked at around the second month of follow-up 
(Figure 2).  
 
 
Figure 2: Kaplan-Meier estimates of linkage to care 
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The overall hazard ratio (HR) was 1.65 (95% CI=1.11-2.44) and was similar after 
adjusting for age, sex, and travel time to the HIV clinic [aHR=1.62, 95% CI=1.12 to 2.33; 
Table 3].  
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There was strong evidence of interaction between trial arm and follow-up time (p=0.009). 
In the first interval (0-2 months), 57 (38.3%) participants linked in the intervention arm 
versus 46 (30.1%) in the control arm [HR=1.32, 95% CI=0.86-2.03; aHR=1.30, 95% 
CI=0.87-1.94]. In the second interval (>2 months), 19 (20.7%) participants linked in the 
intervention arm versus 5 (4.7%) in the control arm [HR=4.87, 95% CI=1.79-13.27; 
aHR=4.78, 95% CI=1.77-12.89]. The cluster-level analysis was also consistent with an 
intervention effect on rate of linkage [rate ratio (RR)=1.84, 95% CI=0.99-3.42; 
aRR=1.92, 95% CI=0.96-3.86)].  
 
Obtaining CD4 counts from HIV clinics: 107 (35.4%) participants obtained CD4 counts; 
67 (45.0%) in the intervention arm versus 40 (26.1%) in the control arm. The overall HR 
was 1.91 (95% CI=1.25-2.93; Table 3) and was similar after adjusting for age, sex, and 
travel time to the HIV clinic [aHR=1.86, 95% CI= 1.23-2.80]. There was some evidence 
of interaction between trial arm and follow-up time (p=0.05). In the first follow-up 
interval, 40 (26.8%) participants obtained CD4 counts in the intervention arm versus 30 
(19.6%) in the control arm [HR=1.45, 95% CI=0.88-2.40; aHR=1.41, 95% CI=0.87-
2.28]. In the second follow-up interval, 27 (24.8%) participants obtained CD4 counts in 
the intervention arm versus 10 (8.1%) in the control arm [HR=3.35, 95% CI=1.59-7.04; 
aHR=3.27, 95% CI=1.57-6.81]. Results from the cluster-level analysis were consistent 
with an intervention effect on time to receiving CD4 counts [RR=2.10, 95% CI=1.14-
3.84; aRR=2.12, 95% CI=1.22-3.70].  
 
ART initiation: 90 (29.8%) participants initiated ART overall; 50 (33.6%) in the 
intervention arm versus 40 (26.1%) in the control arm. The overall HR was 1.31 (95% 
CI=0.85-2.04) and was similar after adjusting for age, sex, and travel time to the HIV 
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clinic [aHR=1.33, 95% CI=0.85-2.06; Table 3]. There was strong evidence of interaction 
between trial arm and follow-up time (p=0.0007). In the first follow-up interval, 25 
(16.8%) participants initiated ART in the intervention arm versus 33 (21.6%) in the 
control arm [HR=0.78, 95% CI=0.46-1.34; aHR=0.79, 95% CI=0.46-1.34]. In the second 
follow-up interval, 25 (20.2%) participants initiated ART in the intervention arm versus 
7 (5.8%) in the control arm [HR=3.90, 95% CI=1.67-9.11; aHR=3.96, 95% CI=1.69-
9.26]. In the cluster-level analysis, the intervention also increased ART initiation overall, 
but there was no evidence of a significant difference [RR=1.21, 95% CI=0.69-2.13; 
aRR=1.27, 95% CI=0.77-2.12]. 
 
Adherence to CTXp: 36.1% of the participants reported adhering to CTXp; adherence was 
higher in the intervention arm compared to the control arm [44.3% versus 28.1%; 
OR=2.15, 95% CI=1.16-3.98; aOR (adjusted for age, sex, and time to the HIV 
clinic)=2.17, 95% CI=1.20-3.93; Table 2]. The cluster-level estimates for the effect of 
intervention on adherence to CTXp were attenuated compared with those from the 
individual-level analysis, but were consistent with significantly higher adherence in the 
intervention arm compared to the control arm [PR=1.69 95% CI=1.04-2.75; aPR=1.70, 
95% CI=1.06-2.74].  
 
Uptake of repeat HCT among HIV-negative participants: overall uptake of repeat HCT 
was 80.0%. There was no evidence of a difference in uptake between intervention and 
control arms [80.8% versus 79.3%; OR=1.08, 95% CI=0.42-2.78; aOR (adjusted for age, 
sex, and time to the HIV clinic)=0.70, 95% CI= 0.24-2.03; Table 2]. Conclusions from 
the cluster-level analysis were similar [PR=0.95, 95% CI=0.76-1.20; aPR=0.90, 95% 
CI=0.72-1.13].  
134
  
 
Contamination: two (<1%) individuals reported that they had discussed the trial with 
participants from villages other than their own.  
 
Coefficient of variation: k values for linkage and rate of linkage were 0.33 and 0.52 
respectively.  
 
Discussion 
This trial showed that an intervention comprising two brief counselling sessions for adults 
identified with HIV through HBHCT strongly increases linkage to care. In the individual-
level analysis, the intervention was associated with a twofold increase in the proportion 
of persons linking to care, and approximately 5-fold increase in the hazard of linkage after 
the second counselling visit; the estimates did not change after adjusting for age, sex, and 
travel time to the HIV clinic. Results from the cluster-level analysis were also consistent 
with an intervention effect on linkage and time to linkage. The trial also showed that 
follow-up counselling significantly increased the rate of obtaining CD4 counts, ART 
initiation, and adherence to CTXp. For all time-to-event outcomes, the intervention effect 
increased with follow-up time, and became apparent after the second follow-up 
counselling visit.  
 
These results support reports from observational studies of enhanced linkage after follow-
up counselling for persons identified with HIV through HBHCT [7, 8, 10]. The effect 
estimates observed in this trial were stronger than those observed in a previous trial that 
investigated the impact of follow-up counselling after community-based HCT (including 
HBHCT) on linkage [12]. Follow-up counselling in that trial increased the proportions of 
individuals linking and initiating ART by only 4% and 23% respectively. This was 
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probably due to the high (89%) level of linkage in the standard-of-care (referral only) arm 
of that trial and the high proportion of ART-eligible participants who did not start ART 
due to the requirement for repeat CD4 count testing at the clinic [participants were 
randomly assigned in a factorial design to counsellor clinic linkage facilitation, counsellor 
follow-up home visits, or standard-of-care, and then either point-of-care CD4 count 
testing or referral for clinic CD4 count testing] and other clinic-level barriers to ART 
initiation. In contrast, linkage in our standard-of-care arm was 33.3%, a figure consistent 
with that observed after routine referral in studies from diverse settings in SSA [15, 16, 
22-25]. Additionally, all HIV care providers in our study area were aware of our trial and 
facilitated the verification of study outcomes for participants who sought care at their 
facilities. It is possible that this collaboration may have reduced the effects of clinic-level 
barriers on the uptake of care services for our trial participants, making it possible to 
detect an intervention effect beyond linkage. Although a reduction in clinic-level barriers 
to uptake of care would have been similar for participants in both treatment arms, those 
in the intervention arm would have been better prepared to take advantage of this than 
their counterparts in the control arm if follow-up counselling increased motivation to 
initiate care.  
 
Consistent with previous studies in generalised epidemic settings [26, 27], uptake of 
repeat HCT among HIV-negative individuals was high. Previous HCT may reduce the 
psychological stress associated with testing hence making it easier to accept repeat HCT. 
Follow-up counselling had no measurable effect on uptake of repeat HCT. This may 
partly be due to the high (79.3%) uptake of HCT in the control arm, and partly due to the 
small sample size.  
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The study had a number of strengths. The trial was conducted under real-world conditions 
in a relatively large area. HIV-positive participants were referred for care to over ten 
facilities that provided standard services. Participation and retention rates were high and 
did not differ by treatment arm thereby reducing risk of selection bias. The cluster 
randomised design further minimised selection bias, and ensured that the risk of 
contamination between treatment arms, and consequently that of diluting the intervention 
effects, was low. Referrals for all participants who reported having linked to care were 
tracked to the clinics to verify linkage, receipt of CD4 counts, initiation of CTXp and 
ART. This minimised the risk of bias that would have resulted from incomplete tracking 
of referrals and reliance on self-reported data. Indeed, 5% of the participants who reported 
having linked had in fact not done so when this information was verified at the clinics, a 
classical example of social desirability bias. 
 
The study also had some limitations. First, it was an open-label study: knowledge of the 
interventions may have influenced participants’ decisions to remain in the study. 
However since there was no differential loss to follow-up between arms, this is unlikely 
to have been a major issue. Second, data on adherence to CTXp was based on self-reports 
and could have been prone to social desirability or recall bias. Third, we did not measure 
the impact of follow-up counselling on retention in care due to the short follow-up period. 
Fourth, the observed k was higher than that used in the sample size estimation implying 
that the trial could potentially have been slightly underpowered.  
 
In summary, this is the second randomised trial designed to evaluate the effect of an 
intervention on linkage to care following HIV diagnosis through HBHCT in SSA. The 
findings suggest that follow-up counselling, a relatively simple intervention delivered by 
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non-medical personnel to HIV-positive adults identified through HBHCT, substantially 
increases linkage to care and uptake of other services including ART. In settings such as 
ours, follow-up counselling may be a useful strategy in achieving the second UNAIDS 
target (i.e. receipt of ART for 90% of the people who know their HIV status) [28] and 
should be considered for scaling up.  
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Additional file 1: Cluster-level summaries  
 
Table 4: Proportions of HIV-positive participants linking to care in each cluster 
Intervention arm Control arm 
Cluster 
Number 
enrolled 
Number 
linked (%) Cluster  
Number 
enrolled 
Number 
linked (%) 
3 6 2 (33.3) 8 15 4 (26.7) 
13 7 2 (28.6) 9 12 6 (50.0) 
17 17 10 (58.8) 19 4 2 (50.0) 
20 12 5 (41.7) 22 6 1 (16.7) 
29 8 3 (37.5) 25 10 5 (50.0) 
33 8 5 (62.5) 37 11 5 (45.5) 
35 9 2 (22.2) 43 6 0 (0.0) 
38 6 4 (66.7) 46 6 2 (33.3) 
52 7 6 (85.7) 50 15 2 (13.2) 
53 13 9 (69.2) 62 17 9 (52.9) 
54 26 11 (42.3) 65 17 8 (47.1) 
73 7 3 (42.9) 70 9 4 (44.4) 
74 13 8 (61.5) 71 17 3 (17.6) 
75 10 6 (60.0) 72 8 0 (0.0) 
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Table 8: Proportions of HIV-positive participants adhering to CTXp in each cluster   
Intervention arm  Control arm  
Cluster 
Number 
enrolled 
Number adhering 
to CTXp (%) Cluster 
Number 
enrolled 
Number adhering 
to CTXp (%) 
3 6 1 (16.7) 8 15 3 (20.0) 
13 7 1 (14.3) 9 12 6 (50.0) 
17 17 10 (58.8) 19 4 1 (25.0) 
20 12 4 (33.3) 22 6 0 (0.0) 
29 8 3 (37.5) 25 10 5 (50.0) 
33 8 5 (62.5) 37 11 4 (36.4) 
35 9 1 (11.1) 43 6 0 (0.0) 
38 6 4 (66.7)) 46 6 1 (16.7) 
52 7 3 (42.9) 50 15 2 (13.3) 
53 13 7 (53.8) 62 17 8 (47.1) 
54 26 10 (38.5) 65 17 7 (41.2) 
73 7 3 (42.9) 70 9 4 (44.4) 
74 13 8 (61.5) 71 17 2 (11.8) 
75 10 6 (60.0) 72 8 0 (0.0) 
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Table 9: Proportions of HIV-negative participants undergoing repeat HIV testing at 6 
months in each cluster 
Intervention arm Control arm 
Cluster 
Number 
enrolled  
Number 
undergoing repeat 
testing (%) Cluster 
Number 
enrolled 
Number 
undergoing repeat 
testing (%) 
3 2 2 (100.0) 8 7 6 (85.7) 
13 3 1 (33.3) 9 8 6 (75.0) 
17 8 7 (87.5) 19 1 1 (100.0) 
20 4 4 (100.0) 22 2 1 (50.0) 
29 2 1 (50.0) 25 4 4 (100.0) 
33 2 1 (50.0) 37 3 2 (66.7) 
35 3 3 (100.0) 43 2 2 (100.0) 
38 2 2 (100.0) 46 3 3 (100.0) 
52 2 2 (100.0) 50 5 4 (80.0) 
53 4 3 (75.0) 62 6 4 (66.7) 
54 10 8 (80.0) 65 7 5 (71.4) 
73 3 2 (66.7) 70 3 2 (66.7) 
74 4 3 (75.0) 71 5 4 (80.0) 
75 3 3 (100.0) 72 2 2 (100.0) 
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Abstract  
We aimed to investigate factors associated with uptake of home-based HIV testing and 
counselling (HBHCT) and access to care among those testing HIV-positive. We used data 
from a cluster-randomised trial which had demonstrated the effectiveness of a post-
HBHCT counselling intervention. The trial results have been reported previously. 
HBHCT was offered to adults (≥18 years) from 28 rural communities from Masaka, 
Uganda; HIV-positive individuals not yet in care were enrolled. The primary outcome 
was linkage (registering with an HIV clinic) status six months post-HBHCT. Random 
effects logistic regression was performed to investigate predictors of HBHCT uptake, 
linkage, obtaining CD4 counts, adherence to cotrimoxazole prophylaxis (CTXp) (≥80% 
intake), and antiretroviral therapy (ART) initiation. Risk factor analysis for uptake of 
post-HBHCT services was adjusted for trial arm. 12,100 (89.9%) of 13,455 persons 
accepted HBHCT. HBHCT uptake was higher among men [adjusted odds ratio (aOR) 
1.20, 95% confidence interval (CI) 1.07-1.36] than women, and decreased with increasing 
age. 551 (4.6%) persons tested HIV-positive, of whom 205 (37.2%) were in care 
(ineligible). 302 individuals (87.3% of those eligible) were enrolled; of these, 42.1% 
linked, 35.4% obtained CD4 counts, 29.8% initiated ART, and 36.1% reported adherence 
153
to CTXp. None of the assessed factors predicted linkage. CD4 count receipt was lower in 
participants who required ≥30 minutes to reach the nearest HIV clinic (aOR 0.60, 95% CI 
0.34-1.06) versus those who required less time. ART initiation was higher in older 
participants (≥45 versus <25, aOR 2.14, 95% CI 0.98-4.65), and lower in single (aOR 
0.60, 95% CI 0.28-1.31) or divorced/separated/widowed (aOR 0.47, 95% CI 0.23-0.93) 
individuals versus the married/cohabiting. These differences were non-significant. In 
summary, HBHCT acceptability was high but care uptake among identified HIV-positive 
persons was low. Interventions to increase enrolment in care are needed and should focus 
on increasing the desire to receive care. 
 
Key words: HIV/AIDS, HIV counselling and testing, linkage to care, Uganda, Africa 
 
Introduction 
HIV counselling and testing (HCT) is essential for expanding HIV prevention and 
treatment services (Matovu & Makumbi, 2007). Although access to HCT in sub-
Saharan Africa (SSA) has increased significantly over the past few years, its uptake 
remains low (WHO, 2015). For instance, only 60% of adults living with HIV know their 
HIV status (UNAIDS, 2016). Consequently, many HIV-positive people present late for 
care (Siedner et al., 2015) and AIDS-related morbidity and mortality remain high 
(UNAIDS, 2014). In order to expand HCT coverage in generalised epidemic settings 
and to achieve the UNAIDS target of diagnosing 90% of all people with HIV by 2020, 
WHO recommends the use of a combination of facility-based and community-based 
HCT models (WHO, 2015).  
 
Home-based HIV testing and counselling (HBHCT) has the potential to substantially 
increase knowledge of HIV status in SSA (Sabapathy, Van den Bergh, Fidler, Hayes, & 
Ford, 2012). HBHCT is highly acceptable (Sabapathy et al., 2012), cost-effective at 
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reaching previously untested persons compared with other HCT models (Menzies et al., 
2009), and may promote uptake of HCT by couples (Mantell et al., 2014) and of 
services to prevent mother-to-child HIV transmission (Wachira, Kimaiyo, Ndege, 
Mamlin, & Braitstein, 2012). Additionally, HBHCT facilitates early HIV diagnosis and 
could potentially promote early linkage to care (Wachira et al., 2012). However, there 
are limited data on linkage to care after HBHCT (Medley et al., 2013). These data 
suggest that in the absence of interventions to facilitate linkage, up to 70% of HIV-
positive persons identified through HBHCT in SSA do not link to care, and that among 
those eligible for antiretroviral therapy (ART), over 80% do not initiate it (Sharma, 
Ying, Tarr, & Barnabas, 2015). In order to design effective HBHCT programs, there is a 
need to understand the determinants of linkage to and uptake of HIV care services after 
HBHCT.  
 
Methods  
Setting and study population 
Data used for this analysis were generated during an open-label cluster randomised trial 
that evaluated the effectiveness of a counselling intervention on linkage to care after 
HBHCT between March 2015 and March 2016 in Masaka district, Uganda 
(ClinicalTrials.gov, 2015). Twenty-eight rural communities (clusters) were randomly 
allocated to intervention (care referral and follow-up counselling) or control (care 
referral only) arms (n=14 clusters/arm). Randomisation was stratified on distance from 
the district capital (≤10 km vs >10 km) and cluster composition (larger single village vs 
combined small villages), and restricted to achieve balance on the following cluster-
level covariates: cluster size; presence of a trading centre; location along a major road; 
lakeshore location; and presence of an HIV clinic within 5 km. The study population 
comprised resident adults (≥18 years) who tested HIV-positive, had never received HIV 
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care and were willing to be followed-up at home for up to 6 months after HIV 
diagnosis.  
 
Study procedures 
These have been described previously (Ruzagira, Baisley, Kamali, & Grosskurth, 2017). 
Briefly, residents in the randomised communities were informed about planned HBHCT 
activities through community meetings and/or door-to-door mobilisation by study staff 
and village health team members. Three to seven days following community 
mobilisation, study counsellors visited all the households in a community, enumerated 
resident adults and collected data on age and sex. HBHCT was offered to all consenting 
adults. Individuals who tested HIV-positive and were not in care were given referral 
letters to take to their preferred HIV clinics. Additionally, they were given information 
about the linkage-to-care trial and invited to participate. Consenting individuals were 
assessed for eligibility, enrolled if eligible, and completed a staff-administered 
questionnaire. Participants were not informed of their community’s allocation until after 
enrolment. In intervention clusters, counsellors visited participants’ homes at one and 
two months after enrolment to provide counselling aiming to encourage linkage to care. 
All participants were revisited six months post-enrolment to collect data on linkage to 
and uptake of HIV care services. Self-reported linkage was confirmed by tracking 
referrals and reviewing clinic records.  
 
Outcomes 
The primary outcome for the HBHCT phase was uptake of HBHCT. Primary outcomes 
of the trial were linkage status six months after enrolment, and time to linkage. This 
paper investigates factors associated with uptake of HBHCT (i.e. the proportion of all 
individuals offered HBHCT who accepted and had an HIV test performed at home); 
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linkage to care (i.e. the proportion of all individuals referred for care who registered 
with an HIV clinic); CD4 count receipt (i.e. the proportion of all individuals referred for 
care who received a CD4 count); adherence to cotrimoxazole prophylaxis (CTXp) (i.e. 
the proportion of all individuals referred for care who initiated CTXp and reported 
taking ≥80% of their doses); and ART initiation (i.e. the proportion of all individuals 
referred for care who initiated ART).  
 
Ethical considerations 
The trial was approved by the Uganda Virus Research Institute Research Ethics 
Committee (GC/127/14/12/491), the Uganda National Council for Science and 
Technology (HS 1732), and the London School of Hygiene and Tropical Medicine 
Ethics Committee (8833). Written informed consent was obtained from each participant 
before study procedures were conducted. All participants who did not link to care or 
who did not have a CD4 count test done by their care provider were offered CD4 count 
testing at the month six visit.  
 
Analysis 
Data were double entered in MS Access and analysed in Stata 12 (StataCorp, College 
Station, Texas, USA). Descriptive statistics were used to summarise participant 
characteristics. Pearson chi-squared statistics with the second-order correction of Rao 
and Scott to account for the clustered design were used to examine differences between 
variables of interest. Random effects logistic regression models were used to investigate 
factors associated with each outcome, accounting for the clustered design. Participants 
who were lost to follow-up were assumed not to have linked to care or attained other 
study outcomes. Age and sex were included a priori in the multivariable model 
investigating factors associated with uptake of HBHCT. Cluster-level variables were 
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then added one at a time and retained if associated with uptake of HBHCT at p<0.10. 
Trial arm and stratum were included a priori in the analysis of factors associated with 
linkage to care, CD4 count receipt, ART initiation and adherence to CTXp. Age and sex 
were then added to the models to evaluate evidence of an association with these 
variables after accounting for trial arm and stratum; both variables were retained in 
subsequent models to account for their confounding effects. Cluster-level variables were 
then added one by one to the trial arm, stratum, age and sex adjusted-analysis and 
retained if they remained associated with outcome at p<0.10. Individual-level variables 
were then added one by one and retained if they remained associated with outcome at 
p<0.10.  
 
Results 
Uptake of HBHCT 
A total of 15,096 adults were enumerated in the 28 clusters; over half were women 
(7946, 52.6%) and under <35 years (7909, 52.4%). 13,455 (89.1%) of those enumerated 
were found at home and offered HBHCT. Absence from home was more common 
among men than women [1313 men (18.4%) vs. 328 women (4.1%); p<0.001] and 
among those aged ≥25 years than those under 25 years [1235 aged ≥ 25 years (11.4%) 
vs. 189 <25 years (4.8%); p< 0.001; age missing for 320 individuals]. 12,100 (89.9%) of 
those found at home accepted HBHCT. HBHCT uptake was higher among men 
[adjusted odds ratio (aOR) 1.20, 95% confidence interval (CI) 1.07-1.36] than women, 
and decreased with increasing age (Table 1). None of the cluster-level characteristics 
was associated with HBHCT uptake. 
 
Prior knowledge of HIV-positive status and receipt of care was the most common 
reason (437, 32.3%) for failing to accept HBHCT; this was more common among 
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women than men [287 (3.8% of women who were offered HBHCT) vs. 150 (2.6% of 
men who were offered HBHCT); p=0.002] and among those aged ≥25 years than those 
under 25 years [401 (4.2%) vs. 21 (0.6%); p< 0.001]. Other reasons were a lack of 
interest in HCT (400, 29.5%); having recently tested for HIV and not wanting a repeat 
test (214, 15.8%); low HIV risk perception (92, 6.8%); and inability to consent (8, 
0.6%). Reasons were not documented for 204 (15.1%) individuals.  
 
Linkage to care 
551 individuals (4.6% of those accepting HBHCT) tested HIV-positive, of whom 205 
(37.2%) were already in care and thus ineligible. 302 individuals (87.3% of those 
eligible) were enrolled. Reasons for not enrolling were: a lack of interest in the study 
(26, 59.1%); unavailability for follow-up (5, 11.4%); inability to consent (1, 2.3%); 
denial of HIV status (1, 2.3%); and ongoing participation in another HIV-related study 
(1, 2.3%). Reasons were not documented for 10 (22.7%) individuals. Of those enrolled, 
most were female (54.6%), under 35 years (63.6%), married/cohabiting (60.3%), had 
incomplete primary school or no formal education (60.3%), and had tested for HIV 
previously (80.5%) (Table 2). Only 12.3% were aware of their HIV-positive status prior 
to this study. Twenty-five (8.3%) participants were lost during the 6 months of follow-
up.  
 
Overall, 127 (42.1%) of the enrolled participants linked to care. As reported elsewhere 
(Ruzagira, Grosskurth, Anatoli, & Kathy, 2017), linkage to care was significantly about 
2-fold higher among participants who had received additional counselling. Linkage to 
care was lower among participants who required ≥30 minutes to travel to the nearest 
HIV clinic than those who required less time, but there was no evidence of a significant 
difference (aOR 0.64, 95% CI 0.36-1.11) (Table 2). Other characteristics (individual-
level or cluster-level) were not associated with linkage to care. In particular, there was 
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no evidence that age, sex, socio-economic status, or level of education were associated 
with linkage.  
 
Receipt of CD4 counts 
Overall, 111 (36.8%) participants provided a blood sample for CD4 count testing; 
results were available for 107 of these (35.4% of all participants and 96.4% of those 
who provided a blood sample). There was some evidence that participants who required 
≥30 minutes of travel time to the nearest HIV clinic were less likely (aOR 0.60, 95% CI 
0.34-1.06) to obtain CD4 counts than those who required less time (Table 3). No other 
characteristics were associated with CD4 count receipt. 
 
Initiation of ART 
Of those enrolled, 90 (29.8% of all participants and 70.9% of those who linked) 
individuals initiated ART within six months of referral. This included 61 (95.3%) of 64 
individuals who had a CD4 count of ≤500 cells/mm3, the ART eligibility threshold at 
the time of the study (Uganda Ministry of Health, 2014). There was weak evidence that 
ART initiation was associated with age, with participants aged 45 years or older most 
likely to initiate ART (aOR 2.14, 95% CI 0.98-4.65, compared with those <25 years) 
(Table 3). Older participants (≥ 45 years) were more likely to have a CD4 count of ≤500 
cells/mm3 than those who were younger [20 (83.3%) vs. 44 (53.0%), p<0.001] at the 
time of linkage. There was also weak evidence of an association with marital status, 
with single (aOR 0.60, 95% CI 0.28-1.31) and divorced/separated/widowed (aOR 0.47, 
95% CI 0.23-0.93) participants less likely to initiate ART than married/cohabiting 
participants. No other characteristics were associated with ART initiation. 
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Adherence to CTXp 
A total of 119 (39.4%) participants initiated CTXp; 109 (36.1% of all participants and 
85.8% of those who linked) reported good adherence to CTXp. Adherence to CTXp was 
lower in men than women (aOR 0.69, 95% CI 0.42-1.14), but there was no evidence of 
a significant difference (Table 3). There was some evidence of an association with 
religion, with adherence highest among Anglicans and lowest among Muslims. None of 
the other characteristics were associated with adherence to CTXp. 
 
Discussion 
We observed high (>80%) levels of HBHCT uptake in this rural population. These 
findings are consistent with those from other settings (Sharma et al., 2015), and reaffirm 
the potential of HBHCT to achieve universal HIV testing in SSA (Plazy et al., 2016). 
Although more women than men were found at home in this study, men were more 
likely than women to accept HBHCT. In contrast to facility-based HCT, men are 
equally or more (Mutale, Michelo, Jurgensen, & Fylkesnes, 2010; Sabapathy et al., 
2012; Sekandi et al., 2011) likely to accept HBHCT. Reasons for this include the 
convenience, privacy and ease of access associated with HBHCT (Osoti et al., 2015). 
Similar to other studies (Dalal et al., 2013; Helleringer, Kohler, Frimpong, & 
Mkandawire, 2009; Sekandi et al., 2011), HBHCT uptake was highest in the youngest 
age group. Possible reasons for this include a lower HIV risk perception in older 
compared to younger persons (Sekandi et al., 2011) and the perception of HBHCT as a 
‘youth friendly’ service (Jurgensen et al., 2013). The HBHCT model removes the need 
to go to a health facility, a major barrier for young people (Mulogo, Abdulaziz, Guerra, 
& Baine, 2011) and is well-suited to their HIV testing delivery preferences. These 
include the need for compassionate, friendly, and competent staff; counselling services 
provided alongside the testing; and testing which is both rapid and free (WHO, 2013). 
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In the context of our study, an additional explanation may be that compared to younger 
persons, older persons are more likely to be already aware of their HIV status. We did 
not collect data on previous HIV-testing at the time of HBHCT and therefore could not 
examine this possible association. However, our finding that older persons who declined 
HBHCT were likely to report that they had previously tested HIV-positive suggests this 
may be the case.  
 
Despite a high uptake of HBHCT, overall linkage to and uptake of HIV care among 
HIV-positive persons who had never been in care was low. Several HBHCT studies 
have reported similarly low or even lower (Genberg et al., 2015; Labhardt et al., 2014; 
Medley et al., 2013; Parker et al., 2015; Plazy et al., 2016; Velen et al., 2016; Wringe et 
al., 2012) levels of linkage to care than observed in our study. In contrast, other studies 
have reported high (>60%) levels of linkage to care (Barnabas et al., 2016 ; Barnabas et 
al., 2014; Naik et al., 2015; Nakigozi et al., 2011; Tumwebaze et al., 2012; van Rooyen 
et al., 2013). As stated by others (Naik et al., 2015; Plazy et al., 2016), it is difficult to 
compare these studies as each used a different definition of linkage to care. 
Additionally, across these studies, populations varied in terms of age composition, 
setting, access to HIV care services, prior knowledge of HIV-positive status, and 
previous engagement in HIV care. It is also worth noting that whereas in some studies 
(Genberg et al., 2015; Medley et al., 2013; Parker et al., 2015; Velen et al., 2016; 
Wringe et al., 2012) HIV-positive persons were offered routine referral only, others 
(Barnabas et al., 2016 ; Barnabas et al., 2014; Naik et al., 2015; Nakigozi et al., 2011; 
Tumwebaze et al., 2012; van Rooyen et al., 2013) included interventions to facilitate 
referral. In general, linkage to care was lower in the former compared to the latter 
studies.  
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As reported previously (Ruzagira, Grosskurth, et al., 2017), participants from our study 
population who received an intervention comprising two follow-up counselling sessions 
in addition to referral were more likely to link to HIV care services than those who were 
referred only. Follow-up counselling may improve care seeking behaviour by providing 
specific information on how to access services (Ware et al., 2016), enhancing personal 
motivation (Knight, Van Rooyen, Humphries, Barnabas, & Celum, 2015), and by 
reducing psychosocial barriers that inhibit linkage to care (Hatcher et al., 2012; Knight 
et al., 2015; Muhamadi et al., 2011).  
 
Surprisingly, some of the factors found in other studies to facilitate or hinder linkage 
were not associated with uptake of care in our study. In particular age, sex, socio-
economic status, time to reach the HIV clinic or level of education, seem not to have 
influenced the care seeking behaviour of our study participants.  
 
Although ART initiation was higher among older adults than their younger 
counterparts, the association was not statistically significant, possibly owing to the 
small number of persons who initiated ART. Compared to younger persons, older 
persons may find it easier to accept their HIV status and may be more likely to have the 
social support and financial resources that facilitate access to care (Naik et al., 2015). In 
the case of our study, it is also possible that many younger persons did not initiate ART 
because they were ineligible under the guidelines that were in effect at the time. Indeed, 
at the time of linkage, only 53.0% of persons aged 18-44 years had a CD4 count of 
≤500 cells/mm3, the ART eligibility threshold (Uganda Ministry of Health, 2014), 
compared to 84.0% among aged ≥45 years.  
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It is worth noting that while the overall proportions of enrolled participants who 
obtained CD4 counts, initiated ART, and adhered to CTXp were low, uptake of these 
services among those who linked to care was high. For instance 95.3% of those who 
linked and had eligible CD4 counts initiated ART. This suggests that the linkage step 
may be the main bottleneck to uptake of HIV care services in this population.  
 
A limitation of our study is the lack of data on baseline CD4 counts and clinical stage of 
the infection, and other potential confounders. Our assumption that individuals who did 
not complete the month six visit did not link to care may have resulted in an 
underestimation of the proportion who linked to care. This is unlikely however, as such 
individuals are likely to have stigma or be exposed to circumstances that are associated 
with reduced linkage to care (Naik et al., 2015). Finally, the relatively small sample size 
may have limited the power to detect associations between potential risk factors and 
outcomes. A strength of our study is that self-reported linkage, ART initiation, and 
receipt of CD4 counts could be verified through clinical records for all participants. 
Hence it is unlikely that uptake of these services was overestimated.  
 
In conclusion, we found a high uptake of HBHCT but low linkage to and uptake of HIV 
care services among HIV-positive adults. Surprisingly, in our study access to HIV care 
was not associated with commonly reported predictors of care uptake. Interventions to 
increase enrolment in care are needed and should focus on increasing the desire to 
receive care.  
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Table 1. Factors associated with uptake of HBHCT in Masaka, Uganda (N=13455) 
   Crude analysis Adjusted analysis  
 
 
N 
Accepted  
HBHCT (%)  
 
OR (95% CI) P-value 
 
aOR (95% CI)§ P-value 
Age and sex       
Age group (years)       
18-24  3732  3595 (96.3)  1 <0.001 1 <0.001 
25-34 3550  3258 (91.8) 0.42 (0.34-0.52)  0.42 (0.34-0.52)  
35-44 2419  2152 (89.0) 0.31 (0.25-0.38)  0.31 (0.25-0.38)  
45+ 3651  3094 (84.7) 0.21 (0.17-0.26)  0.21 (0.17-0.26)  
Missing age 103  1 (<1.0) -  - - 
Sex        
Female  7618 6827 (89.6) 1 0.13 1 0.003 
Male  5837  5273 (90.3) 1.09 (0.97-1.23)  1.20 (1.07-1.36)  
Cluster-level variables     aOR (95% CI)*  
Distance from district capital 
(stratum)       
≥10Km  7956  7106 (89.3) 1 0.23 1 0.41 
<10Km  5499  4994 (90.8) 1.17 (0.91-1.52)  1.10 (0.87-1.39)  
Presence of a trading centre        
No 6825  6095 (89.3) 1 0.43 1 0.39 
Yes 6630  6005 (90.6) 1.11 (0.86-1.44)  1.11 (0.88-1.39)  
Located on lakeshore       
No 11079  9988 (90.2) 1 0.44 1 0.39 
Yes 2376  2112 (88.9) 0.87 (0.60-1.24)  0.87 (0.63-1.20)  
HIV clinic within 5 km       
No 2995  2665 (90.0) 1 0.40 1 0.48 
Yes 10460  9435 (90.2) 1.14 (0.84-1.56)  1.11 (0.84-1.46)  
Located along a major road       
No 9823  8870 (90.3) 1 0.43 1 0.20 
Yes  3632  3,230 (88.9) 0.89 (0.66-1.19)  0.84 (0.65-1.09)  
§Age and sex included a priori;*Adjusted for age and sex  
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 Table 2. Factors associated with linkage to care after HBHCT in Masaka, Uganda 
 
N  
(Column %) 
Linked  
(Row %)  
Crude analysis Adjusted analysis 
OR (95% CI) 
P-
value aOR (95% CI)§ 
P-
value 
Age and sex        
Age group (years)       
18-24  71 (23.5) 25 (35.2) 1 0.37 1 0.28 
25-34  121 (40.1) 51 (42.2)  1.30 (0.69-2.45)  1.28 (0.68-2.40)  
35-44  59 (19.5) 24 (40.7) 1.16 (0.55-2.45)  1.23 (0.59-2.60)  
≥45  51 (16.9) 27 (52.9) 1.96 (0.91-4.22)  2.12 (0.99-4.55)  
Sex        
Female  165 (54.6) 72 (43.6) 1 0.51 1 0.44 
Male  137 (45.4) 55 (40.2)  0.85 (0.53-1.38)  0.83 (0.51-1.34)  
Cluster-level variables     aOR (95% CI)*  
Presence of a trading centre      0.92 
No 177 (58.6)  72 (40.7) 1 0.73 0.97 (0.54-1.73)  
Yes 125 (41.4)  55 (44.0) 1.12 (0.60-2.09)    
Located on lakeshore       
No 237 (78.5)  100 (42.2) 1 0.95 1 0.90 
Yes 65 (21.5)  27 (41.5) 1.03 (0.45-2.33)  0.95 (0.46-1.96)  
HIV clinic within 5 km       
No 80 (26.5)  31 (38.8) 1 0.69 1 0.75 
Yes 222 (73.5)  96 (43.2) 1.16 (0.56-2.41)  0.90 (0.45-1.78)  
Located along a major road       
No 216 (71.5) 87 (40.3) 1 0.46 1 0.47 
Yes  86 (28.5)  40 (46.5) 1.30 (0.65-2.59)  1.26 (0.67-2.36)  
Other individual-level variables     aOR (95% CI)†  
Marital status        
Married/cohabiting 182 (60.3) 75 (41.2) 1 0.41 1 0.86 
Single  48 (15.9) 17 (35.4) 0.79 (0.39-1.58)  0.84 (0.42-1.70)  
Divorced/separated/widowed 72 (23.8) 35 (48.6) 1.33 (0.74-2.37)  1.05 (0.57-1.93)  
Education        
None/incomplete primary 182 (60.3) 78 (42.9)  1 0.94 1 0.86 
Primary 66 (21.9) 26 (39.4) 0.90 (0.49-1.66)  0.84 (0.46-1.56)  
Above primary 54 (17.9) 23 (42.6) 0.93 (0.49-1.78)  0.92 (0.48-1.77)  
Socio-economic status       
Low  117 (38.7) 50 (42.7) 1 0.91 1 0.93 
Middle  108 (35.8) 46 (42.6) 1.01 (0.58-1.77)  1.04 (0.60--1.81)  
High  77 (25.5) 31 (40.3) 0.89 (0.48-1.66)  0.92 (0.49-1.72)  
Religion       
Catholic  213 (70.5)  88 (41.3) 1 0.17 1 0.20 
Anglican  42 (13.9) 22 (52.4) 1.55 (0.76-3.15)  1.45 (0.71-2.96)  
Muslim  34 (11.3)  10 (29.4) 0.54 (0.23-1.26)  0.53 (0.23-1.22)  
Other  13 (4.3)  7 (53.9) 1.70 (0.52-5.50  1.48 (0.45-4.83)  
Time to nearest HIV clinic       
<30 minutes 86 (28.5) 44 (51.2) 1 0.05 1 0.11 
≥30 minutes 216 (71.5) 83 (38.4) 0.58 (0.33-0.99)  0.64 (0.36-1.11)  
Ever tested for HIV        
No  59 (19.5) 24 (40.7) 1 0.75 1 0.87 
Yes  243 (80.5) 103 (42.4) 1.10 (0.60-2.02)  1.05 (0.57-1.95)  
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 N  
(Column %) 
Linked  
(Row %)  
Crude analysis Adjusted analysis 
OR (95% CI) 
P-
value aOR (95% CI)§ 
P-
value 
Aware of HIV-positive status        
No  265 (87.7)  112 (42.3) 1 0.91 1 0.87 
Yes  37 (12.3) 15 (40.5) 0.96 (0.46-2.00)  0.94 (0.45-1.96)  
§Adjusted for trial arm and stratum; *Adjusted for trial arm, stratum, age and sex; †Adjusted for trial arm, stratum, age and sex 
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Chapter 7: General discussion 
 
7.1 Introduction 
The main aims of my PhD research were: to document the currently available evidence on 
linkage to HIV care among individuals newly diagnosed as HIV-positive through HBHCT 
in SSA; and ii) to evaluate the impact of a counselling intervention delivered after HIV 
diagnosis through HBHCT on linkage to HIV care. The research comprised a systematic 
review of the literature on linkage to HIV care after HBHCT in SSA, and an open-label 
cluster randomised trial to evaluate the effectiveness of counselling after HIV diagnosis and 
referral to care, compared to referral to care only, on linkage to care among HIV-positive 
adults (≥18 years) identified through HBHCT in Masaka district, Uganda. The trial was 
conducted between March 2015 and March 2016. During this period, the Uganda national 
treatment guidelines recommended ART initiation for all HIV-positive adults with a CD4 
count of ≤500 cells/mm3 [1]. In addition, ART was recommended for all HIV-positive 
individuals who were co-infected with tuberculosis or hepatitis B, pregnant, breastfeeding, 
categorised as most-at-risk persons (Commercial Sex Workers, Fisher folk and Truck 
drivers), and partners in HIV sero-discordant couples irrespective of WHO clinical stage or 
CD4 count. The study setting and population have been described in chapter 2 of this thesis.  
 
Overall, the results of my research contribute to the quantity and quality of evidence available 
to inform efforts intended for improving access to HIV prevention and care for adults in SSA. 
The systematic review is among the first to summarise available evidence on linkage to care 
among HIV-positive adults newly identified through HBHCT in SSA. I summarised data on 
the numbers and proportions of those who linked to care, and among these, the numbers and 
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proportions who were eligible for and initiated CTXp and ART. I described the definitions 
of linkage and linkage strategies used across the studies included in the review. I also 
assessed the included studies for risk of bias.  
 
The cluster randomised trial is among the first randomised studies designed to evaluate the 
effect of an intervention on linkage to care following HIV diagnosis through HBHCT in SSA. 
I used data from the screening phase of the trial to quantify and identify factors associated 
with HBHCT uptake in the study communities. I investigated whether counselling provided 
subsequent to HIV testing and referral for care increased linkage to care among HIV-positive 
persons identified through HBHCT. Specifically, I investigated the effect of counselling on 
the proportion of persons linking to care as well as the time to linkage. I also investigated the 
effect of counselling on the time to receipt of a CD4 count and ART initiation, and on the 
proportion of persons initiating and adhering to CTXp. Finally, I used data from the trial to 
quantify and identify factors associated with linkage to care, receipt of CD4 counts, 
adherence to CTXp, and ART initiation.  
 
This chapter summarises the main findings from this research and the contribution of the 
research to the literature. This is followed by a description of the methodological strengths 
and challenges. A discussion of ongoing and planned studies that are related to this PhD 
research is provided, and overall conclusions given.  
 
7.2 Summary of the main findings 
7.2.1 Systematic review 
Medline, Embase, Global Health, Web of Science, and Africa-Wide information databases 
were searched, covering the period from 1st January 2000 [time at which roll-out of ART 
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programmes began in SSA [2]] to 19th August 2016 for published studies that investigated 
linkage to care after HBHCT in SSA. 14 studies from 6 countries were included in the review 
[3-16]; only one investigated linkage to care by means of a randomised trial [3]. These studies 
varied widely with regard to design, setting, definition of linkage to care, the time points of 
and the methods applied for ascertaining linkage, and with regard to the strategies used to 
facilitate linkage, hence a pooled analysis was not done. Nine studies used specific strategies 
in addition to routine referral to facilitate linkage to care [3-8, 10, 14, 15]. Linkage to care 
was typically low (<33%) after routine referral but higher (>50%) if additional linkage 
interventions were used. In general, linkage to care was highest (>80%) in the studies that 
used both POC CD4 count testing and follow-up counselling [3, 5-7]. Most of the studies 
were susceptible to outcome ascertainment bias. In conclusion, the systematic review showed 
that there is limited literature on linkage to HIV care among adults newly diagnosed with 
HIV through HBHCT in SSA, that HBHCT without interventions to facilitate referral uptake 
achieved inadequate linkage to care, and highlighted the need for randomised controlled trials 
to confirm the impact of promising linkage strategies before they can be recommended for 
large scale adoption.  
 
7.2.2 Experimental work 
7.2.2.1 Uptake of HBHCT 
The study found a high (89.9%) level of HBHCT uptake. Men were more likely (aOR 1.20, 
95% CI 1.07-1.36) than women to accept HBHCT. This finding is similar to those of previous 
studies in which men were equally or more likely to accept HBHCT compared to women [2, 
17, 18]. Some of the reasons for men’s preference of HBHCT may be its convenience, 
privacy and ease of access [19]. Similar to the results from other studies [12, 17, 20], HBHCT 
uptake was highest in the youngest age group (18-24 years) and decreased with increasing 
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age. Possible reasons for this include a lower HIV risk perception in older compared to 
younger persons [17], the convenience and ease of access to confidential and professional 
HCT afforded by the HBHCT model [21, 22], and the possibility that older persons are more 
likely to have previously tested HIV-positive and consequently less likely to accept HBHCT 
compared to their younger counterparts.  
 
7.2.2.2 Effect of counselling after HIV diagnosis through HBHCT on linkage to care 
Counselling provided at one and two months after HBHCT was associated with a 2.18-fold 
(95% CI=1.26-3.78) increase in the odds of linking to care among HIV-positive participants 
aged 18 years and older (linkage was 51% in the intervention arm versus 33.3% in the control 
arm). The intervention significantly increased the overall rates of linkage and obtaining CD4 
counts but had no effect on the overall rate of ART initiation. There was however evidence 
of interaction between trial arm and follow-up time for these outcomes. The rate of linkage, 
obtaining CD4 counts, and ART initiation did not differ between arms in the first two months 
of follow-up but was subsequently higher in the intervention arm versus the control arm 
[linkage, HR=4.87 (95% CI=1.79-13.27); obtaining CD4 counts, HR=3.35 (95% CI=1.59-
7.04); ART initiation, 3.90 (95% CI=1.67-9.11)]. Follow-up counselling also significantly 
increased reported adherence to CTXp (OR=2.15, 95% CI=1.16-3.98). 
 
Observational studies had previously suggested that follow-up counselling provided after 
referral may substantially increase linkage to care among HIV-positive persons identified 
through HBHCT [5-7]. One randomised trial conducted in South Africa and Uganda 
previously evaluated the effect of follow-up counselling after community-based HCT 
(HBHCT or mobile HCT) on linkage [3]. HIV-positive ART naïve individuals aged ≥16 
years were randomly assigned in a factorial design to receive lay counsellor clinic linkage 
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facilitation, lay counsellor follow-up home visits, or standard-of-care referral, and 
subsequently either to POC CD4 count testing or referral for clinic CD4 count testing. 
Follow-up counselling in this trial showed modest effects, increasing the proportions of 
individuals linking to care and initiating ART by 4% and 23% respectively. The smaller 
effect estimates observed in this trial compared to those observed in my study were probably 
due to the already high (89%) level of linkage in the standard-of-care (referral only) arm of 
that trial and the high proportion of ART-eligible participants who did not start ART due to 
the requirement for repeat CD4 count testing at the clinic and other clinic-level barriers to 
ART initiation. In contrast, linkage in the standard-of-care arm of my study was low (33.3%) 
and consistent with that seen in observational studies in SSA [9, 13, 16, 23, 24]. Additionally, 
HIV care providers in the study area were aware of my study and facilitated the verification 
of study outcomes for participants who sought care at their facilities. It is possible that this 
collaboration may have reduced clinic-level barriers to the uptake of care services 
specifically for participants in my study, leading to a possibly exaggerated intervention effect 
measured in the study. However, any reduction in clinic-level barriers to uptake of care would 
have been similar for participants in both treatment arms since the healthcare workers at HIV 
clinics were not aware of participants’ group assignment.  
 
7.2.2.3 Factors associated with uptake of HIV care services following HBHCT 
Although linkage to care was significantly higher in the intervention arm, it was still only 
51% of those diagnosed – and only 42% across both arms – well below the UNAIDS target 
of 90% [25]. These results are consistent with those of some studies [9, 13, 16, 23, 24] but 
not others where linkage was either lower [11, 15] or higher [4-7]. In general it is difficult to 
compare these studies as they used different definitions of linkage to care, had varied study 
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populations, and whereas some [4-7], like my study, included interventions to facilitate 
linkage, others did not [9, 11, 13, 16, 23, 24].  
 
Although the overall proportions of enrolled participants who obtained CD4 counts (35.4%), 
initiated ART (29.8%), and adhered to CTXp (36.1%) were low, uptake of these services 
among those who linked to care was high [84.3% obtained CD4 counts, 70.9% initiated ART 
(including 95.3% of those who had eligible CD4 counts), and 85.8% reported adhering to 
CTXp]. This finding suggests that in settings where HIV care services are available, linkage 
to care may be the main bottleneck to uptake of these services.  
 
Surprisingly and contrary to findings in other studies, factors commonly associated with 
reducing or increasing entry into HIV care such as age [26], sex [26], distance or travel time 
to a health facility [24, 27-29], socio-economic status [24], and educational attainment [30, 
31] were not associated with linkage to HIV care, receipt of CD4 counts, or ART initiation 
in this study. This finding suggests that the counselling intervention evaluated in this study 
may be helpful in increasing linkage for individuals across different socio-demographic 
groups and that interventions to increase enrolment into care should focus on increasing the 
desire to enrol in care. 
 
Although not statistically significant, older age (≥45 years) was predictive of increased (aOR 
2.14, 95% CI 0.98-4.65) ART initiation. Compared to younger persons, older persons may 
find it easier to accept their HIV status and may be more likely to have the social support and 
financial resources that facilitate access to care [8]. However, it is also possible that many 
young people in my study did not initiate ART because they were not yet eligible under the 
treatment guidelines in use at the time. Indeed, at the time of linkage, only 53.0% of persons 
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aged 18-44 years had a CD4 count of ≤500 cells/mm3, the ART eligibility threshold [1], 
compared to 83.3% among those 45 years and older.  
 
7.3 Contribution of the research to the literature 
The systematic review contributes to our understanding of the extent to which HIV-positive 
adults who are newly identified through HBHCT in SSA are linked to care. The review also 
highlights the need for high quality evidence on the effectiveness of strategies used to 
promote linkage to care following HBHCT in SSA in order to inform HIV policy and 
programmes. One previous review has reported on linkage to HIV care after HBHCT in SSA 
[32]. However, this review did not distinguish linkage outcomes between HIV-positive 
persons identified through HBHCT and those identified through HCT that is provided within 
multi-disease campaigns in mobile clinics, between newly and previously diagnosed HIV-
positive individuals, or between children/adolescents and adults.  
 
Findings from the experimental component of this research contribute to the evidence on the 
potential of HBHCT as a platform for achieving the UNAIDS target of getting 90% of all 
HIV-positive persons to learn their HIV status. The cluster randomised trial contributes new 
and robust evidence on the effectiveness of counselling on linkage to HIV care after HIV 
diagnosis through HBHCT. Additionally, the trial provides evidence of the effect of 
counselling on ART initiation. This is important because as HIV care programmes adopt the 
new WHO guidelines to initiate ART for all HIV-positive persons irrespective of CD4 count, 
these programmes will need to implement interventions that promote immediate linkage to 
ART care [33]. Finally, this research contributes to the small evidence base on factors 
associated with uptake of HIV care services following HIV diagnosis through HBHCT in 
SSA.  
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7.4 Methodological strengths and challenges 
7.4.1 Strengths 
The experimental work in my PhD was a randomised controlled trial. Therefore, the observed 
effect estimates are not prone to the effects of confounding factors. The randomised design 
as well as the high participation and retention rates that were similar across treatment arms 
ensured that risk of selection bias was low. The inclusion of buffer zones between clusters 
minimised the risk of contamination between treatment arms, and consequently that of 
diluting the intervention effects.  
 
Referrals were tracked and medical records examined to verify self-reported linkage, receipt 
of CD4 counts, and ART initiation for all participants (including those who linked to clinics 
outside of the study area) thereby minimising the risk of reporting bias for these outcomes. 
Individuals whose information on self-reported linkage could not be verified by clinic records 
were re-interviewed; all revealed that they had not linked to care. Use of clinic-verified data 
to ascertain linkage outcomes has been infrequent and inconsistent in previous studies. For 
instance, none of the studies included in the systematic review component of this work used 
clinic-verified data to ascertain linkage for all participants. Linkage was either ascertained 
by use of self-reports alone [5, 9, 12, 14], a mixture of self-reported and clinic-verified data 
[4, 8], review of documentation issued to patients by HIV clinics (e.g. clinic cards) [3, 6, 7], 
or clinic-verified data but only for participants who linked to HIV clinics within the areas 
where the studies were conducted [10, 11, 13, 15, 16].  
 
Finally, the trial was conducted under real-world conditions in a relatively large geographical 
area. Participants were free to and did attend their preferred HIV clinics including those 
located outside of Masaka district. Also, participants did not receive monetary or other 
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incentives to participate. Hence, the trial results are likely to be generalizable to other settings 
in Uganda and SSA. The results are likely to be relevant even for settings where ART is 
initiated in all HIV-positive persons irrespective of CD4 count. This is because the 
availability of immediate ART may not translate into increased linkage to care. In a recently 
completed trial in rural KwaZulu-Natal, South Africa, that investigated the impact of 
immediate ART versus ART initiation according to standard-of-care (CD4 ≤350 cells/mm3 
at the time of the study) on HIV incidence, uptake of immediate ART was high (87.3%) 
among those who linked to care but linkage to care within 6 months of HIV diagnosis was 
only 47.5%, and did not differ between arms [10]. Indeed the investigators of this study 
acknowledge the need for interventions to increase linkage to HIV care if the UNAIDS target 
of initiating ART for 90% of all persons with diagnosed HIV infection is to be achieved [24].  
 
7.4.2 Limitations 
The trial used an open-label design hence it was prone to selection and outcome reporting 
bias. As mentioned above, selection bias does not seem to have been a major issue since 
baseline participant characteristics were generally balanced between trial arms and 
participation and retention rates were high and did not differ by treatment arm. Data on 
adherence to CTXp was based on self-report so outcome reporting bias cannot be ruled out 
for this outcome. It is possible that participants in the intervention arm reported good 
adherence to CTXp more frequently than those in the control arm. In general, reporting bias 
is unlikely to have been a major issue since all the primary outcomes and other secondary 
outcomes were based on clinic-verified data.  
 
The assumption that individuals who did not complete the month six visit did not link to care 
may have resulted in an underestimation of the proportion who linked to care if such 
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individuals had in fact linked. The proportion who linked to care might also have been 
underestimated if some of the participants who reported not linking to care had actually 
linked. It is however unlikely that individuals would link to care but choose to report 
otherwise. A related issue is that participants who permanently left the study area were 
assumed to have been in follow-up for at least 3 months i.e. they were censored mid-way 
between the enrolment and the month 6 visit. This assumption may have resulted in biased 
estimates of time to linkage, and time to other outcomes. However, this is unlikely to have 
had a large impact on the estimates since few (<5%) participants were reported to have 
permanently left the study area.  
 
I defined linkage to HIV care as registering with an HIV clinic following HIV diagnosis 
because this is the first step towards receiving ART [33, 34]. Another reason was to enable 
comparison of my research findings with those of several previous studies that have defined 
linkage to HIV care in a similar way [3-7, 9-12, 14-16, 35]. Other definitions of linkage to 
HIV care include attending clinic for a CD4 count measurement [36], obtaining a CD4 count 
[8], screening for ART eligibility [13], and starting ART [36] with time points for 
ascertaining linkage ranging from ≤1 month [12, 14, 15] to 12 months [6, 13]. I chose 6 
months as the time point for assessing linkage status in my study to allow time for the delivery 
of the intervention, enable an assessment of the intervention effect on post-linkage outcomes 
such ART initiation and adherence to CTXp, and facilitate comparisons with other studies 
that assessed linkage at a similar time point. Whereas registering with an HIV care provider 
is a critical step in the HIV care cascade, it may not result into improved long-term care 
outcomes such as viral suppression [37]. Moreover, as the new WHO guidelines 
recommending ART initiation in all HIV-positive persons regardless of CD4 count become 
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widely adopted, future efforts to increase linkage to care are likely to shift focus from just 
registering in care to ART initiation as the next step after HIV diagnosis [10].  
 
A limitation of the short follow-up period is that it was not possible to assess the effect of 
follow-up counselling on longer term outcomes such as retention in care, adherence to ART, 
and viral suppression.  
 
I did not evaluate the cost-effectiveness of the counselling intervention. Although the 
intervention is simple and may easily be incorporated into routine HBHCT programmes, 
cost-effectiveness data may be required to support efforts for its scale up.  
 
A limitation of the analysis of factors associated with linkage to care and uptake of HIV care 
services is that baseline data were not available for a number of factors that have been shown 
to predict these outcomes. It was therefore not possible to control for their confounding 
effects. These factors include: CD4 count at the time of HIV diagnosis [35], knowledge of 
ART [8, 38], anticipated stigma [38], psychological [8] or physical [23, 38] health status, 
living with an HIV-positive person who is receiving HIV care [23] or knowing an HIV-
positive family member [24], wanting to seek care after HIV diagnosis [23, 24], and alcohol 
use [8, 38]. A further limitation of this analysis is that the relatively small sample size may 
have limited the power to investigate associations between potential risk factors and linkage 
to care or other outcomes. 
 
7.4.3 Sample size estimation 
The target population for my study was HIV-positive adults who had not been engaged in 
care before. Data from the 2011 national HIV sero-prevalence survey in which the study area 
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in Masaka district was included had shown that 60% of HIV-positive adults were unaware 
of their HIV status and therefore not in care [41]. However, national-level data showed a 
significant increase in the awareness of HIV status and availability of treatment services in 
the period between the survey and end of 2014 (just before my study was initiated). For 
instance, the number of persons aged ≥15 years who had received HCT in the last 12 months 
and knew their results had increased from 0.9 million in 2011 to 8.6 million while the number 
of health facilities that offered ART had increased from 400 to 1062 in the same period [42]. 
Therefore, for the sample size calculations, I adjusted the estimate of the proportion of HIV-
positive adults who were not in care to 40%. In spite of this adjustment however, self-reported 
engagement in care was a common reason for refusal of HBHCT and study ineligibility from 
the start of the trial. In the end, self-reported engagement in care was the commonest reason 
for refusal of HBHCT (437, 32.3%), and study ineligibility among those who tested HIV-
positive and were not enrolled into the study (205, 82.3%). Consequently, the number of 
eligible HIV-positive persons per cluster was smaller than originally expected.  
 
In order to maintain the original study power of ≥90% to detect the hypothesised intervention 
effect, at least 12 additional clusters (6 per arm) were needed. However, due to logistic and 
budget constraints, only 6 (3 per arm) additional clusters could be recruited; thus the sample 
size was increased from 22 (11 per arm) to 28 clusters (14 per arm). This sample size allowed 
for detection of the same effect but with a reduced power of ≥80%. As a result, the study may 
have had limited power to detect a smaller effect size, or associations with linkage to care or 
other outcomes.  
 
As evidenced by my trial results, the finding that self-reported engagement in care was 
common does not mean that prompt linkage to care after HIV diagnosis is high in this 
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population, and therefore that interventions to enhance it are not needed. The high level of 
self-reported engagement in care may instead be a result of the increased number of HIV-
positive persons enrolled into care following protracted efforts to expand HIV prevention 
and treatment services [42]. It is also possible that some individuals reported being engaged 
in care whereas they were not. As observed in the trial, about 5% of HIV-positive participants 
who reported that they had linked to care after HBHCT had actually not done so. 
 
An additional remark is that the observed k was higher than that used for estimating the 
required sample size for the trial (0.33 versus 0.25). Hence, the trial could potentially have 
been slightly underpowered.  
 
7.4.4 Analysis 
I prepared the trial analysis plan (Appendix 1) before any analyses were performed. However, 
certain unanticipated difficulties arose once I initiated the analyses. After obtaining 
additional advice from Kathy Baisley and Richard Hayes, I updated the plan to address the 
issues as described below.  
 
Clusters with zero outcomes 
A major difficulty related to the analysis of clusters with zero outcomes. I had originally 
planned to log-transform cluster-level summaries e.g. the proportion linking to care, in order 
to obtain more symmetric distributions before conducting cluster-level analysis. However 
log-transformation of cluster-level summaries was not possible since some clusters had zero 
outcomes e.g. no one linked to care in two clusters (the logarithm of zero does not have a 
finite value). A possible solution to this problem is to add a small constant (e.g. 0.5) to the 
number of events in each cluster, obtaining the observed cluster-level rates or proportions 
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and finally applying the log-transformation to these cluster-level summaries [39]. I did not 
use this procedure since it has been shown in simulations not to be very robust, and could 
affect the conclusions of hypothesis testing [40]. I instead used the non-transformed 
rates/risks to estimate rate/risk ratio and the corresponding 95% CI. Since the non-
transformed rates/risks were reasonably normally distributed, I used the t-test to obtain a p-
value for the test of the null hypothesis of no intervention effect.  
 
The cluster-level analyses were done to check the robustness of the results from the 
individual-level analyses, so this change to the analysis plan did not affect the primary 
analyses.  
 
Secondary outcome analysis  
Another other issue is that I had considered two approaches for the secondary outcome 
analysis among HIV-positive participants: i) to restrict the analysis to certain subgroups i.e. 
time to obtaining a CD4 count among participants that linked to care and provided a blood 
sample for CD4 count testing, time to ART initiation among participants who linked to care 
and learnt that they were eligible for ART, and adherence to CTXp among persons that linked 
to care; ii) to do the analysis in all participants who were randomised. After taking advice, I 
dropped the former approach in order to demonstrate overall intervention effects for all 
outcomes and avoid selection bias associated with non-randomised comparisons. 
 
7.5 Ongoing and planned studies related to this PhD research  
I am aware of four other randomised studies in SSA designed to investigate the impact of an 
intervention on linkage to care following HIV diagnosis through HBHCT.  
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The first is a completed but not yet published cluster randomised trial that assessed the 
accuracy, feasibility and acceptability of POC CD4 count testing for HIV-positive persons 
identified through HBHCT, and the (cost-) effectiveness of this intervention in improving 
linkage to care and time to ART initiation in rural western Kenya [41]. Linkage to care, 
defined as visiting an HIV clinic within six months of enrolment, was ascertained by 
participant interview and review of HIV clinic records. This is the first randomised controlled 
trial to evaluate the impact of POC CD4 testing on linkage to care among HIV-positive 
persons identified through HBHCT [42]. Preliminary results from the trial show that POC 
CD4 testing strongly increases linkage to care (risk ratio (RR)=1.73, p<0.001) and ART 
initiation (RR=1.65, p<0.01) [43]. These results are comparable to those observed in my 
study and suggest that POC CD4 count testing and follow-up counselling may be equally 
effective in linking HIV-positive persons identified through HBHCT to care. However, the 
new WHO recommendation to initiate ART in all HIV-positive persons regardless of CD4 
count [25] means that POC CD4 count testing will have a diminished role in promoting 
linkage in the future. This is because the rationale for providing POC CD4 testing i.e. to 
eliminate delays between testing HIV-positive and ART initiation among eligible patients 
resulting from centralised laboratory CD4 testing [42, 44], will become less relevant as the 
new treatment guidelines are adopted. 
 
The second study is an ongoing cluster randomised trial that will evaluate the effectiveness 
of a linkage to care counselling intervention at achieving HIV viral suppression and 
intermediate outcomes of linkage/time to care, time to/receipt of opportunistic infection 
prophylaxis, and ART among HIV-positive adults (18-59 years) identified through HBHCT 
in rural Uganda [45]. Counselling sessions will be delivered by an HIV counsellor at the 
participant's home, clinic, and over the phone. Participants will be followed for 12 months. 
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The trial will provide more evidence on the impact of follow-up counselling on linkage to 
care, receipt of CTXp, and ART initiation as well as on additional outcomes i.e. retention in 
care and viral suppression. The trial will also provide data on the cost-effectiveness of 
counselling as compared to standard of care. The trial is expected to end in 2020. 
 
The third study is an ongoing cluster randomised trial to evaluate the impact of same day 
home-based ART initiation on linkage to and retention in care, ART initiation, and viral 
suppression among HIV-positive adults (≥18 years) identified through community-based 
HIV testing in rural district of Butha-Buthe, in northern Lesotho [46]. This is among the first 
trials to assess immediate ART initiation within the context of HBHCT [47]. The trial has a 
longer duration of follow-up (12 months) than my study and will provide data on extra 
endpoints including retention in care and viral suppression. The trial is expected to end in 
2017. 
 
The fourth trial is part of a larger study that will compare home and other community 
recruitment strategies and HIV testing strategies (self-testing, HCT in a home/mobile setting, 
and facility-based HCT) among young at-risk women, 15-24 years old, in western Kenya 
[48]. Newly identified HIV-positive participants will be initially randomized to receive either 
standard referral or standard referral plus short messaging service (SMS) message reminders 
to link to care. Participants who do not link to care after the first randomization will be re-
randomized to receive either an SMS message reminder or financial incentive to link to care. 
Participants who link to care will receive SMS reminders combined with health status surveys 
at 3, 6, 9, and 12 months. The trial will contribute evidence on linkage to care and on 
effectiveness of interventions to increase linkage to care among adolescent girls and young 
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women, a population with a high burden of HIV in SSA [49]. Unlike my study, this trial will 
provide data on retention in care and cost-effectiveness of the linkage interventions.  
 
In summary, results from the above studies will contribute new evidence on the feasibility, 
cost-effectiveness, and impact of different interventions on linkage to care and on long term 
outcomes (retention in care and viral suppression) following HIV diagnosis through HBHCT. 
For interventions that are shown to be effective, research will be required to identify how 
best they can be introduced into existing HIV care programmes. Also, as the new WHO 
recommendations to initiate ART regardless of CD4 count become adopted, the main goal 
of linkage to care interventions is likely to be ART initiation among newly identified HIV-
positive individuals [50]. It will therefore be important to demonstrate the effectiveness of 
these interventions under the new treatment guidelines.  
 
7.6 Conclusion  
The number and proportion of people who link to HIV care after HBHCT in SSA is 
inadequate. Some studies showed improved linkage when HBHCT was combined with 
additional strategies to facilitate referral. However, these have been observational studies, 
not trials. The present trial, one of the few to evaluate the effect of an intervention on linkage 
to care following HIV diagnosis through HBHCT in SSA, has shown that brief follow-up 
counselling, provided by non-medical personnel to HIV-positive adults identified through 
HBHCT, can substantially increase linkage to care and uptake of HIV care services including 
ART. HBHCT plus follow-up counselling may be a useful strategy in achieving the UNAIDS 
target of ensuring that 90% of HIV-positive persons who know their HIV status access 
treatment [25] and should be considered for scaling up.  
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Chapter 8: Appendices  
 
8.1 Appendix 1: Analysis plan 
 
Study summary 
Background: Data on linkage to HIV care after HIV diagnosis through HBHTC in SSA 
are scarce. Few studies have rigorously evaluated interventions aimed at improving 
linkage to HIV care following HBHTC in SSA.  
 
Aim: To evaluate the effect of follow-up counselling after HIV diagnosis through 
HBHTC on linkage to HIV care in Masaka, south-western Uganda. 
 
Methods: A cluster randomised trial of the effectiveness of referral to HIV care and 
follow-up counselling (intervention) compared to referral to HIV care only (control), for 
individuals diagnosed with HIV through HBHTC. The intervention is administered at 
months 1 and 2, and linkage to care assessed at month-6 post-HBHTC. Data is collected 
on socio-demographic characteristics, HIV testing history, linkage to care, CD4 count 
testing and results, initiation of and adherence to CTXp, and ART initiation. 
Approximately 196 HIV-positive participants from 28 clusters (14/study arm) are 
expected to enrol and complete the study. This sample size will allow for >80% power to 
detect an increase in linkage to HIV care from 35% to 60%, at a significance level of 5%. 
To conceal participants’ HIV status, approximately 84 HIV-negative persons will also be 
recruited into the study. Primary outcomes are: the proportion of HIV-positive 
participants that register with an ART provider within six months of HIV diagnosis, and 
the time between HIV diagnosis and linkage to HIV care. Secondary outcomes are: time 
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between HIV diagnosis and obtaining CD4 counts, time between HIV diagnosis and ART 
initiation, and the proportion of participants who report adherence to daily CTXp six 
months after HIV diagnosis. A further secondary outcome is the proportion of HIV-
negative participants who agree to repeat HIV testing six months after HBHCT. The 
effect of the intervention and 95% confidence intervals (CI) will be estimated using 
individual-level random effects regression models. Likelihood ratio tests will be 
performed for hypothesis testing. Because of the relatively small number of clusters per 
arm, analyses based on cluster-level approaches will also be performed to check the 
robustness of the results from the individual-level analyses. 
 
Study objectives  
Primary objectives 
 To determine the effect of follow-up counselling on the proportion of individuals 
linking to HIV care within six months of HIV diagnosis through HBHTC.  
 To determine the effect of follow-up counselling on the time to linkage to HIV care 
after HIV diagnosis through HBHTC.  
 
Secondary objectives  
 To investigate the effect of follow-up counselling on time to obtaining CD4 counts 
after HIV diagnosis through HBHTC.  
 To investigate the effect of follow-up counselling on time to ART initiation after HIV 
diagnosis through HBHTC.  
 To determine the effect of follow-up counselling on adherence to CTXp six months 
after HIV diagnosis through HBHTC. 
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Other objectives 
 To determine the effect of follow-up counselling on the uptake of repeat HIV testing 
among HIV negative individuals six months after HBHTC.  
 
Study setting  
The study is being conducted in three rural sub-counties in Masaka district, Uganda. Adult 
HIV prevalence in the district has been reported at 10%. HIV care services are provided 
at no cost through government and non-governmental organisation health facilities.  
 
Study design  
The study is an open-label cluster randomised controlled trial of referral to HIV care and 
follow-up counselling (14 clusters) compared to referral to HIV care only (14 clusters), 
for participants diagnosed as HIV-positive through HBHTC.  
 
Study population 
The study population consists of HIV-positive adults identified through HBHTC that 
fulfil study eligibility criteria (see below). HIV-negative individuals are recruited from 
each randomised community to reduce the possibility of revealing the sero-status of HIV-
positive (main) participants.  
 
Eligibility criteria  
 
HIV-positive participants  
Inclusion criteria  
 HIV-positive adult (≥18 years)  
 Willing to provide informed consent 
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 Willing to receive follow-up counselling at home 
 
Exclusion criteria  
 Previous or current receipt of HIV care  
 On-going participation in other health-related research  
 Intention to change residence in the next six months  
 Inability to provide informed consent 
 
HIV-negative participants 
Inclusion criteria  
 HIV negative adult (≥18 years) 
 Willing to provide informed consent 
 Willing to receive follow-up counselling at home 
 
Exclusion criteria 
 Intention to change residence in the next six months  
 Inability to provide informed consent 
 
Definition of clusters  
 Clusters comprise one or more villages i.e. the smallest administrative areas. To ensure 
a reasonable number of eligible participants in each cluster, small (<400 adults) villages 
are combined with adjacent villages into larger clusters of at least 400 adults. Therefore, 
a cluster is defined as a village or a set of villages with at least 400 adults. Clusters are 
separated by a buffer zone of at least one non-participating village to minimise the risk of 
contamination. 
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Sample size  
Sample size was calculated to ensure adequate power to address the hypothesis that 
follow-up counselling would increase the proportion of individuals that link to care. 
Based on previous studies, we assumed an adult HIV prevalence of 10%. The 2011 
Uganda national HIV sero-prevalence survey (Masaka district was included in the survey) 
found that 60% of HIV-positive adults are unaware of their HIV status and are therefore 
not in care. However, this figure is likely to be lower due to increased HTC coverage 
since the survey. Based on these figures and the population estimates from the mapping 
data, the estimated harmonic mean number of potential HIV positive study participants 
in a cluster was 11. Assuming that 25% of the potential participants would refuse to 
participate/be away from home, and that a further 10% would be lost to follow-up, the 
harmonic mean number of HIV positive individuals that was expected to enrol and 
complete the study from each cluster was 7.  
 
We assumed a coefficient of variation, k, of 0.25. This was based on past studies of 
linkage to HIV care that were conducted in settings similar to Masaka in which k ranged 
from 0.12 to 0.33. We assumed linkage of 35% in the control arm based on findings from 
HBHTC studies in which participants received only referrals following HIV diagnosis. 
The estimated intervention effect was based on findings from HBHTC studies that have 
used follow-up counselling to facilitate linkage to care. With a sample of 28 clusters (14 
per arm) and a harmonic mean of 7 participants completing the study in each cluster, the 
study would have 83% power to detect an increase in linkage to care from 35% in the 
control arm to 60% in the intervention arm at a significance level of 0.05. This sample 
size would also give us 85% power to detect a hazard ratio of 1.7 for the effect of the 
intervention on time to linkage. 
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Randomisation of clusters 
Randomisation of clusters was stratified on distance (≤10 km or >10 km) from Masaka 
town, because of availability of HIV care facilities, and whether the cluster was composed 
of a single large village or several small villages. Restricted randomisation was applied 
to achieve balance on the following covariates: cluster size (number of adults in a cluster); 
presence of a trading centre; location along a major road; lakeshore location; and presence 
of an HIV clinic within 5 km. The tolerance thresholds for balance were defined through 
an iterative process in which different thresholds were tried and the number and the 
validity of the acceptable allocations examined. A list of 1000 acceptable allocations was 
randomly generated from which one allocation was selected at public randomisation 
ceremony.  
 
Data management 
Data are collected using paper-based questionnaires. Questionnaires are checked for 
completeness, logic flow and correct entry before data entry. Data are double-entered and 
validated in Microsoft Access. Queries are run on the entered data every fortnight and 
reports sent to the study team for resolution. Data arising from the resolved queries are 
resubmitted for entry and the process is repeated until no more queries are generated.  
 
Outcomes  
Outcome data are collected six months post-enrolment using two methods:  
 Completion of a staff-administered questionnaire to collect self-reported data on 
linkage and other outcomes. 
 Review of HIV clinic records to verify and document self-reported outcomes  
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Self-reported data includes: whether and when the participant registered with an HIV 
clinic following referral (response categories are <1 month, 1-3 months, and >3 months 
ago, since it is anticipated that participants may have difficulty recalling actual dates); 
clinic name and address; clinic registration number assigned to participant (may be 
obtained from clinic documents e.g. appointment card, drug prescription forms etc.); and 
whether the participant was already engaged in care by the time he/she joined the study 
(Yes, No, Refused to answer). Although individuals who are already in care are not 
eligible for enrolment, we anticipate that some individuals who are in care may not reveal 
this information at the time of enrolment in order not to miss out on perceived research-
related health care benefits, but that they may be willing to do so at the exit visit. Other 
reported data include: whether the participant; provided a blood sample for CD4 count 
testing and obtained the results, initiated ART, and CTXp following linkage to care. 
Additional data collected for those who report having initiated CTXp include: whether 
they have missed any doses in the past month and number of doses missed (0-5 tablets, 
≥6 tablets, don’t know) in that period; whether they have missed taking their tablets for 3 
or more days in a row; and how often this has happened in the past month (once, twice, 
more than twice, don’t know).  
 
Clinic-verified data: for participants who report having registered with an HIV clinic, the 
study counsellor visits the clinic and with the help of clinic staff confirms that the 
registration number is authentic and that it is assigned under the participant’s names. The 
counsellor then reviews clinic records (participant’s referral letter, pre-ART and/or ART 
register, and medical forms) and records the registration number assigned to participant, 
date of registration, and whether the participant was registered at this or other HIV clinic 
before his/her enrolment in the study. The counsellor also collects data on whether and 
when the participant: had CD4 count testing and obtained the results, started CTXp and 
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initiated ART. Participants whose records are not found at the HIV clinic are re-contacted, 
informed of the verification outcome, and asked to clarify if they actually registered for 
care or not.  
 
All HIV-negative participants are offered repeat HIV testing at the month-6 visit. Data 
on willingness to have repeat HIV testing (Yes, No) and the repeat HIV test result 
(positive, negative or indeterminate) is recorded.  
 
Information on whether participants who are not seen at the month-6 visit have 
permanently left the study area or not is obtained from household members, neighbours 
and/or other village residents. 
 
Primary outcomes 
1) The proportion of HIV-positive participants that link to HIV care within six months 
of HIV diagnosis and referral.  
2) The time between HIV diagnosis and linkage to HIV care.  
 
 Linkage to HIV care is defined as confirmed registration (i.e. clinic-verified) with 
an HIV clinic following HBHTC and referral.  
 The analysis population will comprise all randomised participants. Participants 
whose clinic-verified registration date precedes the date of enrolment into the study 
will be considered to have been ineligible for the study, and will be excluded from 
the analysis.  
 Participants who report not to have registered with an HIV clinic, those who report 
to have registered but whose registration cannot be verified, and those lost to 
follow-up will be considered not to have linked to care. 
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 Time to linkage will be calculated from the date of enrolment in the study to the 
date that the participant was registered at the HIV clinic as per the clinic records. 
Participants who have not linked to care will be censored at the month-6 visit date. 
Participants who have permanently left the study area will be censored mid-way 
between the enrolment and 6 months. Those who are still in the study area but do 
not complete the month-6 visit will be censored at 6 months.  
 
Secondary outcomes 
1) Time between HIV diagnosis and obtaining CD4 count results. 
 The analysis population will comprise all randomised participants as described for 
the primary outcome.  
 Participants who report not to have obtained a CD4 count, those who report to have 
obtained a CD4 count but whose clinic records cannot be verified, and those lost 
to follow-up will be considered not to have a obtained CD4 count. 
 Time to obtaining first CD4 count will be calculated from the date of enrolment in 
the study to the date that the participant obtains his/her first CD4 count results. 
Participants who have not obtained a CD4 count will be censored at the month-6 
visit date. Participants who have permanently left the study area will be censored 
mid-way between the enrolment and 6 months. Those who are still in the study 
area but do not complete the month-6 visit will be censored at 6 months.  
 
2) The time between HIV diagnosis and ART initiation. 
 The analysis population will comprise all randomised participants as described for 
the primary outcome.  
205
  
 Participants who report not to have initiated ART, those who report to have 
initiated ART but whose clinic records cannot be verified, and those lost to follow-
up will be considered not to have initiated ART. 
 Time to ART initiation will be calculated from the date of enrolment in the study 
to the date that ARV drugs were first prescribed as per clinic records.  
 Participants who have not initiated ART will be censored at the month-6 visit date. 
Participants who have permanently left the study area will be censored mid-way 
between the enrolment and 6 months. Those who are still in the study area but do 
not complete the month-6 visit will be censored at 6 months.  
  
3) The proportion of participants who report adherence to daily CTXp at six months after 
HIV diagnosis through HBHTC.  
 The analysis population will comprise all randomised participants as described for 
the primary outcome.  
 Participants who report not to have initiated CTXp, those who report to have 
initiated CTXp but whose clinic records cannot be verified, and those lost to 
follow-up will be considered not to have initiated CTXp. 
 Adherence to CTXp will be defined as a reported intake of >80% (missing 0-5 
tablets only) of tablets in the month preceding the month-6 visit. Participants who 
report not taking their tablets for ≥3 consecutive days on two or more occasions 
will be classified as poor adherers i.e. ≤80% intake.  
 
The analysis population for secondary outcomes will comprise all randomised 
participants rather than those who linked in order to avoid potential selection bias 
associated with sub group analyses, and to allow for the evaluation of the overall 
intervention effect on all outcomes.  
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4) The proportion of individuals who undergo repeat HIV testing within six months of 
testing HIV negative through HBHTC.  
 The analysis population will comprise all randomised HIV-negative participants.  
 Participants lost to follow-up will be assumed not to have accepted repeat HIV 
testing.  
 
Baseline cluster and individual level characteristics  
Baseline cluster- and individual-level variables will be summarised by trial arm to 
describe the study participants and assess their distribution between trial arms (balance):  
 
Cluster-level variables included in the restricted randomisation 
The following cluster-level variables were included in the restricted randomisation:  
 Location along a major road (Yes, No) 
 Lakeshore location (Yes, No) 
 Presence of a trading centre (Yes, No) 
 HIV clinic within 5 km (Yes, No) 
 Cluster size (number of adults in a cluster) 
 
Restricted randomised was used to ensure these variables were balanced between 
intervention and control arms within the following tolerance limits:  
 Similar number of communities located along a major road in each arm (maximum 
difference of 1) 
 Equal number of lakeshore communities in each arm 
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 Similar number of communities with a trading centre in each arm (maximum 
difference of 2)  
 Similar number of communities with an ART clinic <5km of some households in 
each arm (maximum difference of 2) 
 Maximum difference in mean cluster size between intervention & control 
communities of 95 adults 
 
Other cluster-level variables 
 Number of individuals enumerated 
 Number of individuals contacted (% of all enumerated) 
 Number of individuals that accept HBHCT (% of all contacted) 
 Number of individuals that test HIV positive (% of all tested)  
 Number of individuals that test HIV positive and are not in care (% of all positive)  
 
Individual-level variables 
Overall summaries of individual-level variables at baseline will be obtained by trial arm 
for all participants. These include:  
 Age in years  
 Sex (Male, Female) 
 Marital status (Single, Married, Cohabiting, Widowed, Divorced/separated). 
 Education level [No formal education, Incomplete primary, Complete primary, 
Secondary (O level), Secondary (A level), University/College]  
 Household ownership of the following items: bicycle, motorcycle, motor vehicle, 
sewing machine, radio, television, refrigerator, electric/gas cooker, telephone 
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(landline), mobile phone, goats, cows, property rented for income; and having 
electricity in the household.  
 Religion (Roman Catholic, Anglican, other Christian, Muslim, Traditional, Other, 
None) 
 Travel time nearest HIV clinic (<30 minutes, 30 to 60 minutes, and >60 minutes).  
 Ever tested for HIV (No, Yes)  
 Results of last HIV test (Positive, negative, don’t know) 
 Previous awareness of HIV-positive status (HIV-positive participants only) (No, 
Yes) 
Data for this variable will be derived from responses to the above HIV testing 
history questions. The ‘No’ response will be assigned to persons who report that 
they have never tested for HIV, those whose last HIV test result was negative and 
those who do not know the results of their last HIV test. The ‘Yes’ response will be 
assigned to persons who report that their last HIV test result was positive. 
 
Data reduction 
 Age will be categorised into: 18-24, 25-34, 35-44, and 45+  
 Socio-economic status categories (Low, Middle, and High) will be created based 
on household ownership of selected items using principal component analysis.  
 For some variables, categories observed to have few participants after collection 
of baseline data will be combined with others to form larger groups. The affected 
variables are: 
o Marital status 
New categories: Single, Married/Cohabiting, and, 
Widowed/Divorced/Separated. 
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o Education level 
New categories: None/incomplete primary, Primary, and Above primary  
 
o Religion  
New categories: Roman Catholic, Anglican, Muslim, and Other. 
 
o Travel time to nearest HIV clinic 
New categories: <30 minutes, and ≥30 minutes 
 
Trial flow  
A consort diagram will be used to show the flow of clusters and participants through the 
trial i.e. from group assignment to analysis. 
 
Analysis  
Analyses will be intention to treat and based on individual-level data. Random effects 
logistic and Cox regression models (i.e. with shared frailty) will be used to estimate the 
effects of the intervention on the proportion of participants linking to care and time to 
linkage, respectively. Likelihood ratio tests will be performed for hypothesis testing. 
Similar methods will be used to estimate the effect of the intervention on the proportions 
of participants that adhere to CTXp and undergo repeat HIV testing, and on time to 
obtaining CD4 count results, and to ART initiation. The primary analysis of the 
intervention effect for all outcomes will be adjusted for randomisation stratum as a fixed 
effect. Exploratory analyses adjusting for age and sex a priori, and other characteristics 
that show substantial baseline imbalance, will also be carried out. It is expected that the 
effect of the intervention might change over time due to the nature of the intervention i.e. 
repeated counselling sessions. Therefore, the proportional hazards assumption will be 
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examined by splitting follow-up time into two intervals (0-2 months and >2 months) at a 
point corresponding with the time of the second counselling session, and testing for an 
interaction between trial arm and follow-up time. Although the primary analyses will be 
based on individual-level approaches, sensitivity analyses based on cluster-level methods 
[1] will also be performed to check the robustness of the results. All analyses will be 
conducted in Stata 12. 
 
Individual-level analysis  
 
Individual-level analysis for binomial outcomes  
Unadjusted analysis  
The effect of follow-up counselling on the proportions of participants that link to care, 
report adherence to daily CTXp, and undergo repeat HIV testing will be estimated using 
random effects logistic regression to account for the clustered design. Randomisation 
strata will be included in the models as a fixed effect. A likelihood ratio test of the null 
hypothesis of no treatment effect will be performed by comparing the model with the 
exposure (trial arm) and strata to a model with only a term for strata.  
 
Adjusted analysis 
Age and sex will be included a priori in the adjusted models. In addition, models will be 
adjusted for variables for which there is substantial baseline imbalance between study 
arms for the respective analysis populations. A likelihood ratio test of the null hypothesis 
of no treatment effect will be performed by comparing the model with the exposure (trial 
arm), randomisation strata, age, sex and any other variables that show substantial baseline 
imbalance to a model with only the strata, sex, age and the variables that show baseline 
imbalance (i.e. without the term for trial arm).  
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Individual-level analysis for time-to-event outcomes  
Unadjusted analysis 
The effect of the intervention on time to: linkage, obtaining CD4 counts, and ART 
initiation will be estimated using a shared frailty Cox regression model to account for the 
clustered design. Randomisation strata will be included in the model as a fixed effect. A 
likelihood ratio test of the null hypothesis of no treatment effect will be performed by 
comparing the model with the exposure (trial arm), and strata to a model with only a term 
for strata.  
 
Adjusted analysis 
Age and sex will be included a priori in the adjusted models. In addition, an adjusted 
analysis to take into account any substantial imbalance that may occur between study 
arms in baseline variables for the respective study populations will be performed. A 
likelihood ratio test of the null hypothesis of no treatment effect will be performed by 
comparing the model with the exposure (trial arm), strata, age, sex and any other variables 
that show substantial baseline imbalance to a model with only strata, sex, age and the 
variables that show substantial baseline imbalance. 
 
Proportional hazards assumption 
The proportional hazards assumption will be examined as described above, for the 
unadjusted and adjusted analyses of all time-to-event outcomes. 
 
Cluster-level analysis  
Some clusters have zero outcomes e.g. no one linked to care. Therefore cluster-level 
summaries will not be log-transformed before conducting analyses. Instead raw 
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(untransformed) rates/risks will be used to obtain intervention effects and their 95% 
confidence intervals.  
 
Cluster-level analysis for binomial outcomes  
Unadjusted analysis 
Linkage to care will be measured using prevalence ratios (PR). For each study arm, the 
cluster-specific proportions of individuals linking to HIV care will be obtained and their 
mean calculated. The PR will be calculated as the ratio of the arithmetic means of the 
cluster-specific proportions of individuals linking to care in each arm. The 95% CI for 
the PR will be obtained by dividing and multiplying the estimated PR by the error factor 
(EF). The EF is given by the following formula:  
 
𝐸𝐹 =  𝑒𝑥𝑝 (𝑡𝑣,0.025 × √𝑉)  
 
Where,  
𝑡𝑣,0.025 = 𝑡ℎ𝑒 𝑢𝑝𝑝𝑒𝑟 2.5% 𝑝𝑜𝑖𝑛𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑡 𝑑𝑖𝑡𝑠𝑟𝑖𝑏𝑢𝑡𝑖𝑜𝑛 𝑤𝑖𝑡ℎ 𝑣 𝑑𝑒𝑔𝑟𝑒𝑒𝑠 𝑜𝑓 𝑓𝑟𝑒𝑒𝑑𝑜𝑚  
𝑣 =  𝛴𝑐𝑠𝑖 − 2𝑆  
𝑐𝑠𝑖 =  𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑙𝑢𝑠𝑡𝑒𝑟𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑡ℎ 𝑠𝑡𝑟𝑎𝑡𝑢𝑚 𝑖𝑛 𝑡ℎ𝑒 𝑖𝑡ℎ 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑎𝑟𝑚 
𝑆 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑡𝑟𝑎𝑡𝑎 
𝑉 = 𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒 𝑟𝑎𝑡𝑖𝑜  
𝑆𝑖𝑛𝑐𝑒 𝑒𝑞𝑢𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟𝑠 𝑜𝑓 𝑐𝑙𝑢𝑠𝑡𝑒𝑟𝑠 𝑎𝑟𝑒 𝑎𝑙𝑙𝑜𝑐𝑎𝑡𝑒𝑑 𝑡𝑜 𝑡ℎ𝑒 𝑡𝑤𝑜 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑎𝑟𝑚𝑠 𝑤𝑖𝑡ℎ𝑖𝑛 𝑒𝑎𝑐ℎ 𝑠𝑡𝑟𝑎𝑡𝑢𝑚 
𝑉 =  
𝑠2
𝑐1 × ?̅?1
2 
+  
𝑠2
𝑐0  ×  ?̅?0
2  
𝑠2 =  𝑝𝑜𝑜𝑙𝑒𝑑 𝑒𝑠𝑡𝑖𝑚𝑎𝑡𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑤𝑖𝑡ℎ𝑖𝑛-𝑠𝑡𝑟𝑎𝑡𝑢𝑚 𝑏𝑒𝑡𝑤𝑒𝑒𝑛-𝑐𝑙𝑢𝑠𝑡𝑒𝑟 𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑  
𝑐𝑙𝑢𝑠𝑡𝑒𝑟-𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛𝑠 𝑙𝑖𝑛𝑘𝑖𝑛𝑔 𝑡𝑜 𝑐𝑎𝑟𝑒 𝑤𝑖𝑡ℎ𝑖𝑛 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑎𝑟𝑚𝑠, 𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝑎𝑠 𝑑𝑒𝑠𝑐𝑟𝑖𝑏𝑒𝑑 𝑏𝑒𝑙𝑜𝑤  
𝑐1 =  𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑙𝑢𝑠𝑡𝑒𝑟𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 𝑎𝑟𝑚  
?̅?1 =  𝑚𝑒𝑎𝑛 𝑜𝑓 𝑐𝑙𝑢𝑠𝑡𝑒𝑟-s𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛𝑠 𝑙𝑖𝑛𝑘𝑖𝑛𝑔 𝑡𝑜 𝑐𝑎𝑟𝑒 𝑖𝑛 𝑡ℎ𝑒 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 𝑎𝑟𝑚 
𝑐0 =  𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑙𝑢𝑠𝑡𝑒𝑟𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑎𝑟𝑚  
?̅?0 =  𝑚𝑒𝑎𝑛 𝑜𝑓 𝑡ℎ𝑒 𝑐𝑙𝑢𝑠𝑡𝑒𝑟-𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛𝑠 𝑙𝑖𝑛𝑘𝑖𝑛𝑔 𝑡𝑜 𝑐𝑎𝑟𝑒 𝑖𝑛 𝑡ℎ𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑎𝑟𝑚 
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An estimate of the pooled within-stratum between-cluster variance, s2, will be obtained 
as the residual mean square from a two-way analysis of variance of the proportions 
linking to care per cluster including the interaction between stratum and trial arm.  
 
A stratified t-test of the null hypothesis of no intervention effect will be conducted using 
the following formula: 𝑡𝑠 =  (log (𝑃𝑅))/√𝑉 
 
Adjusted analysis 
The same variables as identified in the individual level analysis will be adjusted for in the 
cluster-level analysis. The analysis will be conducted as follows:  
 
 An individual-level logistic regression analysis of linkage to care (outcome) 
against stratum, age group, sex, and variables for which there is imbalance between 
study arms will be performed. This will be a standard logistic regression analysis; 
the model will not include trial arm, and will not account for clustering.  
 The expected numbers who linked to care will be predicted from the regression 
model. 
 The sum of the observed and expected numbers who linked to care in each cluster 
will be obtained. 
 Ratio residuals will be obtained by dividing the total observed number who linked 
to care by the total expected number in each cluster  
 The ratio residuals will then be used to obtain an adjusted PR (and its 95% CI) and 
perform the stratified t-test using the formulae given above. 
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The same methods will be used to estimate the effect of the intervention on the 
proportions of participants who: report adherence to daily CTXp and undergo repeat HIV 
testing.  
 
Cluster-level analysis for time-to-event outcomes  
Unadjusted analysis  
The effect of follow-up counselling on time to linkage will be measured using rate ratios 
(RR). For each study arm, the cluster-specific linkage rates will be obtained as the number 
of events divided by person-time in each cluster, and their mean calculated. The RR will 
be calculated as the ratio of the arithmetic means of the cluster-specific rates of linkage 
in each arm. The 95% CI for the RR will be obtained by dividing and multiplying the 
estimated RR by the error factor (EF). The same formulae as described for PRs will be 
used but replacing cluster specific prevalences with cluster-specific rates.  
 
Adjusted analyses 
The same methods as described for binary outcomes will be used for the adjusted 
analyses, with the exception that a standard Poisson regression model will be used to 
calculate the predicted (expected) number of events 
 
The same methods will be used to estimate the unadjusted and adjusted effects of the 
intervention on time to: obtaining CD4 counts and ART initiation. 
 
Estimation of the coefficient of variation 
Data from the control arm will be used to estimate the actual coefficient of variation in 
the proportion of persons linking to care. The following formula will be used: 
?̂?𝑚 =  ∑ 𝑘𝑚𝑠/𝑆 .  
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Where, 
?̂?𝑚 =  𝑤𝑖𝑡ℎ𝑖𝑛-s𝑡𝑟𝑎𝑡𝑢𝑚 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑜𝑓 𝑣𝑎𝑟𝑖𝑎𝑡𝑖𝑜𝑛 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑐𝑙𝑢𝑠𝑡𝑒𝑟𝑠 
𝑘𝑚𝑠 = 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑜𝑓 𝑣𝑎𝑟𝑖𝑎𝑡𝑖𝑜𝑛 𝑘𝑚 𝑖𝑛 𝑡ℎ𝑒 𝑠
𝑡ℎ𝑠𝑡𝑟𝑎𝑡𝑢𝑚  
𝑆 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑡𝑟𝑎𝑡𝑎  
𝑘𝑚𝑠 =  ?̂?𝐵𝑠/𝑝𝑠  
?̂?𝐵𝑠 = 𝑡ℎ𝑒 𝑒𝑠𝑡𝑖𝑚𝑎𝑡𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑏𝑒𝑡𝑤𝑒𝑒𝑛-𝑐𝑙𝑢𝑠𝑡𝑒𝑟 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑡ℎ𝑒 𝑠
𝑡ℎ𝑠𝑡𝑟𝑎𝑡𝑢𝑚  
𝑝𝑠 = 𝑂𝑣𝑒𝑟𝑎𝑙𝑙 𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛𝑠 𝑙𝑖𝑛𝑘𝑖𝑛𝑔 𝑡𝑜 𝑐𝑎𝑟𝑒 𝑖𝑛 𝑡ℎ𝑒 𝑠
𝑡ℎ𝑠𝑡𝑟𝑎𝑡𝑢𝑚 
?̂?𝐵𝑠  = √𝑠𝑠
2 −
𝑝𝑠(1 − 𝑝𝑠)
?̅?Hs
 
𝑠𝑠
2 = 𝑉𝑎𝑟𝑖𝑎𝑛𝑐𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛𝑠 𝑙𝑖𝑛𝑘𝑖𝑛𝑔 𝑡𝑜 𝑐𝑎𝑟𝑒 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑡ℎ𝑠𝑡𝑟𝑎𝑡𝑢𝑚 
?̅?Hs = ℎ𝑎𝑟𝑚𝑜𝑛𝑖𝑐 𝑚𝑒𝑎𝑛 𝑜𝑓 𝑡ℎ𝑒 𝑐𝑙𝑢𝑠𝑡𝑒𝑟 𝑠𝑖𝑧𝑒 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑡ℎ𝑠𝑡𝑟𝑎𝑡𝑢𝑚 
𝑠𝑠
2 = ∑ (𝜋𝑠 − ?̅?𝑠)
2 (𝑐𝑠 − 1)⁄   
𝜋𝑠 = 𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛 𝑙𝑖𝑛𝑘𝑖𝑛𝑔 𝑡𝑜 𝑐𝑎𝑟𝑒 𝑖𝑛 𝑡ℎ𝑒 𝑗
𝑡ℎ 𝑐𝑙𝑢𝑠𝑡𝑒𝑟 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑡ℎ𝑠𝑡𝑟𝑎𝑡𝑢𝑚 
?̅?𝑠 = 𝑚𝑒𝑎𝑛 𝑜𝑓 𝑡ℎ𝑒 𝑐𝑙𝑢𝑠𝑡𝑒𝑟-𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛𝑠 𝑙𝑖𝑛𝑘𝑖𝑛𝑔 𝑡𝑜 𝑐𝑎𝑟𝑒 𝑖𝑛 𝑡ℎ𝑒 𝑠
𝑡ℎ𝑠𝑡𝑟𝑎𝑡𝑢𝑚 
𝑐𝑠 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑙𝑢𝑠𝑡𝑒𝑟𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑠
𝑡ℎ𝑠𝑡𝑟𝑎𝑡𝑢𝑚 
?̅?Hs = 
1
∑(1 𝑚⁄ ) 𝑐𝑠⁄
  
𝑚 = 𝑐𝑙𝑢𝑠𝑡𝑒𝑟 𝑠𝑖𝑧𝑒  
  
216
  
References 
1. Hayes JR, Moulton HL. Cluster randomised trials. Boca Raton: Taylor & Francis; 
2009. 201 p. 
 
 
217
8
.2
 A
p
p
en
d
ix
 2
: 
H
o
u
se
h
o
ld
 d
a
ta
 f
o
rm
 
 
L
in
k
a
g
e 
to
 p
re
-A
R
T
 c
a
re
 s
tu
d
y
- 
H
o
u
se
h
o
ld
 D
a
ta
 F
o
r
m
 
C
lu
st
er
 n
u
m
b
er
: 
|_
_
|_
_
|C
L
U
S
N
  
V
il
la
g
e 
n
a
m
e:
 _
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
V
IL
L
  
H
o
u
se
h
o
ld
  
n
u
m
b
er
  
N
a
m
e
s 
o
f 
h
o
u
se
h
o
ld
  
m
e
m
b
er
s 
 
a
g
ed
 ≥
1
8
 y
ea
rs
 
V
C
T
  
n
u
m
b
er
 
A
g
e 
 
S
ex
 
V
is
it
 1
 
V
is
it
 2
 
V
is
it
 3
 
C
o
m
m
en
ts
 
(p
ro
v
id
e 
te
le
p
h
o
n
e
 
n
u
m
b
er
 i
f 
en
ro
ll
e
d
) 
 
D
a
te
 
L
a
b
o
ra
to
ry
 
n
u
m
b
er
 
D
a
te
 
L
a
b
o
ra
to
ry
 
n
u
m
b
er
 
D
a
te
 
L
a
b
o
ra
to
ry
 
n
u
m
b
er
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 In
te
rv
ie
w
er
’s
 i
n
it
ia
ls
: 
¦_
_
_
¦_
_
_
¦_
_
_
¦ 
218
8
.3
 A
p
p
en
d
ix
 3
: 
H
IV
 c
o
u
n
se
ll
in
g
 a
n
d
 t
es
ti
n
g
 w
o
rk
sh
ee
t 
L
in
k
a
g
e 
to
 H
IV
 c
a
re
 s
tu
d
y
 -
 F
ie
ld
 H
IV
 c
o
u
n
se
ll
in
g
 &
 t
es
ti
n
g
 w
o
rk
sh
ee
t 
C
lu
st
er
 n
u
m
b
er
: 
|_
_
|_
_
| 
  
  
 V
il
la
g
e 
N
u
m
b
er
: 
D
a
te
 
V
C
T
 n
u
m
b
er
 
V
is
it
 c
o
d
e
 (
1
, 
2
, 
…
) 
S
ex
 (
1
=
M
, 
2
=
F
) 
A
g
e
 
T
es
t 
(0
=
N
eg
a
ti
v
e
,1
=
P
o
si
ti
v
e)
 
L
a
b
o
ra
to
ry
 n
u
m
b
er
  
S
ta
ff
 i
n
it
ia
ls
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
219
8.4 Appendix 4: Informed consent document - English v1.1 26Jan15 
 
INFORMED CONSENT DOCUMENT: LINKAGE TO HIV CARE STUDY 
PARTICIPANT INFORMATION 
Study Title:  The effectiveness of a counseling intervention on the uptake of HIV care 
services among HIV infected patients in Uganda. 
 
Study purpose: The purpose of this study is to find out whether follow-up counseling 
for persons who are counseled and tested for HIV from their homes makes it easier for 
them to; 1) take up HIV care services; 2) test again for HIV. Results from this study will 
contribute to HIV prevention and care efforts in Uganda.  
 
Study participants: The study will be conducted in twenty-two randomly selected 
communities in Mukungwe and Buwunga sub-counties, Masaka district. Counselors 
will visit all households in the 22 communities and offer counseling and testing for HIV 
to all adults in each home. Participants for the study will be identified from those 
individuals that undergo counseling and testing for HIV in their homes. Up to 500 
individuals with and without HIV infection will participate in the study.   
 
Study duration: You will be in the study for a total of 6 months. You may have up to 3 
follow up visits at one, two, and six months after you join the study. All study visits will 
be conducted in your home.  
 
Study visits 
Screening/Enrolment visit: After you receive your HIV test results, you will be given 
information about the study and invited to participate. If you agree to participate, you 
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will be asked questions about your personal details including HIV testing experiences. 
If you are found to have HIV infection, the counselor will give you information about 
the available HIV care services in your area, and refer you to an HIV care provider of 
your choice for care and support.  
 
Month 1 and 2 follow-up visits: At one and at two months after joining the study, 
counselors will visit participants in 11 randomly selected communities to provide 
follow-up counseling. Participants in the remaining 11 communities will not have 
month 1 and 2 follow-up visits and will not have follow-up counseling.  You will be 
informed by a study counselor if and when you will be receiving follow-up counseling 
or not.  
 
Month 6 follow-up visit: Six months after joining the study, study counselors will visit 
participants in all the 22 communities. If you have HIV infection, you will be asked if 
you registered for and are receiving HIV care. You will also be asked about the 
laboratory tests that you have had and details of the drugs you are taking. If you have 
not had a CD4 cell count test done, the counselor will ask you to provide a blood sample 
for CD4 cell count testing. If you do not have HIV infection, the counselor will offer 
you another HIV test. Written CD4 cell count or HIV test results will be delivered to 
you within 1 week. 
 
 Review of medical records: If you have HIV and are receiving care; we will 
visit your HIV care provider to collect details about the care that you are 
receiving.  
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Interviews on uptake of HIV care and repeat HIV testing: You may be selected to 
participate in interviews to get your thoughts about uptake of HIV care services and 
getting another HIV test. If you are selected, a study staff will visit your home 2-3 
months after the month 6 follow-up visit to conduct the interview. The interview will 
take approximately 45 minutes.    
 
Risks and discomforts: This study involves visits by study staff to your home. This 
may inconvenience you or cause you some discomfort. You may feel pain and get 
bruising where the needle goes into your arm while drawing blood. You may also feel 
dizzy or faint at the time of drawing blood but this is not common.  You may become 
worried, or anxious when discussing sex and HIV, while undergoing HIV testing, and 
when you receive HIV positive results. The counsellor will help you with any feelings 
or questions you may have. If you are HIV-infected and other people learn about it, they 
may treat you unfairly. This study will enroll HIV-infected and uninfected persons. This 
may decrease the chance of other people knowing your HIV status. 
 
Benefits: You will learn your HIV status and receive information about HIV prevention 
and care services. If you have HIV, you will be referred to an HIV care facility where 
you will receive treatment and support. If you do not have HIV, you will be given 
information on ways to reduce the risk of getting HIV. If you are male and would like to 
get circumcised in order to reduce your risk of getting HIV, you will be provided a 
written referral to a facility where you can undergo safe male circumcision.  
 
Your participation is voluntary: You will sign or make a thumb print on 2 copies of 
this form to indicate that you voluntarily agree to take participate in the study; one copy 
will be given to you and the other will be kept at the MRC/UVRI Masaka office.  You 
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may withdraw from the study at any time. If you decide not to participate in or 
withdraw from the study, you will not lose any rights or benefits.  
 
Supervision of the study: Approvals for this study have been obtained from the UVRI 
Research Ethics Committee, the London School of Hygiene & Tropical Medicine Ethics 
committee, and the Uganda National Council for Science and Technology. The study 
will be monitored by someone who is not involved in its conduct.  
 
Confidentiality: Your participation in the study, all information collected about you 
and laboratory test results are confidential. You will have your own unique study 
number that will only be known to you and the study staff.  Your blood specimens will 
only be identified by this number. Any documents containing your name will be locked 
away in a secure place at the MRC/UVRI- Masaka office. 
 
Contact numbers: If you have any questions about the study, please call Dr. Eugene 
Ruzagira on Tel: 0481421211 or 0701030782 at the MRC/UVRI Masaka clinic. If you 
have a question about your rights as a study volunteer please contact Mr. Tom Lutalo, 
the Chairman of the UVRI Research Ethics Committee on Tel: 0414321962.  
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CONSENT FORM 
I, (name of participant)…………………………………………………………………… 
of (address)……………………………………………………………………………….. 
agree to take part in the study entitled: “The effectiveness of a counseling 
intervention on the uptake of HIV care services among HIV infected patients in 
Uganda”. I have read/been read to this study’s information sheet and I understand what 
will be required of me if I take part in this study. My questions regarding this study have 
been answered. I understand that at any time, I may withdraw from this study without 
giving a reason and without affecting my normal medical care and management. 
   
Participant signature/Thumb print  Date 
 
Study staff obtaining consent: I have explained the nature, purpose, demands and 
foreseeable risks of the above study to the participant. I have answered all the 
participant’s questions to the best of my ability. 
   
Study staff signature  Date 
 
Impartial witness (only necessary if participant was not able to read and understand 
this Informed Consent Document): I affirm that the Informed Consent Document has 
been read to the participant and he/she understands the study, had his/her questions 
answered, and I have witnessed the participant’s consent to study participation. 
   
Impartial witness signature  Date 
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8.5 Appendix 5: Informed consent document - Luganda v1.1 26Jan15  
 
EKIWANDIIKO E’KYOKUNNYONNYOLA ANETABA MUKUNOONYEREZA 
ANEETABAMU BYALINA OKUMANYA 
Omutwe gw’okunoonyereza: Okunoonyereza okugenderera okuzuula oba nga 
okulungamya abantu abalina akawuka ka silimu mu Uganda kibayambako okweyunira 
okufuna obujjanjabi bwakawuka kano.   
 
Ekigendererwa ky’okunoonyereza: Ekigendererwa ky’okunoonyereza kuno kwe 
kuzuula oba okulondoola n’okulungamya abantu ababa bakeberebbwa akawuka ka 
silimu mu maka gabwe kiyinza okubayamba: 1) okweyunira okufuna obujjanjabi bwa 
kawuka kano; 2) okuddamu okwekebeza akawuka ka silimu. Ebinaava mu 
kunoonyereza kuno bijja kuyamba mu kawefube w’okuziyiza n’okujjanjaba akawuka ka 
silimu mu Uganda.  
 
Abaneetaba mu kunoonyereza: Okunoonyereza kuno kujja kukolebwa mu bitundu 22 
mu magombolola g’e Buwunga ne Mukungwe Mu Masaka disitulikiti. Abalungamya 
bajja kukyalira amaka gona mu bitundu bino 22 bawe okulangamya n’okukebera 
akawuka ka silimu eri abantu abakulu bonna mu buli maka. Abanetaba 
mukunoonyereza kunno bajja kuva mwabo abanaba balungamiziddwa era 
nebakeberebwa akawuka ka silimu ngabasangibwa mu maka gabwe. Abantu nga 500 
abalina nabatalina kawuka ka siliimu be baneetaba mu kunoonyereza kuno. 
 
Ebbanga okunoonyereza lye kunaamala: Ojja kubeera mu kunoonyereza okumala 
emyezi nga 6. Oyinza okukyalilwa emirundi essatu: oluvanyuma lwomwezi 1, emyezi 
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2, ne 6 nga oyingidde mu kunoonyereza. Enkyala z’okunoonyereza zonna zijja 
kukolebwa mu maka go.   
 
Enkyala z’okunoonyereza  
Olukyala olwokuyingizibwa mu kunoonyereza: Nga omaze okufuna ebivudde mu 
kukeberebwa akawuka ka silimu, ojja kunnyonnyolwa ebikwata kunoonyereza kuno era 
osabibwe okukwetabamu. Bw’okkiriza okwetabamu, ojja kubuuzibwa ebibuuzo ku 
bikwatako ng’omuntu nebikwata ku kwekebeza akawuka ka siliimu. Bw’nosangibbwa 
ng’olina akawuka ka siliimu, omulungamya ajja kukuwa ebikwata ku w’oyinza okufuna 
obujjanjabi bw’embeera eno ate akuwe n’ebbaluwa ekwanjula eyo gye wandyagadde 
okufuna obujjanjabi buno n’obuyambi obulala.  
 
Olukyala kumwezi 1 ne 2: Ku mwezi ogusooka, nemyezi ebiri oluvanyuma 
lwokuyingira mukonoonyereza, mu bitundu 11 ebinalondebwa mu ngeri yakalulu, 
abalungamya bajja kukyalira abantu abanaba betabye mukonoonyereza bongere 
okubalungamya kubikwatagana n’akawuka ka silimu. Abantu abanaba betabye 
mukunoonyereza mubitundu 11 ebinaba bisagadde tebagya kukyalilwa era tebagya 
kufuna kulungamizibwa mu biseera bino.  Omulungamya mu kunoonyereza kuno ajja 
kukutegeza oba oli mwabo abanayongera okulungamizibwa era nebisera 
mwonalungamizibwa abikubulire.    
 
Olukyala ku myezi 6: Nga emyezi 6 gyiweze oluvanyuma lwokuyingira 
mukonoonyereza, abalungamya mu kunoonyereza bajja kukyalira abantu bona abanaba 
bakutabyemu mu bitundu ebyo 22. Bwoba olina akawuka ka silimu, ojja kubuzibwa oba 
watandika okufuna obujjanjabi, ebyakukeberwako, n’eddagala lyokozesa.  Bw’oba nga 
tokeberebwanga bungi bwa butofaali obwa CD4; omulungamya ajja kukusaba oweyo 
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omusaayi gukeberebwe obutofaali. Bw’oba tolina kawuka ka siliimu, omulungamya ajja 
kukuwa omukisa ogwokudamu okwekebeza akawuka ka siliimu.  Ebinava 
mukukeberebwa kw’obutofaali oba akawuka ka silimu bijja kukudizibwa mu 
buwandiike mu bbanga eritassukka wiiki 1.  
 Okufuna n’okuyita mu biwandiiko ebikwata ku bujjaanjabi: Bw’oba nga 
olina akawuka ka siliimu ate ng’olina gyofuna obujjanjabi; tujja kutuukirira eyo 
gy’ofunira obujjanjabi okuyita mu biwandiiko byo n’okufuna ebikwata ku 
bujjaanjabi bw’ofuna.  
 
Ebibuuzo ebikwata ku kufuna obujjanjabi bw’akawuka ka siliimu n’okuddamu 
okwekebeza akawuka kano: Okyayinza okulondebwa okwetaba mukubuzibwa 
ebibuzo okumanya endowoza yo kukyokweyunira okufuna obujanjabi bwa kawuka ka 
silimu n’ekyokudangamu okwekebeza akawuka kano.  Bw’onolondebwa, omukozi mu 
kunoonyereza kuno ajja kukukyalira ewaka wo wakati we myezi 2-3 oluvanyuma 
lw’olukyala olw’emyezi 6 okukubuuza ebibuuzo bino.  Okubuzibwa kuno kujja kutwala 
eddakika nga 45.     
 
Obuzibu n’obutayisibwa bulungi: Okunoonyereza kuno kulimu abakozi ku mulimu 
guno okukukyalira ewaka. Kino kiyinza okukutataganya oba obutakuyisa bulungi. 
Oyinza okufuna obulumi n’okunubuka awo empiso weyingirira mu mukono gwo nga 
ojjibwako omusayi. Okyayinza okuwulira kamunguluze oba okuggwamu amanyi mu 
kaseera akokujibwako omusayi naye kino tekitera kubaawo. Oyinza okweraliikirira oba 
okwewanika omutima nga mukubaganya ebirowoozo ku by’okutaabagana mu bikolwa 
eby’ekyaama n’akawuka ka siliimu, ng’okeberebwa akawuka ka siliimu oba 
ebivuddemu bwe biraga nti olina akawuka kano. Omulungamya ajja kukuyamba ku 
mbeera eno n’okuddamu ebibuuzo by’oyinza okuba nabyo. Bw’oba olina akawuka ka 
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siliimu ate abantu abalala ne bakimanyako, bakyayinza obutakuyisa bulungi.  
Okunoonyereza kuno kujja kubaamu abantu abalina n’abatalina kawuka kano. Kino 
kikyayinza okukendeeza obuzibu bw’abantu abalala okumanya embeera y’obulamu 
bwo ku kawuka ka siliimu.   
 
Ebyokuganyulwa: Ojja kumanya oba olina akawuka ka silimu oba tokalina era 
otegezebwe ku ntekateka z’okwetangira n’okujjanjaba akawuka kano. Bw’oba ng’olina 
akawuka ka siliimu ojja kuweerezebwa gy’osobola okufuna obujjaanjabi 
n’okuyambibwa. Bw’oba tolina kawuka ka siliimu ojja kutegezebwa engeri gyoyinza 
okwetangiramu akawuka kano. Bw’oba nga olimusajja era ng’awandyagade 
okomolebwe okusobola okunkendeza ku katyabaga kokwatibwa akawuka ka silimu, 
ojjakuwebwa ebbaluwa ekusindika kudwaliro woyinza okukumolebwa.   
 
Okwetabamu kwa kyayagalire: Oja kusa omukono oba ekinkumu ku kopi bbiri 
ez’ekiwandiko kino okulaga nti okwetabamu ko kwa kyeyagalire; kopi emu ejja 
kukuwebwa ate endala eterekebwe ku kitebe kya MRC/UVRI e Masaka.   Okyayinza 
okuva mu kunoonyereza kuno obudde bwonna. Bw’osalawo obutetabaamu oba 
okuvaamu, tolina ddembe ly’abuntu oba by’obadde olina okufuna by’ofiirwa. 
 
Okulondola engeri okunoonyereza gye kunaakolebwamu: Olukusa lw’okukola 
okunoonyereza kuno lwaweereddwa okuva mu bukiiko obukwasisa empisa n’amateeta 
mubyokunoonyereza obwebitongole bino: Uganda Virus Research Institute, London 
School of Hygiene and Tropical Medicine, ne Uganda National Council for Science and 
Technology. Okunoonyereza kujja kulondolwa omuntu eyeetengeredde atali omu 
kwabo abakola okunoonyereza. 
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Okukuuma ebyaama: Okwetaba kwo mu kunoonyereza, byonna by’etukunganyako 
n’ebyo ebiva mu kukeberebwako bya kyaama.  Ojja kuba ne nnamba eyiyo ku bubwo 
ekwawula ku muntu omulala yenna era nga emanyiddwa gwe wekka n’abo abakola 
okunoonyereza. Omusaayi ogukugyibwako okukeberebwa gujja kulambibwa ne 
nnamba yo yokka. Ekiwandiiko kyonna ekiriko amannya go kijja kukuumirwa awantu 
awekusifu ku kitebe kya MRC/UVRI Masaka.  
 
Nnamba z’essimu: Bw’oba n’ekibuuzo kyonna ku kunoonyereza, mwattu kubira Dr. 
Eugene Ruzagira ku 0481421211 oba 0701030782 ku ddwaliro lya MRC/UVRI 
Masaka.  Bw’oba n’ekibuuzo ku dembe lyo nga nakyewa eyetabye mu kunoonyereza, 
mwattu tuukirira Mwami Tom Lutalo, ssentebe w’akakiiko ka sayaansi, amateeka 
n’empisa aka UVRI ku ssimu 0414321962. 
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FOOMU Y’OKUKIRIZA OKWETABA MU KUNOONYEREZA  
Nze, (erinya ly’etabyemu)……………………………………………………………… 
owe (gyabera)…………………………………………nzirikiriza okwetaba mu 
kunoonyereza okugenderera okuzuula oba nga okulungamya abantu abalina akawuka ka 
silimu mu Uganda kibayambako okweyunira okufuna obujjanjabi bwakawuka kano. 
Nsomye/nsomeddwa ekiwandiiko ekinnyonnyola ebikwata ku kunoonyereza kuno era 
ntegede ekineetagisa bwenkwetabamu. Ebibuuzo byange ku kunoonyereza kuno 
bididdwamu. Nkitegeera nti obudde bwonna nsobola okuva mukunoonyereza kuno nga 
siwadde nsonga era kino tekikosa bujjanjabi bwenina kufuna.  
   
Omukono (ekinkumu) gw’eyatabyemu  Ennaku z’omwezi 
 
Oyo annyonnyode ebikwata ku kunoonyereza: Omuntu ono munnyonnyodde 
ekigendererwa ky’okunoonyereza kuno, ebyetaagisa, n’obuzibu obuyinza okubamu. 
Ebibuuzo bye byonna mbizeemu nga bwensobola 
   
Omukono gw’oyo annyonnyode ebikwata 
ku kunoonyereza 
 Ennaku z’omwezi 
 
Omujjulizi atalina kyekubiira: (Kino kyetaagisa singa omuntu akirizza okwetaba 
mukunonyereza tasobola kwesomera biri mu kiwandiiko ekinnyonnyola ku 
kunoonyereza kuno): Nkakasa nti ekiwandiiko ekinnyonnyola ebikwata ku kunonyereza 
kuno omuntu ono kimusomeddwa era okunoonyereza akutegedde bulungi, ebibuuzo bye 
biddiddwamu era mbaddewo ng’omujjulizi nga akkiriza okwetaba mu kunoonyereza 
kuno  
   
Omukono gw’omujjulizi atalina 
kyekuubiira 
 Ennaku z’omwezi 
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8.6 Appendix 6: Informed consent document - English v2.0 15May15 
 
INFORMED CONSENT DOCUMENT: LINKAGE TO HIV CARE STUDY 
PARTICIPANT INFORMATION 
Study Title:  The effectiveness of a counseling intervention on the uptake of HIV care 
services among HIV infected patients in Uganda. 
 
Study purpose: The purpose of this study is to find out whether follow-up counseling 
for persons who are counseled and tested for HIV from their homes makes it easier for 
them to; 1) take up HIV care services; 2) test again for HIV. Results from this study will 
contribute to HIV prevention and care efforts in Uganda.  
 
Study participants: The study will be conducted in twenty-eight randomly selected 
communities in Mukungwe, Buwunga, and Kyanamukaaka sub-counties, Masaka 
district. Counselors will visit all households in the 28 communities and offer counseling 
and testing for HIV to all adults in each home. Participants for the study will be 
identified from those individuals that undergo counseling and testing for HIV in their 
homes. Up to 308 individuals with and without HIV infection will participate in the 
study.   
 
Study duration: You will be in the study for a total of 6 months. You may have up to 3 
follow up visits at one, two, and six months after you join the study. All study visits will 
be conducted in your home.  
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Study visits 
Screening/Enrolment visit: After you receive your HIV test results, you will be given 
information about the study and invited to participate. If you agree to participate, you 
will be asked questions about your personal details including HIV testing experiences. 
If you are found to have HIV infection, the counselor will give you information about 
the available HIV care services in your area, and refer you to an HIV care provider of 
your choice for care and support.  
 
Month 1 and 2 follow-up visits: At one and at two months after joining the study, 
counsellors will visit participants in 14 randomly selected communities to provide 
follow-up counselling. Participants in the remaining 14 communities will not have 
month 1 and 2 follow-up visits and will not have follow-up counseling. You will be 
informed by a study counselor if and when you will be receiving follow-up counseling 
or not.  
 
Month 6 follow-up visit: Six months after joining the study, study counselors will visit 
participants in all the 28 communities. If you have HIV infection, you will be asked if 
you registered for and are receiving HIV care. You will also be asked about the 
laboratory tests that you have had and details of the drugs you are taking. If you have 
not had a CD4 cell count test done, the counselor will ask you to provide a blood sample 
for CD4 cell count testing. If you do not have HIV infection, the counselor will offer 
you another HIV test. Written CD4 cell count or HIV test results will be delivered to 
you within 1 week. 
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 Review of medical records: If you have HIV and are receiving care; we will 
visit your HIV care provider to collect details about the care that you are 
receiving.  
 
Interviews on uptake of HIV care and repeat HIV testing: You may be selected to 
participate in interviews to get your thoughts about uptake of HIV care services and 
getting another HIV test. If you are selected, a study staff will visit your home 2-3 
months after the month 6 follow-up visit to conduct the interview. The interview will 
take approximately 45 minutes.    
 
Risks and discomforts: This study involves visits by study staff to your home. This 
may inconvenience you or cause you some discomfort. You may feel pain and get 
bruising where the needle goes into your arm while drawing blood. You may also feel 
dizzy or faint at the time of drawing blood but this is not common.  You may become 
worried, or anxious when discussing sex and HIV, while undergoing HIV testing, and 
when you receive HIV positive results. The counselor will help you with any feelings or 
questions you may have. If you are HIV-infected and other people learn about it, they 
may treat you unfairly. This study will enroll HIV-infected and uninfected persons. This 
may decrease the chance of other people knowing your HIV status. 
 
Benefits: You will learn your HIV status and receive information about HIV prevention 
and care services. If you have HIV, you will be referred to an HIV care facility where 
you will receive treatment and support. If you do not have HIV, you will be given 
information on ways to reduce the risk of getting HIV. If you are male and would like to 
get circumcised in order to reduce your risk of getting HIV, you will be provided a 
written referral to a facility where you can undergo safe male circumcision.  
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 Your participation is voluntary: You will sign or make a thumb print on 2 copies of 
this form to indicate that you voluntarily agree to take participate in the study; one copy 
will be given to you and the other will be kept at the MRC/UVRI Masaka office.  You 
may withdraw from the study at any time. If you decide not to participate in or 
withdraw from the study, you will not lose any rights or benefits.  
 
Supervision of the study: Approvals for this study have been obtained from the UVRI 
Research Ethics Committee, the London School of Hygiene & Tropical Medicine Ethics 
committee, and the Uganda National Council for Science and Technology. The study 
will be monitored by someone who is not involved in its conduct.  
 
Confidentiality: Your participation in the study, all information collected about you 
and laboratory test results are confidential. You will have your own unique study 
number that will only be known to you and the study staff.  Your blood specimens will 
only be identified by this number. Any documents containing your name will be locked 
away in a secure place at the MRC/UVRI- Masaka office. 
 
Contact numbers: If you have any questions about the study, please call Dr. Eugene 
Ruzagira on Tel: 0481421211 or 0701030782 at the MRC/UVRI Masaka clinic. If you 
have a question about your rights as a study volunteer please contact Mr. Tom Lutalo, 
the Chairman of the UVRI Research Ethics Committee on Tel: 0414321962.  
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CONSENT FORM 
I, (name of participant)…………………………………………………………………… 
of (address)……………………………………………………………………………… 
agree to take part in the study entitled: “The effectiveness of a counseling 
intervention on the uptake of HIV care services among HIV infected patients in 
Uganda”. I have read/been read to this study’s information sheet and I understand what 
will be required of me if I take part in this study. My questions regarding this study have 
been answered. I understand that at any time, I may withdraw from this study without 
giving a reason and without affecting my normal medical care and management. 
   
Participant signature/Thumb print  Date 
 
Study staff obtaining consent 
I have explained the nature, purpose, demands and foreseeable risks of the above study 
to the participant. I have answered all the participant’s questions to the best of my 
ability. 
   
Study staff signature  Date 
 
Impartial witness (only necessary if participant was not able to read and understand 
this Informed Consent Document): I affirm that the Informed Consent Document has 
been read to the participant and he/she understands the study, had his/her questions 
answered, and I have witnessed the participant’s consent to study participation. 
   
Impartial witness signature  Date 
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8.7 Appendix 7: Informed consent document - Luganda v2.0 15May15 
 
EKIWANDIIKO E’KYOKUNNYONNYOLA ANETABA MUKUNOONYEREZA 
ANEETABAMU BYALINA OKUMANYA 
Omutwe gw’okunoonyereza: Okunoonyereza okugenderera okuzuula oba nga 
okulungamya abantu abalina akawuka ka silimu mu Uganda kibayambako okweyunira 
okufuna obujjanjabi bwakawuka kano.   
 
Ekigendererwa ky’okunoonyereza: Ekigendererwa ky’okunoonyereza kuno kwe 
kuzuula oba okulondoola n’okulungamya abantu ababa bakeberebbwa akawuka ka 
silimu mu maka gabwe kiyinza okubayamba: 1) okweyunira okufuna obujjanjabi bwa 
kawuka kano; 2) okuddamu okwekebeza akawuka ka silimu. Ebinaava mu 
kunoonyereza kuno bijja kuyamba mu kawefube w’okuziyiza n’okujjanjaba akawuka ka 
silimu mu Uganda.  
 
Abaneetaba mu kunoonyereza: Okunoonyereza kuno kujja kukolebwa mu bitundu 28 
mu magombolola g’e Buwunga, Mukungwe, ne Kyanamukaaka Mu Masaka disitulikiti. 
Abalungamya bajja kukyalira amaka gona mu bitundu bino 28 bawe okulangamya 
n’okukebera akawuka ka silimu eri abantu abakulu bonna mu buli maka. Abanetaba 
mukunoonyereza kunno bajja kuva mwabo abanaba balungamiziddwa era 
nebakeberebwa akawuka ka silimu ngabasangibwa mu maka gabwe. Abantu nga 308 
abalina nabatalina kawuka ka siliimu be baneetaba mu kunoonyereza kuno. 
 
Ebbanga okunoonyereza lye kunaamala: Ojja kubeera mu kunoonyereza okumala 
emyezi nga 6. Oyinza okukyalilwa emirundi essatu: oluvanyuma lwomwezi 1, emyezi 
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2, ne 6 nga oyingidde mu kunoonyereza. Enkyala z’okunoonyereza zonna zijja 
kukolebwa mu maka go.   
 
Enkyala z’okunoonyereza  
Olukyala olwokuyingizibwa mu kunoonyereza: Nga omaze okufuna ebivudde mu 
kukeberebwa akawuka ka silimu, ojja kunnyonnyolwa ebikwata kunoonyereza kuno era 
osabibwe okukwetabamu. Bw’okkiriza okwetabamu, ojja kubuuzibwa ebibuuzo ku 
bikwatako ng’omuntu nebikwata ku kwekebeza akawuka ka siliimu. Bw’nosangibbwa 
ng’olina akawuka ka siliimu, omulungamya ajja kukuwa ebikwata ku w’oyinza okufuna 
obujjanjabi bw’embeera eno ate akuwe n’ebbaluwa ekwanjula eyo gye wandyagadde 
okufuna obujjanjabi buno n’obuyambi obulala.  
 
Olukyala kumwezi 1 ne 2: Ku mwezi ogusooka, nemyezi ebiri oluvanyuma 
lwokuyingira mukonoonyereza, mu bitundu 14 ebinalondebwa mu ngeri yakalulu, 
abalungamya bajja kukyalira abantu abanaba betabye mukonoonyereza bongere 
okubalungamya kubikwatagana n’akawuka ka silimu. Abantu abanaba betabye 
mukunoonyereza mubitundu 14 ebinaba bisagadde tebagya kukyalilwa era tebagya 
kufuna kulungamizibwa mu biseera bino.  Omulungamya mu kunoonyereza kuno ajja 
kukutegeza oba oli mwabo abanayongera okulungamizibwa era nebisera 
mwonalungamizibwa abikubulire.    
 
Olukyala ku myezi 6: Nga emyezi 6 gyiweze oluvanyuma lwokuyingira 
mukonoonyereza, abalungamya mu kunoonyereza bajja kukyalira abantu bona abanaba 
bakutabyemu mu bitundu ebyo 28. Bwoba olina akawuka ka silimu, ojja kubuzibwa oba 
watandika okufuna obujjanjabi, ebyakukeberwako, n’eddagala lyokozesa.  Bw’oba nga 
tokeberebwanga bungi bwa butofaali obwa CD4; omulungamya ajja kukusaba oweyo 
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omusaayi gukeberebwe obutofaali. Bw’oba tolina kawuka ka siliimu, omulungamya ajja 
kukuwa omukisa ogwokudamu okwekebeza akawuka ka siliimu.  Ebinava 
mukukeberebwa kw’obutofaali oba akawuka ka silimu bijja kukudizibwa mu 
buwandiike mu bbanga eritassukka wiiki 1.  
 Okufuna n’okuyita mu biwandiiko ebikwata ku bujjaanjabi: Bw’oba nga 
olina akawuka ka siliimu ate ng’olina gyofuna obujjanjabi; tujja kutuukirira eyo 
gy’ofunira obujjanjabi okuyita mu biwandiiko byo n’okufuna ebikwata ku 
bujjaanjabi bw’ofuna.  
 
Ebibuuzo ebikwata ku kufuna obujjanjabi bw’akawuka ka siliimu n’okuddamu 
okwekebeza akawuka kano: Okyayinza okulondebwa okwetaba mukubuzibwa 
ebibuzo okumanya endowoza yo kukyokweyunira okufuna obujanjabi bwa kawuka ka 
silimu n’ekyokudangamu okwekebeza akawuka kano.Bw’onolondebwa, omukozi mu 
kunoonyereza kuno ajja kukukyalira ewaka wo wakati we myezi 2-3 oluvanyuma 
lw’olukyala olw’emyezi 6 okukubuuza ebibuuzo bino.  Okubuzibwa kuno kujja kutwala 
eddakika nga 45.     
 
Obuzibu n’obutayisibwa bulungi: Okunoonyereza kuno kulimu abakozi ku mulimu 
guno okukukyalira ewaka. Kino kiyinza okukutataganya oba obutakuyisa bulungi. 
Oyinza okufuna obulumi n’okunubuka awo empiso weyingirira mu mukono gwo nga 
ojjibwako omusayi. Okyayinza okuwulira kamunguluze oba okuggwamu amanyi mu 
kaseera akokujibwako omusayi naye kino tekitera kubaawo. Oyinza okweraliikirira oba 
okwewanika omutima nga mukubaganya ebirowoozo ku by’okutaabagana mu bikolwa 
eby’ekyaama n’akawuka ka siliimu, ng’okeberebwa akawuka ka siliimu oba 
ebivuddemu bwe biraga nti olina akawuka kano. Omulungamya ajja kukuyamba ku 
mbeera eno n’okuddamu ebibuuzo by’oyinza okuba nabyo. Bw’oba olina akawuka ka 
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siliimu ate abantu abalala ne bakimanyako, bakyayinza obutakuyisa bulungi.  
Okunoonyereza kuno kujja kubaamu abantu abalina n’abatalina kawuka kano. Kino 
kikyayinza okukendeeza obuzibu bw’abantu abalala okumanya embeera y’obulamu 
bwo ku kawuka ka siliimu.   
 
Ebyokuganyulwa: Ojja kumanya oba olina akawuka ka silimu oba tokalina era 
otegezebwe ku ntekateka z’okwetangira n’okujjanjaba akawuka kano. Bw’oba ng’olina 
akawuka ka siliimu ojja kuweerezebwa gy’osobola okufuna obujjaanjabi 
n’okuyambibwa. Bw’oba tolina kawuka ka siliimu ojja kutegezebwa engeri gyoyinza 
okwetangiramu akawuka kano. Bw’oba nga olimusajja era ng’awandyagade 
okomolebwe okusobola okunkendeza ku katyabaga kokwatibwa akawuka ka silimu, 
ojjakuwebwa ebbaluwa ekusindika kudwaliro woyinza okukumolebwa.   
 
Okwetabamu kwa kyayagalire: Oja kusa omukono oba ekinkumu ku kopi bbiri 
ez’ekiwandiko kino okulaga nti okwetabamu ko kwa kyeyagalire; kopi emu ejja 
kukuwebwa ate endala eterekebwe ku kitebe kya MRC/UVRI e Masaka.   Okyayinza 
okuva mu kunoonyereza kuno obudde bwonna. Bw’osalawo obutetabaamu oba 
okuvaamu, tolina ddembe ly’abuntu oba by’obadde olina okufuna by’ofiirwa. 
 
Okulondola engeri okunoonyereza gye kunaakolebwamu: Olukusa lw’okukola 
okunoonyereza kuno lwaweereddwa okuva mu bukiiko obukwasisa empisa n’amateeta 
mubyokunoonyereza obwebitongole bino: Uganda Virus Research Institute, London 
School of Hygiene and Tropical Medicine, ne Uganda National Council for Science and 
Technology. Okunoonyereza kujja kulondolwa omuntu eyeetengeredde atali omu 
kwabo abakola okunoonyereza. 
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Okukuuma ebyaama: Okwetaba kwo mu kunoonyereza, byonna by’etukunganyako 
n’ebyo ebiva mu kukeberebwako bya kyaama.  Ojja kuba ne nnamba eyiyo ku bubwo 
ekwawula ku muntu omulala yenna era nga emanyiddwa gwe wekka n’abo abakola 
okunoonyereza. Omusaayi ogukugyibwako okukeberebwa gujja kulambibwa ne 
nnamba yo yokka. Ekiwandiiko kyonna ekiriko amannya go kijja kukuumirwa awantu 
awekusifu ku kitebe kya MRC/UVRI Masaka.  
 
Nnamba z’essimu: Bw’oba n’ekibuuzo kyonna ku kunoonyereza, mwattu kubira Dr. 
Eugene Ruzagira ku 0481421211 oba 0701030782 ku ddwaliro lya MRC/UVRI 
Masaka.  Bw’oba n’ekibuuzo ku dembe lyo nga nakyewa eyetabye mu kunoonyereza, 
mwattu tuukirira Mwami Tom Lutalo, ssentebe w’akakiiko ka sayaansi, amateeka 
n’empisa aka UVRI ku ssimu 0414321962. 
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FOOMU Y’OKUKIRIZA OKWETABA MU KUNOONYEREZA  
Nze, (erinya ly’etabyemu)……………………………………………………………… 
owe (gyabera)……………………………………………………………………………. 
nzirikiriza okwetaba mu kunoonyereza okugenderera okuzuula oba nga okulungamya 
abantu abalina akawuka ka silimu mu Uganda kibayambako okweyunira okufuna 
obujjanjabi bwakawuka kano. Nsomye/nsomeddwa ekiwandiiko ekinnyonnyola 
ebikwata ku kunoonyereza kuno era ntegede ekineetagisa bwenkwetabamu. Ebibuuzo 
byange ku kunoonyereza kuno bididdwamu.  Nkitegeera nti obudde bwonna nsobola 
okuva mukunoonyereza kuno nga siwadde nsonga era kino tekikosa bujjanjabi bwenina 
kufuna.  
   
Omukono (ekinkumu) gw’eyatabyemu  Ennaku z’omwezi 
 
Oyo annyonnyode ebikwata ku kunoonyereza: Omuntu ono munnyonnyodde 
ekigendererwa ky’okunoonyereza kuno, ebyetaagisa, n’obuzibu obuyinza okubamu. 
Ebibuuzo bye byonna mbizeemu nga bwensobola 
   
Omukono gw’oyo annyonnyode ebikwata 
ku kunoonyereza 
 Ennaku z’omwezi 
Omujjulizi atalina kyekubiira: (Kino kyetaagisa singa omuntu akirizza okwetaba 
mukunonyereza tasobola kwesomera biri mu kiwandiiko ekinnyonnyola ku 
kunoonyereza kuno): Nkakasa nti ekiwandiiko ekinnyonnyola ebikwata ku kunonyereza 
kuno omuntu ono kimusomeddwa era okunoonyereza akutegedde bulungi, ebibuuzo bye 
biddiddwamu era mbaddewo ng’omujjulizi nga akkiriza okwetaba mu kunoonyereza 
kuno  
   
Omukono gw’omujjulizi atalina kyekuubiira  Ennaku z’omwezi 
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8.8 Appendix 8: Eligibility assessment form 
Linkage to pre-ART care study- eligibility assessment form 
 
HCT Lab number: MC|__|__|__|__|__|__|__|LABN     Cluster number: |__|__|CLUSN 
Village name: ____________________________VILL Household ID: |__|__|__|HHN 
Eligibility assessment form v2.1 12Mar15  Page 1 of 1 
HIV positive 
Inclusion criteria 
Aged ≥18 years  Yes ¦___¦ No ¦___¦ 
Willing to provide informed consent  Yes ¦___¦ No ¦___¦ 
Willing to receive follow-up counselling at home Yes ¦___¦ No ¦___¦ 
Exclusion criteria  
Previous or current receipt of HIV care from an ART provider  Yes ¦___¦ No ¦___¦ 
On-going participation in other health-related research  Yes ¦___¦ No ¦___¦ 
Intending to change residence in the next 6 months   Yes ¦___¦ No ¦___¦ 
Conditions that may make it difficult to provide informed 
consent 
Yes ¦___¦ No ¦___¦ 
HIV negative 
Inclusion criteria 
Age: ≥18 years  Yes ¦___¦ No ¦___¦ 
Willing to provide informed consent  Yes ¦___¦ No ¦___¦ 
Willing to receive follow-up counselling at home Yes ¦___¦ No ¦___¦ 
Exclusion criteria 
Intending to change residence in the next 6 months   Yes ¦___¦ No ¦___¦ 
Conditions that make it difficult to provide informed consent Yes ¦___¦ No ¦___¦ 
 
Individual eligible for enrolment  Yes ¦___¦ No ¦___¦ 
 
If eligible, assign study number:                                                       HCT-¦___¦___¦___¦___¦ 
                                                                                                          (e.g. HCT-888Z, HCT-999X,….)               
 
 
Interview date                                                          
 
|__|__||__|__|__||__|__|__|__| 
                            dd MMM yyyy 
 
Interviewer’s initials                                                                               
 
¦___¦___¦___¦ 
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Linkage to pre-ART care study- Socio-demographic questionnaire 
 
HCT Lab number: MC|__|__|__|__|__|__|__|LABN     Cluster number: |__|__|CLUSN 
Village name: ____________________________VILL Household ID: |__|__|__|HHN   
Study number: HCT-|__|__|__|__|SN    
Socio-demographic questionnaire V2.2 13Jul15 (Luganda)   Page 1 of 3 
No. Code Questions and filters  Coding categories  Skip  
1.  SC Sub-county                                                         Mukungwe 
                                                           Buwunga 
Kyanamukaaka 
1 
2 
3 
 
2.  SEX Sex                                                                Male 
                                                           Female 
1 
2 
 
3.  AGE Age                          |__|__|Years  
4.  MSTAT Marital status                                                                                                  Single 
                                                          Married 
                                                     Cohabiting 
                                                       Widowed 
                                    Divorced/separated 
1 
2 
3 
4 
5 
 
5.  EDUC Highest level of education attained                                    No formal education 
                                     Incomplete primary 
                                        Complete primary 
                                     Secondary (O level) 
                                      Secondary (A level) 
                                       University/College 
1 
2 
3 
4 
5 
6 
 
6.    What is your occupation? 
(Multiple responses allowed)                                                                                           
 
Yes 
 
No 
 
 OCC1 
OCC2 
OCC3 
OCC4 
OCC5 
OCC6 
OCC7 
OCC8 
OCC9 
OCC10 
OTHOCC 
             Subsistence farmer 
          Fishing/fish-related work 
                 Own small business 
        Shopkeeper/market salesperson 
Craftsman                                                    
Housewife 
          Professional worker 
                    Casual labourer 
Student                                                          
Unemployed  
Other                                                  
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
 SOTHOCC  Specify other:___________________________ 
7.  REL Religion                                             Roman Catholic 
                                                         Anglican 
                                             Other Christian 
                                                           Muslim 
                                                     Traditional 
Other (specify)……………………………………… 
                                                              None 
1 
2 
3 
4 
5 
6 
7 
 
 
8.9 Appendix 9: Sociodemographic questionnaire
243
Linkage to pre-ART care study- Socio-demographic questionnaire 
 
HCT Lab number: MC|__|__|__|__|__|__|__|LABN     Cluster number: |__|__|CLUSN 
Village name: ____________________________VILL Household ID: |__|__|__|HHN   
Study number: HCT-|__|__|__|__|SN    
Socio-demographic questionnaire V2.2 13Jul15 (Luganda)   Page 2 of 3 
 
No. Code Questions and filters  Coding categories  Skip  
8.   Ku bantu ababeera mu nyumba eno nga naawe mw’oli, 
waliwo alina ebintu bino wammanga?  
(Does any member of your household (including yourself) own any 
of the following?) 
(Prompt all responses) 
 
 
Yes  
 
 
No 
 
 BICY 
MOTCY 
CAR 
SEWM 
RADIO 
TELE 
FRIDG 
STOVE  
 
TEL  
MOB 
GOAT 
COW 
PROP 
Eggaali (Bicycle)            
Pikipiki (Motorcycle)  
Emmotoka (Car/van/truck)               
Ekyalaani (Sewing machine) 
Ladiyo (Radio/cd player)                            
TV (Television)  
Firiigi (Refrigerator) 
Amasiga g’amasanyalaze oba gaasi (Electricity/gas 
cooking stove) 
Essimu eyomunyumba [Telephone (landline)]  
Essimu ey’omungalo (Mobile phone) 
Embuzi(Goat) 
Ente (Cow) 
Enyumba epangisibwa (Property rented for income)  
1 
1 
1 
1 
1 
1 
1 
1 
 
1 
1 
1 
1 
1 
2 
2 
2 
2 
2 
2 
2 
2 
 
2 
2 
2 
2 
2 
9.  HHS Bantu bameka abaweza emyaka 18 egy’obukulu 
ababeera mu nyumba eno?  
(How many people aged 18 years and above, including you live in 
this household?) 
 
|__|__| 
  
10.  ROOM Enyumba yo erina ebisenge bimeka ebisulwamu?  
How many rooms in your household are used for sleeping? 
 
|__|__| 
  
11.  ELEC Olina amasanyalaze mu nyumba yo? (Do you have electricity 
in your household?) 
No 
Yes 
1 
2 
If No, skip 
to Q13 
12.  WELEC Mu bbanga ery’emyezi essatu egiyise, nnaku meka 
z’otaalina masanyalaze mu nyumba yo?  
(How many days was your household without working electricity In 
the past 3 months?) 
 
|__|__| 
 
13.  DHC 
 
Kitwala banga ki okutuuka ku ddwaliro erijjanjaba 
abalwadde ba siliimu erisinga okuba okumpi 
n’ewakawo?  
(How long does it take to travel to the ART provider nearest to your 
home?) 
Less than 30 minutes 
30 to 60 minutes  
More than 60 minutes 
1 
2 
3 
 
 
 
 
 
 
 
No. Code Questions and filters  Coding categories  Skip 
14.  ETEST Wali wekebezaako akawuka siliimu?  
(Have you tested for HIV before?)  
Yes                                                                   
No                                                                    
1 
2 
If No, skip
to Q18
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HCT Lab number: MC|__|__|__|__|__|__|__|LABN     Cluster number: |__|__|CLUSN 
Village name: ____________________________VILL Household ID: |__|__|__|HHN   
Study number: HCT-|__|__|__|__|SN    
Socio-demographic questionnaire V2.2 13Jul15 (Luganda)   Page 3 of 3 
15.  LTEST Wasemba ddi okwekebeza akawuka ka silimu?    
(When did you last test for HIV?)   
                                                             
Past 3 months                                               
Past 6 months  
Past 12 months  
Over 12 months ago                                                                                                                                
1 
2 
3 
4 
 
16.  LTESTR Ebyaava mu kukwebeza akawuka ka siliimu ku mukundi 
ogwasemba byalaga ki?  
(What were the results of your last HIV test?) 
Positive                                                          
Negative  
Don’t know                                                         
                                                    
1 
2 
3 
If
Negative/D
on’t know,
skip to Q18
17.  INCARE Bw’oba olina akawuka ka siliimu, ofuna obujjanjabi 
bw’obulwadde buno?  
(If HIV positive, do you receive regular medication for your HIV 
infection?) 
 
(Probe for receipt of daily septrin prophylaxis and/or 
ARVs) 
Yes                                                           
No 
Refused to answer                                             
                          
1 
2 
3 
 
18.  SPTEST Omanyi omwagalwawo bwayimiridde ku kawuka ka 
siliimu? 
(Do you know your spouse/partner’s HIV status?) 
Yes                                                                  
No  
No spouse/partner                                                                    
1 
2 
3 
If No/ No
spouse, 
stop here 
19.  SPSTAT Omwagalwawo ayimiridde atya ku by’akawuka ka 
siliimu?  
(What is your spouse/partner’s HIV status?) 
 
Positive                                                          
Negative  
Don’t know                                                        
Refused to answer  
                                                    
1 
2 
3 
4 
If Negative,
/Don’t 
know/refus
ed to 
answer,
stop here 
20.  SPCARE Omwagalwawo bw’aba nga alina akawuka ka siliimu, 
afuna obujjanjabi bw’obulwadde buno?  
(If your spouse/partner is HIV positive, is he/she receiving regular 
medication for his/her HIV infection?) 
 
(Probe for receipt of daily septrin prophylaxis and/or 
ARVs) 
Yes                                          
No  
Don’t know                                           
Refused to answer  
                                             
                       
1 
2 
3 
4 
 
 
INTD Interview date 
 
|__|__||__|__|__||__|__|__|__| 
                          dd MMM yyyy 
  
INT 
 
Interviewer’s initials |__|__|__| 
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8.10: Appendix 10: Locator form 
 
Linkage to pre-ART care study- Locator form 
 
Cluster number: |__|__|CLUSN   Study number: HCT-|__|__|__|__|SN   
Enrolment date: ¦___¦___¦¦___¦___¦___¦¦___¦___¦___¦___¦ENDAT 
                                    ddMMMyyyy 
 
Locator form V2.0 26Mar15  Page 1 of 1 
1.  Participant’s name:____________________________________________________________PNAM 
2.  Partner’s names: _____________________________________________________________SPOUSE 
3.  Village name :______________________________________________________________________VILG 
4.  Household number                                                                                |__|__|__|HHN 
5.  Name of household head:__________________________________________________HHNAM 
6.  Phone number:                                           ¦___¦___¦___¦___¦___¦___¦___¦___¦___¦___¦PHON 
7.  Additional locator information_______________________________________________________ 
_______________________________________________________________________________________ 
_______________________________________________________________________________________ 
_______________________________________________________________________________________ 
_______________________________________________________________________________________ 
_______________________________________________________________________________________ 
Interviewer’s name: _____________________________________________________________ 
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8.11  Appendix 11: HIV test certificate and referral form 
 
MEDICAL RESEARCH COUNCIL/UVRI RESEARCH UNIT ON AIDS 
HIV TEST CERTIFICATE 
Name: ……………………………………… ….Signature: …………………………… 
Age: ……………………………………………Sub-county/District: ...………………… 
Village: …………………………………………Sex:.………………………………… 
The above named person tested Positive HIV antibodies on (Date): …………………… 
This test was carried out at the National HIV Reference Centre, Uganda Virus Research 
Institute Entebbe. 
Referred to……………………………………….Date of reporting…………………… 
Signed:………………………………..................Name:………………………………… 
MRC
 Position:……………………………...Date: ………………………………… 
Note: This slip should be filed by the receiving Institution. 
 
 
MEDICAL RESEARCH COUNCIL/UVRI RESEARCH UNIT ON AIDS 
HIV TEST CERTIFICATE 
Name: ……………………………………… ….Signature: …………………………… 
Age: ……………………………………………Sub-county/District: ...………………… 
Village: …………………………………………Sex:.………………………………… 
The above named person tested Positive HIV antibodies on (Date): …………………… 
This test was carried out at the National HIV Reference Centre, Uganda Virus Research 
Institute Entebbe. 
Referred to……………………………………….Date of reporting…………………… 
Signed:………………………………..................Name:………………………………… 
MRC
 Position:……………………………...Date: ……………………………… 
Note: This slip should be filed by the Counselor. 
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Study number: HCT-|__|__|__|__|SN    Cluster number: |__|__|CLUSN  
Village name: ____________________________VILL   
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Complete at the month-6 visit for all HIV-infected study participants  
No. Code Questions and filters  Coding categories Skip  
1.  DISCL Wali obuuliddeko omuntu yenna nga bw’olina 
akawuka ka siliimu?  
(Have you disclosed your HIV status to anyone?)                   
Yes 
No  
1 
2 
If No, skip 
to Qn3                                                                                                                                                                                               
2.   Ani gwewabuulilako  
(Who have you disclosed your HIV status to?)  
 
(Prompt all responses)    
 
 
 
Yes 
 
 
 
No 
Skip to Qn4 
 DISCSPO 
DISCFAM 
DISCFR 
DISCSPIR 
DISCHW 
DISCOTH 
Omwagalwawo (Spouse/partner) 
Ow’oluganda (Other family member) 
Mukwano gwo (Friend) 
Omukulu w’eddini (Spiritual leader) 
Omusawo (Health care worker)  
Omuntu omulala (Other person) 
1 
1 
1 
1 
1 
1  
2 
2 
2 
2 
2 
2 
DISCOTHS Specify other person:     
3.   Oba nedda, lwaki tewali muntu gwe wali 
obuuliddeko nga bw’oyimiredde ku ky’akawuka 
ka siliimu?  
(If no, why haven’t you disclosed your HIV status to anyone?)  
 
(Prompt all responses)    
  
 
 
 
 
Yes 
 
 
 
 
 
No 
 
NDJUDG 
 
NDABU 
 
 
NDRELB 
 
NDDISCR 
NDTRST 
NDDOUT 
 
NDINCO 
 
NDOTH 
okutya abantu okunjogerera (Fear of being judged by 
others) 
Okutya omwagalwa wange 
okunkijjanya/okumpisa obubi (Fear of abuse/violence by 
partner) 
Okutya okwawukana n’omwagalwa wange (Fear of 
relationship break-up) 
Okutya okusosolebwa (Fear of discrimination)  
Tewali muntu gwenesiga (Do not trust anyone)  
Ssikakasa nti nina akawuka ka siliimu (Doubt HIV 
status)  
Okutya okufiirwa omulimu/eby’enfuna (Fear of 
job/income loss) 
Ensonga endala (Other reason)  
1 
 
1 
 
 
1 
 
1 
1 
1 
 
1 
 
1 
2 
 
2 
 
 
2 
 
2 
2 
2 
 
2 
 
2 
NDOTHS Specify other reason:  
4.  RG  Okuva lwewawerezebwa okufuna obujjanjabi 
bw’obulwadde bwa siliimu, wali wewandiisizza ku 
ddwaliro erijjanjaba obulwadde buno era nga 
ligaba n’eddagala eribuweweeza (ARV)?  
(Have you registered with an HIV clinic that also provides ARV 
drugs since you were referred for HIV care?)            
 
Yes 
No  
1 
2 
If Yes, skip 
to Qn6                                                      
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No. Code Questions and filters  Coding categories Skip  
 
 
5.   Lwaki toneewandiisa ku ddwaliro lijjanjaba 
bulwadde bwa siliimu?  
(Why haven’t you registered with an HIV clinic?)   
 
(Multiple responses allowed)                                                                                           
 
 
 
 
Yes  
 
 
 
 
No 
Skip to 
Qn36 
 NRGM 
NRGD 
NRGT 
NRGW 
NRGSE 
 
NRGTR 
 
NRGSTG 
 
NRGDUT 
 
NROTH 
Kubulwa sente zantambula (Lack money for transport) 
Eddwaliro liri wala (Health centre is far away) 
Kubulwa budde (lack of time) 
Sewuliramu bulwadde (I do not feel sick) 
Okutya okuyisibwa obubi eddagala (Fear ARV side 
effects) 
Nkozesa ddagala lya kinnaansi (Using herbal/other 
medicines)  
Okutya okulabibwa ku ddwaliro ewajjanjabirwa 
obulwadde bwa siliimu (Fear being seen at the HIV clinic)  
Ssikakasa nti nina akawuka ka siliimu (Doubt HIV 
status)  
Ensonga endala (Other reason) 
1 
1 
1 
1 
1 
 
1 
 
1 
 
1 
 
1  
2 
2 
2 
2 
2 
 
2 
 
2 
 
2 
 
2 
 NROTHS Specify other: 
6.  CLNAM Eddwaliro gyewewandiisiza baliyita batya?  
(What is the name of the HIV clinic where you registered?) 
   
7.  CLADD Eddwaliro lino lisaangibwa wa?  
(Where is the HIV clinic located?) 
   
8.  RGNO Ennamba eyakuwebwa kulw’okwewandiisa eri ki?  
(What is your HIV clinic registration number?)  
 
(Obtain clinic registration number from clinic 
documents e.g. appointment card, drug 
prescription forms etc.) 
 
 
|__|__|__|__|__|__|__|__| 
  
9.  RGDAT Wayiseewo bbanga ki okuva lw’ewewandiisa?  
(How long ago did you register with the HIV clinic?) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Less than 1 month  
1-3 months 
More than 3 months 
1 
2 
3 
 
8.12 Appendix 12: Linkage status questionnaire
249
 Linkage to pre-ART care study- Linkage status questionnaire 
Study number: HCT-|__|__|__|__|SN    Cluster number: |__|__|CLUSN  
Village name: ____________________________VILL   
Linkage status questionnaire v2.2 3Sep15       Page 3 of 7 
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10.   Lwaki wewandiisa ku ddwaliro erijjanjaba siliimu? 
(Why did you register with an HIV clinic?) 
 
(Multiple responses allowed)                                                                                           
 
 
 
Yes  
 
 
 
No 
 
RGSIC 
RGCON 
 
RGCD4 
 
RGELI 
 
RGART 
 
RGMON 
 
RGOTH 
Nali sewulira bulungi (Was feeling sick) 
Okukasa bwenyimiridde ku ky’akawuka ka siliimu 
(To confirm my HIV status) 
Okumanya obutofaali bw’omusayi gwange 
bwebwenkana (To know my CD4 count)  
Okumanya oba nga nsaanidde okutandika (To know 
eligibility for ARV drugs)   
okufuna eddagala eriweweeza ku kawuka ka 
siliimu (To start taking ARV drugs)   
Okukeberebwanga okumanya obulamu bwange 
bwe buyimiridde (To receive regular health monitoring)  
Ensonga endala (Other)   
1 
1 
 
1 
 
1 
 
1 
 
1 
 
1  
2 
2 
 
2 
 
2 
 
2 
 
2 
 
2 
RGOTHS Specify other: 
11.  FUV Wali ozeeyoko ku ddwaliro erijjanjaba siliimu 
okuva lwewewandiisa?  
(Have you attended the HIV clinic again since you registered?)  
Yes  
No  
1 
2 
If No, skip 
to Qn13 
12.  TOTV Emirundi emeka gy’ozeeyo ku ddwaliro lino 
okuva lwewewandiisa? (How many total visits have you 
made to the HIV clinic since you registered?)  
 
|__|__| 
Skip to 
Qn15 
13.   Lwaki toddangayo ku ddwaliro lino?  
(Why haven’t you visited the HIV clinic again?) 
 
(Multiple responses allowed)  
 
 
 
Yes  
 
 
 
No 
 
 FUVMON 
FUVDIST 
FUVTIM 
FUVHTHY 
FUVSE 
 
FUVTR 
 
FUVSTIG 
 
FUVDUT 
 
FUVAPP 
Kubulwa sente zantambula (Lack of money for transport) 
Eddwaliro liri wala (Health centre is far away) 
Kubulwa budde (lack of time) 
Ssewulira bubi (Feeling well) 
Ntya okuyisibwa obubi eddagala lya kawuka ka 
siliimu (Fear of ARV drug side effects)  
Nkozesa ddagala lya kinnaansi (Using 
traditional/alternative medicines) 
Ntya okulabibwa ku ddwaliro awajjanjabirwa 
obulwadde obwa siliimu (Fear being seen at the HIV clinic) 
Sikakasa nti nina akawuka ka siliimu (Doubtful of HIV 
status) 
Nindiridde olunaku olwampebwa okuddayo 
1 
1 
1 
1 
1 
 
1 
 
1 
 
1 
 
1 
2 
2 
2 
2 
2 
 
2 
 
2 
 
2 
 
2 
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No. Code Questions and filters  Coding categories Skip  
 
FUVOTH 
(Awaiting appointment date)  
Ensonga endala (Other reason) 
 
1 
 
2 
 FUVOTHS Specify  other reason: 
 
14.  FUTVIS Olina ekirowoozo ky’okuddayo ku ddwaliro lino 
gye bujja?  
(Do you plan to visit the HIV clinic again in future?) 
Yes  
No 
Not sure  
1 
2 
3 
 
15.  CD4SAMP Wawaayo omusaayi okukeberebwa obutofaali 
bw’omusaayi ku ddwaliro?  
(Did you provide a blood sample for CD4 cell count testing at the 
HIV clinic?)                            
Yes  
No 
Not sure 
1 
2 
3 
If No/Not 
sure, skip to 
Qn24 
16.  CDSAMDT Wayitawo bbanga ki ng’omaze okwewandiisa 
olyoke oweeyo omusaayi okukeberebwa 
obutofaali bw’omusaayi?  
(How soon after registering with the clinic did you provide a 
sample for CD4 cell count testing?)  
Less than 1 month 
1-3 months 
Over 3 months 
Don’t know 
1 
2 
3 
4 
 
17.  CDSDAY Ebyaava mukukebera obutofaali bw’omusaayi 
omulundi ogwasooka wabifunirawo ku lunaku 
olwo lwewawaayo omusaayi?  
(Did you receive your CD4 cell count test result on the same day 
that you provided a sample?) 
Yes 
No 
Not sure  
1 
2 
3 
If Yes, skip 
to Qn22 
18.  ASKRTCD Wasabibwa okuddayo ku ddwaliro okufuna 
ebyaava mu kukebera obutofaali bw’omusaayi 
gwo ku lunaku olulala?  
(Were you asked to return to the clinic to collect your CD4 count 
test results on another day?) 
Yes 
No 
Not sure   
1 
2 
3 
 
19.  RTCD Waddayo ku ddwaliro okufuna ebyaava mu 
kukebera obutofaali bw’omusaayi gwo? (Did you 
return to the clinic to collect your CD4 count test results?) 
Yes  
No 
1 
2 
If No, skip 
to Qn23 
20.   Emirundi emeka gyewadda ku ddwaliro okufuna 
ebyaava mu kukebera obutofaali bw’omusaayi 
gwo?  
(How many times did you return to the clinic to collect your CD4 
cell count test results?) 
 
|__|__| 
  
21.  RESREC Wafuna ebyaava mukukeberebwa obutofaali 
bw’omusaayi gwo?  
(Did you receive your CD4 cell count test result?)     
Yes  
No 
Don’t know 
1 
2 
3 
If No/don’t 
know, skip 
to Qn24 
22.  CLCCD4 Obutofaali bw’omusaayi gwo bwali bwenkana ki? 
(What was your CD4 cell count?           
 
 
 
 
 
 
 
|__|__|__|__| 
9999 if do not remember/not available 
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23.   Lwaki toddanga ku ddwaliro kufuna byaava mu 
kukebera butofaali (CD4) bwo?  
(Why didn’t you return to the clinic to collect your CD4 count test 
results?)  
  
(Multiple responses allowed) 
 
 
 
 
 
Yes  
 
 
 
 
 
No 
 
 RTTRANS 
RTDIST 
RTTIME 
RTWELL 
RTARVE 
 
RTHERB 
 
RTSTIG 
 
RTFORG 
RTOTH 
Kubulwa sente zantambula (Lack of money for transport) 
Eddwaliro liri wala (HIV clinic is far away) 
Kubulwa budde (lack of time) 
Ssewulira bubi (Feeling well) 
Ntya okuyisibwa obubi eddagala lya kawuka ka 
siliimu (Fear of ARV side effects) 
Nkozesa ddagala lyakinnansi (using herbal/other 
medicines) 
Ntya okulabibwa ku ddwaliro awajjanjabirwa 
obulwadde bwa siliimu (Fear being seen at the HIV clinic) 
Neerabira (Forgot)  
Ensonga endala (Other reason)  
1 
1 
1 
1 
1 
 
1 
 
1 
 
1 
1 
2 
2 
2 
2 
2 
 
2 
 
2 
 
2 
2 
 RTOTHS Specify other reason 
24.  CTXP Watandisibwa ku kumira septrin owa buli lunaku? 
(Were you started on daily Septrin prophylaxis at the HIV clinic?)                           
Yes 
No 
Don’t know  
1 
2 
3 
If No/Don’t 
know, skip 
to Qn31 
25.  CTXSTAT Ku mulundi gwa kumeka kw’egyo gy’ogenze ku 
ddwaliro kwewatandisibwako septrin 
owabulilunaku?  
(At which clinic visit were you started on Septrin prophylaxis)               
First visit  
Second visit 
Third or later visit  
1 
2 
3 
 
26.  CTXADH Mu wiiki 4 eziyise, waliwo lw’otamizze septrin? 
(Have you missed any of your Septrin doses in the past 4 weeks?)                                  
Yes 
No 
1 
2 
If No, skip 
to Qn31 
27.  MISDOS Ddoozi eza septrin meka z’otamizze mu wiiki 4 
eziyise?  
(How many Septrin doses have you missed in the last 4 weeks?)              
0-5 tablets  
6 or more tablets 
Don’t know 
1 
2 
3 
 
28.  MISDAY Wali oyosezaako ennaku 3 eziddiringana oba 
okusingawo   nga tomize mpeke za septrin  
(Have you ever missed taking your Septrin tablets for 3 or more 
days in a row?) 
Yes 
No 
Don’t remember 
1 
2 
3 
 
29.  MISDAYF Mu bbanga lya wiiki 4 eziyise, mirundi emeka Once  1  
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gy’otasobode kumira septrin okumala ennaku 3 
eziddiringana oba ezisingawo?  
(In the last 4 weeks, how often have you missed taking your 
Septrin tablets for 3 or more days in a row?)  
 
 
 
 
Twice  
More than twice 
Don’t know 
2 
3 
4 
30.   Nsonga ki ezaakuleetera obutamira septrin?  
(Reasons for missing Septrin doses) 
  
(Multiple responses allowed)                                                                 
 
 
 
Yes 
 
 
 
No 
 
 MISFGT 
MISAWE 
MISRO 
MISOS 
 
MISWEL 
MISSIC 
MISSTIG 
 
MISFAT 
MISSEFF 
MISOTH 
Nerabira (Forgot) 
Ssaali waka (Was away from home) 
Amakerenda ganzigwako (Ran out of pills) 
Septin teyaliyo ku ddwaliro (Septrin was out of stock at 
the clinic) 
Nali seewulira bubi (Do not feel sick) 
Septrin andwaza (Septrin makes me feel sick) 
Nali ssaagala bantu kundaba/kumanya (Did not want 
others to notice) 
Nali nkooye okumira amakerenda (Tired of taking pills) 
Okutya okukosebwa eddagala (Fear of side effects)  
Ensonga endala (Other)  
1 
1 
1 
1 
 
1 
1 
1 
 
1 
1 
1 
2 
2 
2 
2 
 
2 
2 
2 
 
2 
2 
2 
 MISOTHS Specify other 
31.  ARVELINF Abasawo ku ddwaliro balina kye bakubuuliddeko 
ku ddi lw’olina okutandisibwa eddagala 
eriweweeza ku kawuka ka siliimu (ARVs)?  
(Have you received any information from the HIV clinic staff 
regarding your eligibility for antiretroviral drugs?)                                                                                                  
Yes 
No 
Don’t remember 
1 
2 
3 
If No/don’t 
remember, 
skip to 
Qn36 
32.  ARTELI Kiki ekyagugambibwa ku ky’okutuusa ekiseera 
eky’okufuna eddagala eriweweza ku kawuka ka 
siliimu (ARVs)?  
(What have you been told regarding your eligibility for 
antiretroviral drugs?)       
Eligible  
Not eligible 
Don’t remember 
1 
2 
3 
if Not 
eligible/ 
don’t 
remember, 
skip to 
Qn36 
33.  ELIDT Wayise bbanga ki ng’okitegedde nti olina okufuna 
eddagala eriweweeza akawuka ka siliimu?  
(For how long have you known that you are eligible for 
antiretroviral drugs?)                   
Less than 1 month  
1-3 months 
Over 3 months 
Don’t remember 
1 
2 
3 
4 
 
34.  ARTIN   Watandika okumira eddagala eriweweeza ku 
bulwadde bwa siliimu?  
(Have you started taking antiretroviral drugs?)                                                          
Yes 
No 
Not sure 
1 
2 
3 
 
35.  ARTDT Omaze bbanga ki ng’okozesa eddagala Less than 1 month  1  
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eriweweeza ku bulwadde bwa siliimu?  
(For how long have you been taking antiretroviral drugs now?) 
1-3 months 
Over 3 months 
Don’t remember 
2 
3 
4 
36.  KNOSTAT Wali okimanyi nti olina akawuka ka siliimu nga 
tonayingizibwa mu mukunoonyereza kuno?  
(Did you know that you were HIV positive before joining this 
study?)  
 
 
Yes  
No  
Refused to answer 
1 
2 
3 
If 
No/refused 
to answer, 
skip to 
Qn38 
37.  INCARE Nga tonayingizibwa mu mukunoonyereza kuno, 
wali ofuna obujjanjabi bwa kawuka ka siliimu?  
(Were you already attending an HIV care clinic by the time you 
joined this study?) 
Yes  
No  
Refused to answer 
1 
2 
3 
 
38.  KNOWSP Waliwo abantu abalala b’omanyi mu byalo 
eby’omuliraano abetabye mu kunoonyereza 
kuno? (Do you know of other persons in neighbouring villages 
who are participating in this study?) 
Yes 
No  
1 
2 
If No, stop 
here 
39.  DISCSP   Wali okubaganyizaako ebirowoozo ku 
kunoonyereza kuno   n’abantu abalala 
abakwetabyemu  abali mu byalo ebirala?   
(Have you discussed this study with these other study participants 
in other villages?)                                                
Yes 
No  
1 
2 
If No, stop 
here 
40.   Oba yee, abantu bano bali mu byalo ki?  
(If yes, in which villages do these persons live?) 
 
VOTHP1 Village 1:_________________________________________________________________ 
VOTHP2 Village 2:_________________________________________________________________ 
 
INTD Interview date 
 
|__|__||__|__|__||__|__|__|__| 
 
 
INT Interviewer’s initials 
 
|__|__|__| 
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Linkage to pre-ART care study                                     CD4 count & repeat HIV test form 
 
Study number: HCT-|__|__|__|__|SN      Cluster number: |__|__|CLUSN 
 
Village name: ____________________________VILL 
 
Lab number: MC|__|__|__|__|__|__|__|LABN (if CD4 or repeat HIV test done)   
Linkage status questionnaire v2.2 3Sep15       Page 1 of 1 
 
No. Code Questions and filters  Coding categories  Skip 
1.  BSTAT Participant’s baseline HIV status Positive 
Negative 
1 
2 
If positive, 
skip to Qn5 
2.  WRHIV Is participant willing to have repeat HIV 
testing? 
Yes  
No 
1 
2 
If no, skip 
to Qn9 
3.  RHIVDAT Repeat HIV test sample collection date                       
|__|__||__|__|__||__|__|__|__| 
ddd        MMM                   yyyy 
 
4.  RHIVRES Repeat HIV test result Positive   
Negative 
Indeterminate 
1 
2 
3 
Skip to Qn9 
5.  KNOCD4 Does participant know his/her CD4 cell 
count?  
(Offer CD4 cell count testing to only 
participants who have not had the test 
and those who have had the test but 
have not received the results) 
Yes  
No 
 
 
 
 
1 
2 
 
 
 
 
If yes, skip 
to Qn9 
6.  WSCD4 Is participant willing to have CD4 count 
testing?  
Yes  
No 
1 
2 
If no, skip 
to Qn9 
7.  SCD4DAT Study CD4 sample collection date                      
|__|__||__|__|__||__|__|__|__| 
ddd        MMM                   yyyy 
 
8.  SCD4COU Study CD4 cell count  
|__|__|__|__| 
(103cells/uL or 109cells/L) 
 
9.  DATCOM Date form completed   
|__|__||__|__|__||__|__|__|__| 
ddd        MMM                   yyyy 
 
10.  STAF Staff initials    
|__|__|__| 
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Linkage to pre-ART care study- Follow-up visit form 
 
Cluster number: |__|__|CLUSN Village name: ____________________________VILL 
Study number: HCT-|__|__|__|__|SN     
Follow-up visit form v2.2 13Jul15  Page 1 of 1 
Complete this form at months 1 & 2 (participants in the intervention arm) & month 
6 (all participants) follow-up visits  
 
No. Code Questions and filters Coding categories 
1.  FUV Specify follow-up visit  Month 1 follow-up visit 
Month 2 follow-up visit 
Month 6 follow-up visit 
1 
2 
3 
2.  FUD Date of follow-up visit 
 
¦___¦___¦¦___¦___¦___¦¦___¦___¦___¦___¦ 
dd MMM yyyy 
3.  PSTAT Participant status 
Completed visit  
Refused follow-up  
Withdrawn  
Died  
Not contacted  
Missed visit  
Late visit (>7 days after expected date of 
follow-up) 
1 
2 
3 
4 
5 
6 
7 
4.  COM 
 
Comments  
(e.g. in care at time of enrolment) 
 
 
 
 
 
5.  FCD Form completion date 
 
¦___¦___¦¦___¦___¦___¦¦___¦___¦___¦___¦ 
dd MMM yyyy 
6.  INT Interviewer’s initials 
 
¦___¦___¦___¦ 
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Linkage to pre-ART care study- Medical records form  
 
Study number: HCT-|__|__|__|__|SN      Cluster number: |__|__|CLUSN 
Village name: ____________________________VILL 
Medical records form v2.4 7Oct15  Page 1 of 3 
 
Complete at the month-6 visit for participants who report having registered with an HIV clinic  
No. Code Questions and filters  Coding categories  Skip  
1.  CLINIC Name of HIV clinic where the participant 
registered 
  
2.  RCLINIC Did the participant register for care at this 
clinic? 
Yes 
No 
1 
2 
If No, stop 
here 
3.  REGNO Unique HIV clinic assigned patient 
number   
 
|__|__|__|__|__|__|__|__| 
 
4.  REGDAT Date participant was registered at HIV 
clinic              
 
|__|__||__|__|__||__|__|__|__| 
 
5.  REGBEF Was the participant registered at this or 
other HIV clinic before his/her enrolment 
in the current study?  
Yes 
No 
1 
2 
If Yes, stop 
here 
6.  CTXP Was daily septrin prescribed?                                                    Yes 
No 
1 
2 
If No, skip to 
Qn8 
7.  CTXD Was septrin dispensed?   Yes 
No/Not documented 
1 
2 
 
8.  STAGE Was participant’s HIV disease staged? Yes  
No/Not documented 
1 
2 
If No/Not 
documented, 
skip to Qn10 
9.  FSTAGE First documented WHO HIV disease stage                                                                 
 
Stage one  
Stage two 
Stage three  
Stage four  
1 
2 
3 
4 
 
10.  CD4 Was CD4 cell count testing done?                                                                                      
 
Yes  
No/Not documented 
1 
2 
If No/Not 
documented, 
skip to Qn12 
11.  CD4COUNT First CD4 cell count test result                                                                     
|__|__|__|__| 
  
12.  ARVP Have antiretroviral drugs been 
prescribed?                                                                      
Yes 
No 
1 
2 
If No, skip to 
Qn14 
13.  ARVDATE Date antiretroviral drugs prescribed                                                                      
|__|__||__|__|__||__|__|__|__| 
  
14.  FUVT Has participant had any follow-up visits?    Yes  
No  
1 
2 
If No, stop 
here 
15.  NFUV Number of follow-up visits?   
|__|__| 
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Linkage to pre-ART care study- Medical records form  
 
Study number: HCT-|__|__|__|__|SN      Cluster number: |__|__|CLUSN 
Village name: ____________________________VILL 
Medical records form v2.4 7Oct15  Page 2 of 3 
 
No. Code Questions and filters  Coding categories  Skip 
16.  FIRFVR Main reason for 1st follow-up visit   Provide sample for CD4 cell count test  
Collect CD4 cell count test results  
Collect septrin 
Collect ARVs  
Medical complaint 
Routine visit 
Other (specify)………………………………….. 
…………………………………………………………. 
1 
2 
3 
4 
5 
6 
7 
 
Stop here 
if only 1 
follow-up 
visit 
17.  SECFVR 
 
Main reason for 2nd follow-up visit   Provide sample for CD4 cell count test  
Collect CD4 cell count test results  
Collect septrin 
Collect ARVs  
Medical complaint 
Routine visit 
Other (specify)………………………………… 
………………………………………………………… 
1 
2 
3 
4 
5 
6 
7 
Stop here 
if only 2 
follow-up 
visits 
18.  THIRFVR 
 
Main reason for 3rd follow-up visit   Provide sample for CD4 cell count test  
Collect CD4 cell count test results  
Collect septrin 
Collect ARVs  
Medical complaint 
Routine visit 
Other (specify)………………………………….... 
……………………………………………………………  
1 
2 
3 
4 
5 
6 
7 
Stop here 
if only 3 
follow-up 
visits 
19.  FORFVR Main reason for 4th follow-up visit   Provide sample for CD4 cell count test  
Collect CD4 cell count test results  
Collect septrin 
Collect ARVs  
Medical complaint 
Routine visit 
Other……………………………………….............. 
……………………………………………………………. 
1 
2 
3 
4 
5 
6 
7 
 
 
Date Date 
 
|__|__||__|__|__||__|__|__|__| 
 
 
STAF Staff initials 
 
|__|__|__| 
 
 
8.15 Appendix 15: Medical records form
258
 
Linkage to pre-ART care study- Medical records form  
 
Study number: HCT-|__|__|__|__|SN      Cluster number: |__|__|CLUSN 
Village name: ____________________________VILL 
Medical records form v2.4 7Oct15  Page 3 of 3 
Complete at the month-6 visit for participants who report having registered with an HIV clinic  
 
Linkage to pre-ART care study- Addendum to Medical records form  
 
No. Code Questions and filters  Coding categories  
20.  CD4SMPDAT Date participant provided sample for first 
CD4 cell count testing 
 
|__|__||__|__|__||__|__|__|__| 
21.  CD4RESDAT Date participant obtained first CD4 cell count 
test results 
 
|__|__||__|__|__||__|__|__|__| 
22.  FIRFVRDAT 1st follow-up visit date    
|__|__||__|__|__||__|__|__|__| 
23.  SECFVRDAT 
 
2nd follow-up visit date    
|__|__||__|__|__||__|__|__|__| 
24.  THIRFVRDAT 
 
3rd follow-up visit date    
|__|__||__|__|__||__|__|__|__| 
25.  FORFVRDAT 4th follow-up visit date    
|__|__||__|__|__||__|__|__|__| 
 
Date Date 
 
|__|__||__|__|__||__|__|__|__| 
 
STAF Staff initials 
 
|__|__|__| 
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                                        Observational / Interventions Research Ethics Committee
Dr Eugene Ruzagira
LSHTM
21 January 2015 
Dear Dr. Ruzagira , 
Study Title:  A CRT of the effectiveness of referral to pre‑ART care & follow‑up counselling compared to referral to pre‑ART care only, for individuals diagnosed with HIV through
home‑based HCT in Masaka, SW Uganda 
LSHTM Ethics Ref: 8833 
The Interventions Committee reviewed the above application.
The documents reviewed were:
Document Type File Name Date Version
Protocol / Proposal Protocol‑ Linkage to pre‑ART care study‑ version 26Nov14.doc 26/11/2014 1.0
Protocol / Proposal Baseline SD questionnaire‑ Linkage study‑v1.0 26Nov14.doc 26/11/2014 1.0
Protocol / Proposal Linkage status questionnaire‑Linkage study‑v1.0 26Nov14.doc 26/11/2014 1.0
Protocol / Proposal Medical records form‑Linkage study‑v1.0 26Nov14.doc 26/11/2014 1.0
Information Sheet Informed consent document‑Linkage study‑v1.0 26Nov14.doc 26/11/2014 1.0
Investigator CV Eugene Ruzagira CV‑ Nov14.doc 28/11/2014 1
Investigator CV Kathy Baisley CV‑Nov14.doc 28/11/2014 1
Investigator CV Anatoli Kamali CV‑ Sep14.doc 28/11/2014 1
Investigator CV Heiner Grosskurth CV‑Nov14.doc 28/11/2014 1
Sponsor Letter Research project sponsorship letter‑Linkage study.pdf 01/12/2014 1
 
Provisional opinion
The Committee would be content to give a favourable ethical opinion of the research, subject to receiving a complete response to the request for further information set out below.
The Committee will delegate authority to confirm its final opinion on the application to the Chair.
Further information or clarification required
1. Information Sheet: please amend the participant information sheet so that it is written more clearly and use simpler language to make it easier to understand. Has the information
sheet been tested for lay understanding or had any input from potential participants? If not, it is recommended that you have some input to be rewritten for the lay public to understand
2. Project title: the title of this project is difficult to read and understand. This is likely not to be acceptable to a scientific journal or in any public information. It is important that
researchers consider at this stage who will be able to understand this title. Please comment
When submitting your response to the Committee, please submit a revised copy of the application form through the ethics online applications website: http://leo.lshtm.ac.uk 
Please list the changes and requested clarification in a covering letter addressed to the Committee. Please send any revised documentation, where appropriate underlining or otherwise
highlighting the changes you have made and giving revised version numbers and dates as well as making any necessary changes to the application form.  For further instructions, in
the 'Help' section on the website, please refer to the section on 'Provisional Approvals ‑ submitting responses to queries raised by the committee'.
Yours sincerely,
 
Professor John DH Porter
Chair
ethics@lshtm.ac.uk
http://www.lshtm.ac.uk/ethics/ 
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Observational / Interventions Research Ethics Committee
 
 
 
Dr. Eugene Ruzagira
LSHTM
30 January 2015 
Dear Dr Ruzagira
Study Title: The effectiveness of a counselling intervention on the uptake of HIV care services among HIV infected patients in Uganda. 
LSHTM Ethics Ref: 8833 
Thank you for responding to the Observational  Committee’s request for further information on the above research and submitting revised documentation.
The further information has been considered on behalf of the Committee by the Chair. 
Confirmation of ethical opinion
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, protocol and supporting documentation
as revised, subject to the conditions specified below.
Conditions of the favourable opinion
Approval is dependent on local ethical approval having been received, where relevant. 
Approved documents
The final list of documents reviewed and approved by the Committee is as follows:
Document Type File Name Date Version
Protocol / Proposal Baseline SD questionnaire‑ Linkage study‑v1.0 26Nov14.doc 26/11/2014 1.0
Protocol / Proposal Linkage status questionnaire‑Linkage study‑v1.0 26Nov14.doc 26/11/2014 1.0
Protocol / Proposal Medical records form‑Linkage study‑v1.0 26Nov14.doc 26/11/2014 1.0
Information Sheet Informed consent document‑Linkage study‑v1.0 26Nov14.doc 26/11/2014 1.0
Protocol / Proposal Protocol‑ Linkage to pre‑ART care study‑ version 26Nov14 26/11/2014 1.0
Protocol / Proposal Protocol‑ Linkage to pre‑ART care study‑ version 26Nov14.doc 26/11/2014 1.0
Investigator CV Eugene Ruzagira CV‑ Nov14.doc 28/11/2014 1
Investigator CV Kathy Baisley CV‑Nov14.doc 28/11/2014 1
Investigator CV Anatoli Kamali CV‑ Sep14.doc 28/11/2014 1
Investigator CV Heiner Grosskurth CV‑Nov14.doc 28/11/2014 1
Sponsor Letter Research project sponsorship letter‑Linkage study.pdf 01/12/2014 1
Protocol / Proposal Protocol‑ Linkage to HIV care study‑ v1.1 26Jan15 26/01/2015 1.1
Information Sheet Informed consent document‑Linkage to HIV care study‑v1.1 26Jan15 26/01/2015 1.1
Covering Letter Cover letter‑ response to LSHTM ethics queries‑ 29Jan15 29/01/2015 1.0
   
After ethical review
The Chief Investigator (CI) or delegate is responsible for informing the ethics committee of any subsequent changes to the application.  These must be submitted to the Committee for review
using an Amendment form.  Amendments must not be initiated before receipt of written favourable opinion from the committee.  
The CI or delegate is also required to notify the ethics committee of any protocol violations and/or Suspected Unexpected Serious Adverse Reactions (SUSARs) which occur during the project
by submitting a Serious Adverse Event form. 
At the end of the study, the CI or delegate must notify the committee using an End of Study form. 
All aforementioned forms are available on the ethics online applications website and can only be submitted to the committee via the website at: http://leo.lshtm.ac.uk
Additional information is available at: www.lshtm.ac.uk/ethics
Yours sincerely,
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Professor John DH Porter
Chair
ethics@lshtm.ac.uk
http://www.lshtm.ac.uk/ethics/ 
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